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Foreword 
 
It is for me a pleasure to introduce the final report of the GenTEE project, which is the 
first worldwide effort to systematically survey and assess the current state of medical 
genetic services in emerging economies. 
 
Due to the epidemiological transition – witnessed by a change in mortality and 
morbidity patterns – the emerging economies in Asia, Latin America, the Middle East 
and Africa are facing an increasing proportion of infant morbidity and mortality due to 
congenital and genetic disorders and an increasing exposure of their adult population 
to risks for non-communicable chronic diseases such as: heart disease, stroke, 
cancer and diabetes - diseases that all have subgroups with significant genetic risk 
components. These changes in risk factors result in an increasing need for genetic 
services. 
 
The GenTEE international network initiative responds to these challenges by 
facilitating inter- and intra-country comparison of the current state-of-the-art in the 
field of genetic services and testing development, with the help of a systematic 
survey conducted in eight countries selected for their capability and readiness to 
conduct such a survey including: Argentina, Brazil, China, Egypt, India, Oman, the 
Philippines and South Africa. Although these countries represent different health care 
systems and funding schemes, different social structures and cultural backgrounds, 
they share significant commonalities like the requirement to adjust new demands for 
essential genetic testing services and for capacity building functions that strategically 
respond to the needs of those affected by or at risk for congenital/genetic disorders. 
Strengthening genetic services is a gradual process that can be facilitated and 
supported by international networking. This international project stands in the 
tradition of previous networking projects funded by the European Commission on the 
collection of comparative data on genetic services, namely the "Concerted Action on 
Genetics Services in Europe" (CAGSE, funded by FP5), the European Commission 
Joint Research Centre Institute for Prospective Technological Studies’ (IPTS) survey 
"Towards quality assurance and harmonisation of genetic testing services in the EU", 
“Capacity Building for the Transfer of Genetic Knowledge into Practice and 
Prevention” (CAPABILITY, funded by FP6) and “Genetic Testing in Europe - Network 
for the further development, harmonization, validation and standardization of 
services” (EuroGentest, funded by FP6 and FP7). 
One of the key roles of the JRC is to use its neutral position and scientific expertise to 
contribute through pilot projects and networking, to the foundation for a wide public 
health policy. The survey has generated important data for key stake-holders and 
policy makers in the participating countries and initiated collaboration among 
scientists from EU member states and international non EU cooperation partners. I 
am glad that the support given by the IHCP so far has contributed significantly to the 
high visibility and success of GenTEE.
 
 

  
 
 
 
The Report 
 
 
 
 

1 
 
I Background 
 
The GenTEE project is the first project worldwide that systematically reports and 
assesses the development and current state of medical genetic services in eight 
emerging economies: Argentina, Brazil, China1, Egypt, India, Oman, Philippines 
and South Africa (in the following referred to as GenTEE countries). The project is 
intended to inform policy decisions for the challenges of delivering equitable high 
quality genetic services and to promote international collaboration for capacity 
building. 
 
Due to the epidemiological transition in the emerging economies of Asia, Latin 
America, the Middle East and South Africa, characterized by 
 
(i) a significant reduction of infant mortality from infectious diseases and 
malnutrition (Figure 1.1) 
 
 
Figure 1.1 Infant mortality rate, probability of dying by age 1 year per 1 000 live 
births (GenTEE countries, 1970 - 2010) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
and 
 
(ii) increasing life expectancy2 (Figure 1.2). 
                                                        
1
 Without the Special Administrative Region Hong Kong; The People’s Republic of China is referred to throughout the report as 
China. 
2
 South Africa, affected by the HIV/AIDS epidemic, exemplifies that the transition process is not always unidirectional and 
progress may be halted, reversed or overlapping in different segments of the population. 
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Figure 1.2 Life expectancy at birth of total population, years 
(GenTEE countries, 1970 - 2009)3 
 
 
 
 
 
 
 
 
 
 
 
these economies are facing an increasing proportion of infant morbidity and mortality 
due to congenital and genetic disorders and an increasing exposure of their adult 
population to risks for non-communicable chronic diseases such as: heart disease, 
stroke, cancer and diabetes - diseases that all have subgroups with significant 
genetic risk components. 
The changes in risk factors involved in the epidemiological transition result in an 
increasing need for genetic services to improve both individual patient outcomes and 
overall population health in these countries. 
 
 
 
 
 
 
 
 
 
 
                                                        
3
 The figures 1.1/1.2: these developments are not linear however this presentation is widely accepted and was adapted from 
Fineberg H: “A Successful and Sustainable Health System — How to Get There from Here”. N Engl J Med 2012;366:1020-7. 
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The challenges the GenTEE emerging economies are facing are manifold: 
 
 develop a service delivery infrastructure, including health workforce training, 
quality guidelines and procedures leading to equitable and affordable access to high 
quality genetic/genomic testing services; 
 
 reap the potential benefits that the rapid development of genetic/genomic 
technologies & knowledge brings and 
 
 ensure the successful translation of genetics/genomics laboratory and academic 
research into quality assured pathways. 
 
3 
 
 
The GenTEE Global Network 
 
The GenTEE international network initiative responds to these challenges by 
facilitating inter- and intra-country comparison on the current state of genetic service 
and testing development with the help of (i) a systematic international survey 
conducted in the eight countries 4  selected for their capability and readiness to 
conduct such a survey and (ii) demonstration projects for capacity building. 
 
Reported here are the concept and the outcome of the international GenTEE survey. 
 
The GenTEE network closely links leading experts in medical genetics from 
Argentina, Brazil, China, Egypt, India, Oman, the Philippines and South Africa 
(GenTEE countries) with European Union (EU) programmes and institutions that are 
tasked to develop, harmonize, validate and standardize genetic testing services in 
the 27 EU Member States (MS) namely: EuroGentest5 and the Institute for Health 
and Consumer Protection (IHCP), one of the European Commission’s (EC) joint 
research centres. 
 
In addition, the GenTEE network is linked with other international networking 
activities such as the March of Dimes (MoD) Global Network for Maternal and Infant 
Health and the international parent & patient alliance (International Genetic Alliance, 
IGA). 
 
 
Figure 1.3 The GenTEE Global Network 
                                                        
4
 The survey was conducted in 2010-2012. 
5
 www.eurogentest.org (accessed May 16, 2013) 
4 
 
 
Differences and commonalities 
 
The GenTEE countries are characterised by major differences such as: 
 
 geographic size and population size ranging from a population of 2.78 
million in Oman6 (2010) to 1.35 billion in China7 (2010) and a geographical 
size from 299,764 square kilometres (the Philippines, including more than 
7000 islands) to 9,596,961 square kilometres (China). 
 
 levels of development, wealth distribution and income, representing 
countries with different HDI ranks such as Argentina (very high human 
development), Brazil and Oman (high development) and China, Egypt, India, 
the Philippines and South Africa (medium human development) (Figure 
1.4). The GenTEE country with the highest income is Oman (high-income 
country), Argentina, Brazil, China and South Africa represent upper-middle 
income countries and Egypt, India and the Philippines represent lower-
middle income countries (Table 1.1). 
 
 
Figure 1.4 Human Development Index (HDI): GenTEE countries8 
 
 Very high human development (rank 1 – 47) 
 High human development (rank 48 – 94) 
                                                        
6
 World Health Statistics, WHO 2012, p.162. Online available at: 
http://www.who.int/healthinfo/EN_WHS2012_Full.pdf (accessed January 21, 2013) 
7
 World Health Statistics, WHO 2012, p.158. Online available at: 
http://www.who.int/healthinfo/EN_WHS2012_Full.pdf (accessed January 21, 2013) 
8
 Human Development Report 2011: http://hdr.undp.org/en/media/HDR_2011_EN_Complete.pdf (accessed May 
16, 2013) 
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 Medium human development (rank 95 – 141) 
 
Table 1.1 Classification of GenTEE countries‘ economies  
          by the World Bank (2012) 9 
      Argentina: 
      Brazil: 
      China: 
      Egypt: 
      India: 
      Oman: 
      Philippines: 
      South Africa: 
upper-middle-income 
upper-middle-income 
upper-middle-income 
lower-middle-income 
lower-middle-income 
high-income 
lower-middle-income 
upper-middle-income 
 
GenTEE countries represent different health care systems and funding schemes 
resulting in different proportions of public vs. private spending. For example, in 
Oman10  public/government expenditure accounts for more than 75% of the total 
health expenditure and the public sector funds more than 90% of the hospitals, 
employs most physicians and nurses and is a principal provider of preventive, 
promotive and rehabilitation services. In other countries such as Brazil, China, 
Egypt, India and the Philippines private expenditure on health is relatively high and 
consists mostly of direct out-of-pocket based funding (Table 1.2). 
 
                                                        
9
 World Bank, World Bank list of economies, April 2012, source: 
http://siteresources.worldbank.org/DATASTATISTICS/Resources/CLASS.XLS (accessed May 16, 2013) 
10
 For Omani nationals there is universal coverage and health care services are free, for foreigners working in 
Oman health costs are covered by health insurance through their employers 
6 
 
 
Table 1.2 Private expenditure on health in GenTEE countries (2009)11 
country Private expenditure 
on health 
as % of total 
expenditure on health 
Out-of-pocket 
expenditure as % of 
private expenditure on 
health 
      Argentina 33.6 59.2 
      Brazil 56.4 57.2 
      China 47.5 78.9 
      Egypt 60.5 97.7 
      India 69.7 86.4 
      Oman 21.2 63.5 
      Philippines 64.9 83.6 
      South Africa 56.2 29.6 
 
 
Countries represented in the GenTEE survey differ in their cultural backgrounds and 
include secular countries (China, South Africa), countries with strong Catholic 
traditions (Argentina, Brazil, the Philippines), Muslim countries (Egypt, Oman) and 
India, a country where the northern, northeastern and southern parts have distinct 
ethnic groups, different languages and different religious and cultural traditions. The 
religious groups vary from the predominant Hindus (80.5%), to Muslims (13.4%), 
Christians (2.3 %) and Sikhs (1.9%)12. Mainland China has 56 different ethnic groups 
officially recognized by the government. 
 
 
 
 
 
 
 
 
 
 
                                                        
11
 World Health Statistics, WHO 2012, p.134-141. Online available at: 
http://www.who.int/healthinfo/EN_WHS2012_Full.pdf (accessed January 21, 2013) 
12
 http://censusindia.gov.in/Ad_Campaign/drop_in_articles/04-Distribution_by_Religion.pdf (accessed April 9, 
2013) 
GenTEE countries share significant commonalities: 
 
 changing demography and disease patterns; 
 
 increasing congenital disorders/genetic disorder burden; 
 
 need to adjust new demands for essential genetic services; 
 
 need for capacity building functions that strategically respond to the needs of 
those affected by or at risk for congenital/genetic disorders (and their families), 
identify unmet needs and support priority choices as needs and given resources 
determine. 
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II GenTEE objectives, concept and survey methodology 
 
The GenTEE concept has been developed by the multidisciplinary international 
GenTEE partnership/consortium representing complementary expertise in medical 
genetics, genetic epidemiology, genetic testing and service development, quality 
assessment, genetic education and strategic patient and family-centred advocacy for 
service improvement. 
 
The GenTEE partners come from European research institutions, international parent 
and patient organizations and in Argentina, Brazil, China, Egypt, India, Oman, the 
Philippines and South Africa from academia and public health institutions that have 
been tasked by their national health care systems with policy-planning and service 
development for the care and prevention of congenital disorders and genetic 
diseases in their respective countries. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The international GenTEE networking project stands in the tradition of previous 
projects funded by the EC and other international organizations on the collection of 
comparative data on genetic services development, namely the "Concerted Action on 
Genetics Services in Europe" (CAGSE, funded by FP5) 13 , the Institute for 
Prospective Technological Studies’ (IPTS) survey "Towards quality assurance and 
harmonisation of genetic testing services in the EU"14, the Organisation for Economic 
Co-operation and Development (OECD) survey “Quality Assurance and Proficiency 
Testing for Molecular Genetic Testing” (2005) 15  and “Capacity Building for the 
Transfer of Genetic Knowledge into Practice and Prevention” (CAPABILITY, funded 
by FP6)16. 
                                                        
13
 European Journal of Human Genetics 1997; 5 (suppl 2) 
14
 http://ipts.jrc.ec.europa.eu/publications/pub.cfm?id=1124 (accessed May 16, 2013) 
15
 www.oecd.org/dataoecd/43/6/38839788.pdf (accessed May 16, 2013) 
16
 www.http://capabilitynet.eu/ (accessed May 16, 2013) 
The main objectives of the GenTEE networking project are: 
 
 to document and compare current practices and the state of genetic service 
provision in the participating GenTEE countries via a standardized survey 
(GenTEE survey); 
 
 to promote an internationally shared set of basic quality standards for genetic 
testing and the provision of appropriate genetics/genomics services that will 
facilitate future joint research, the exchange and transfer of knowledge and new 
technologies such as high throughput genome analyses via demonstration 
projects (GenTEE demonstration projects); 
 
 to support joint networking activities by consensus. 
 
8 
 
 
 
 
 
 
 
 
The GenTEE survey: methods 
 
The GenTEE survey 
 
 documents and compares current practices and the state of genetic service 
provision in participating GenTEE countries; 
 identifies current knowledge gaps; 
 identifies unmet service needs. 
 
The GenTEE survey is based upon a common method/framework (Box 2.1) for data 
ascertainment, thus allowing examination and comparison of  
 
 service development in the context of a broader view of the existing health 
care systems; 
 given service resources; 
 national health policies and genetic testing services development; 
 factors related to the state of genetic service delivery such as the 
demographic, socio-economic and legal factors. 
 
 
 
 
 
 
Box 2.1 The GenTEE survey conceptional framework 
9 
 
The GenTEE survey addresses the following key dimensions using a core set of 
indicators selected by the GenTEE consortium for their relevance and comparability: 
 
 Demography and health indicators 
Includes the demographic context in which the health care systems operate, 
describes variations across countries in population size, birth rates, life 
expectancy, mortality and other measures of population health status. 
 
 Health expenditure and financing 
Compares how much countries spend on health and describes how health 
services are paid for in the countries (e.g.: public funding, mix between public 
funding and private health insurance where it exists and out-of-pocket 
payments by patients). 
 
 Indicators of congenital/genetic "disorder burden" 
Documents the available data on birth prevalence of congenital and genetic 
disorders, and their potential for prevention, known exposure to risk factors 
that impact birth prevalence and prevalence and specific distribution of 
congenital and genetic disorders in ethnicities. 
 
 Availability of genetic services 
 Describes the development (history) of genetic services, reviews the 
availability of a key set of genetic services for different health purposes and 
in different settings, including the availability of medical support services such 
as medical termination of pregnancy (MToP) and counselling services. 
Addresses trends in genetic testing and provision of service activities and 
identifies potential drivers for service development. 
 
 Access to genetic services 
 Describes costs and reimbursement systems, identifies potential barriers to 
access to genetic services. Potential barriers include: financial barriers (e.g. 
not being able to afford the costs of a test/service), geographic barriers (e.g. 
unavailability or paucity of genetic services in a particular area), no timely 
access (e.g. excessive waiting time), unavailability of particular genetic tests 
and others barriers. 
 
 State of genetic services 
 Addresses: available workforce, supply of qualified health personnel, supply 
and use of technologies, most common type of tests performed and most 
commonly tested conditions, migration/brain drain, availability of process of 
"care" recommendations, guidelines and regulatory frameworks. 
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Genetic testing is an analysis of human tissue samples with the aim of detecting or 
excluding the presence of or risk for particular disorders/conditions with a genetic 
component.  
This includes DNA-based, cytogenetic and biochemical methods.  
The purpose of the test should be medical or research related. 
 Research priorities in genetics/genomics 
 Addresses current national (government) funding policies and research 
priorities in genetic/genomics, and research funding by private agencies. 
 
 Patient organisations and public education in genetics 
 Reviews the availability and structure of parent/patient organisations, 
including funding, objectives and provision of services. 
 
 Future outlook for service development in each country 
Assesses the potential service development taking into account the survey 
outcome. 
 
The following health care settings for genetic testing services are targeted by the 
survey: 
 
 Prenatal testing (PND) and pre-implantation genetic diagnosis (PGD); 
 Newborn screening; 
 Carrier screening; 
 Diagnostic testing for congenital and genetic disorders, including testing for 
common disorders with a major gene subgroup17; 
 Pharmacogenetic testing; 
 Genetic susceptibility testing (e.g. for infectious diseases). 
 
 
Non-medical use or non-genetic use of gene technology are being excluded in the 
GenTEE survey. 
 
 
                                                        
17
 Molecular diagnostic testing for infectious diseases is available in all the countries. This underlines the 
recognition and acceptance by the GenTEE countries of molecular genetic diagnostic testing in disciplines outside 
medical genetics. 
Box 2.2 The GenTEE definition of genetic testing 
11 
 
Data ascertainment 
 
The data collection of the survey in each country is based on: 
 
 published data, including so-called grey-literature18; 
 accessible unpublished reports/data; 
 
and where deemed necessary: 
 expert opinion. 
 
When data are not available for a specific dimension or indicator, this is documented 
as "unknown/data not available". The survey itself did not set out to generate data 
when data were not available. 
 
Data for each country are presented as “country reports”19, each country following 
the same structure while being able to address individual country characteristics and 
singular developments. Before a country report was accepted by the GenTEE 
consortium it had to be submitted to an external expert review for validation. 
The country reports were completed (including validation) in 2012. 
 
Single country reports will be published in a forthcoming special issue of the Journal 
of Community Genetics in 2013. 
                                                        
18
 The definition of the term „grey literature“ varies. In the context of the GenTEE survey it is understood as 
information produced by government, academics, non-government organizations in electronic or print formats that 
is usually available through specialized channels or the internet and does not enter usual systems of publication 
distribution and bibliographic or peer review control. 
19
 are included in the GenTEE report as appendixes 
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 Congenital disorder: any structural or functional abnormality that is present from 
birth.1  
 Genetic disorder: a disorder that is typically addressed by medical geneticists 
through genetic testing, genetic counselling or both, namely constitutive 
chromosomal abnormalities, single-gene disorders (including the monogenic 
subgroups of some common disorders) and multifactorial disorders. 
 
1 The cause may be genetic or due to abnormality in the post conception environment, including teratogens, foetal 
disruption and constraint. 
 
 
 
III Congenital and genetic disorder burden 
 
 
The survey highlights significant gaps in most GenTEE countries in terms of national 
epidemiological data availability on congenital and genetic disorders. 
 
 
 
Availability of national data on congenital and genetic disorder burden 
 
None of the eight GenTEE countries has established comprehensive population 
based congenital disorder surveillance systems or registries that document the birth 
prevalence and population prevalence of congenital and genetic disorders. The lack 
of national epidemiological data in the GenTEE countries clearly impairs health policy 
decision-makers’ abilities to assess the impact of congenital and genetic disorders. 
This in turn impacts severely the capacity to make evidence-informed decisions on 
planned service development. 
 
 
 
 
Box 3.1 GenTEE definitions of “congenital and genetic disorders” 
13 
 
 
 
 
Most countries have hospital-based registries or surveys that provide figures on the 
birth prevalence of individual congenital anomalies visible and diagnosable at birth 
(Brazil, China, India, Oman, South Africa). However data may be restricted to 
individual hospitals, districts, regions or provinces/states (Brazil, India), not open for 
the public (China), or discontinued due to lacking funds and priority in the given 
setting (South Africa). 
 
In Argentina, until recently, the closest estimation of prevalence at birth of congenital 
defects was that of the 27 congenital malformations registered by ECLAMC, a non-
governmental organization (NGO) devoted to develop registries of congenital 
malformations in South America.20  
 
Starting in 2011, the National Ministry of Health (MoH) initiated a National Registry of 
Congenital Anomalies (RENAC), centrally coordinated by the National Medical 
Genetics Center, an agency of the Ministry. In the period 2009-2011, 182,070 live 
neonates (28% of the total annual number of births of the country) were examined in 
107 hospitals, finding 3,234 neonates with major structural defects (1.78%).21 
 
In India, the Birth Defects Registry of India (BDRI)22 based in Chennai gets reports 
from 309 hospitals from all parts of India. Almost 1 million births have been covered. 
                                                        
20
. Campaña H, Pawluk MS, López Camelo JS, 2010. ECLAMC Study Group. Birth prevalence of 27 selected 
congenital anomalies in 7 geographic regions of Argentina. Arch Arg Pediatr 108 (5):409-417. See Table 1 for 
data on Argentina. 
21
 RENAC-Ar (2012). Registro Nacional de Anomaías Congénitas de Argentina. Publication of the Ministry of 
Health of Argentina. 
22
 http://www.fcrf.org.in/bdri_abus.asp (accessed April 15, 2013) 
 
 
 
 Argentina and Brazil participate in the ongoing Latin-American Collaborative 
Study of Congenital Malformations – ECLAMC; 
 Brazil contributes data to the international genetic sequence database 
(GenBank); 
 China and Egypt have recently started to report data from hospital-based 
diagnostic testing laboratories to the Human Variome Project (HVP); 
 China and India participate in the International Cancer Genome Consortium; 
 India and South Africa provide data to the International Clearinghouse for Birth 
Defects. (South Africa provides data on neural tube defects only.); 
 Oman provides data on genetic disorders in Oman for the Centre for Arab 
Genomic Studies (CAGS1). 
 
1Tadmouri GO et al. (2008): Genetic Disorders in Arab World: Oman. Vol 3. Publication of Center for Arab Genomic 
Studies (CAGS), Dubai, UAE 
Box 3.2 Seven out of the eight GenTEE countries contribute data to 
international genetic data bases 
 
14 
 
The commonest malformations reported are of the nervous system, comprising 34.8 
% of all anomalies. 
 
National health data bases – the problem of underreporting 
 
Some countries such as Brazil (Box 3.3) have instruments which – in theory – could 
provide accurate data on the birth prevalence of congenital and genetic disorders. In 
practice however, due to ineffective implementation of the instruments, the reliability 
of this data is questionable. 
15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Oman has a “Central Notification of Birth Defects and Congenital Disorders 
detectable at Birth” monitoring system. 23  However, systematic and accurate 
centralised national data collection is hampered by the marked absence of the 
correct identification at birth of children with congenital conditions. 
Countries with national newborn screening programmes (Argentina, Brazil, China, 
Egypt, Oman, the Philippines) are able to provide data on the birth prevalence of 
country specific selected disorders including certain autosomal-recessive disorders. 
However due to restricted coverage of births (coverage may vary among provinces, 
rural and urban areas), namely in Argentina, Brazil, China and India data may be 
underreporting true national birth prevalence of the disorders reported. 
                                                        
23
 Khandekar R, Jaffer Y. (2010): Incidence and Determinants of Birth Defects and Enzyme Deficiencies among 
Live Births in Oman: A review of the 2005 National Register. Sultan Qaboos Univ Med J. 10(1):23-30 
 
 
 
In 2000, the Brazilian government introduced a new data field in the “Liveborn 
Declaration”, an official document issued by hospitals that would have allowed 
congenital anomalies present at birth to be registered systematically. 
 
However, analysing data available through DATASUS related to births in Brazil in 
2006, only 0.6% of live born infants were registered as having a congenital 
anomaly, suggesting that congenital anomalies are being underreported. In 2008, 
the last year available in the database, the figures remained very similar. When 
comparing data from deaths caused by a congenital anomaly with data from the 
live born registry, Cunha (2002) demonstrated an underreporting of 60.7% of 
congenital anomalies on birth certificates. Guerra (2008a, 2008b), who also 
suggested an underreporting, showed unsatisfactory reliability in the coding of the 
recorded anomalies by the secretary of health. 
______________________ 
Cunha J et al. (2002): Defeitos congênitos em Porto Alegre: uma investigação da qualidade dos dados 
registrados na Declaração de Nascido Vivo. Revista Brasileira de Epidemiologia (supl.)51. 
Guerra FA et al. (2008a): Defeitos congênitos no Município do Rio de Janeiro, Brasil: uma avaliação através do 
SINASC (2000-2004) Cad. Saúde Pública, Rio de Janeiro, 24(1):140-149. 
Guerra FA et al. (2008b): Confiabilidade das informações das declarações de nascido vivo com registro de 
defeitos congênitos no Município do Rio de Janeiro, Brasil, 2004 Cad. Saúde Pública, Rio de Janeiro, 24(2):438-
446. 
Box 3.3 Data on the birth prevalence of congenital anomalies from the 
Brazilian MoH database (DATASUS) 
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Limited coverage impacts the availability of national birth prevalence data and may lead to 
underreporting cases: According to the Brazilian National Newborn Screening Programme 
(Programa Nacional de Triagem Neonatal – PNTN), the sickle cell disease birth prevalence 
in 2007 was 0.375/1000 live births which would be equivalent to 1140 new cases (PNTN 
2007)1. The programme, however, screens for haemoglobin disorders only in selected 
states. In these states the birth prevalence is 0.493 per 1000 live births which could 
represent 1496 new cases in the country if all states were routinely screening for 
haemoglobin disorders2. Since coverage by the national screening programme is not 100% 
(a safer estimate would be 85% births covered by the programme), nor do these figures 
include screening covered by private insurance, there could be up to 1760 new yearly 
cases. 
 
Figure 3.1 Map of the S gene for sickle cell in Brazil in the states that screen newborns for  
                       the disease 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AS: sickle cell trait; DF: sickle cell disease. The overall prevalence of AS is estimated as 4% (2-8%) among 
general population, and 6-10% among afro-descendents. Source: Brazilian Ministry of Health (Cançado Delfini 
R (2007): Doenças Falciformes. Prática Hospitalar, Ano IX, N° 50, Mar-Abr/2007, available at 
http://www.scielo.br/pdf/rbhh/v29n3/v29n3a02.pdf (accessed May 16, 2013)) 
__________________________ 
1 
PNTN - Programa Nacional de Triagem Neonatal – relatório 2007 - (National Newborn Screening Program – 2007 
report) http://portal.saude.gov.br/portal/arquivos/pdf/INDICADORES_TRIAGEM_NEONATAL.pdf (accessed May 16, 
2013) 
 
2 
It must be pointed out that the distribution of the disease is very heterogeneous throughout the country, being more 
prevalent in the southeast and northeast regions, and less prevalent in the south. Such differences can be explained by 
the historical composition of the Brazilian population, with migration of African slaves, Europeans and Orientals to specific 
regions in different colonization periods and economic cycles. 
 
Box 3.4 Underreporting of cases: Brazil  
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In some countries hospitals keep data on all their congenital and genetic disorder 
diagnosed patients (China, Egypt, India, Oman), while others have funded single 
population based studies to obtain data on the birth prevalence and prevalence of 
specific disorders. In particular Oman, where communicable diseases are 
successfully controlled, has produced a wealth of data on autosomal recessive 
disorders which cumulatively, are “common” in Oman. This reflects the situation in a 
traditional Muslim community with a higher rate of consanguinity and where 
prevention measures for genetic disorders are still in a preparatory phase. Autosomal 
recessive disorders are thus major contributors to childhood morbidity and mortality 
constituting a specific disorder burden for Oman. 
 
In India neonatological services are well established. The National Neonatoloy 
Forum24, a country wide organization of neonatologists in India, maintains a perinatal 
database which records causes of neonatal mortality. Visible malformations are 
documented. During 2002-2003 data were recorded from 151,436 deliveries. 
145,623 were live births and 5,813 were stillbirths. Malformations accounted for 9.2 
% of all neonatal deaths, and 7.9 % of stillbirths. 
 
 
Estimated birth prevalence rates for congenital disorders 
 
The GenTEE national reports provide an overview on the current state of the 
availability of data on congenital and genetic disorders and importantly document the 
current data knowledge gaps. Underreporting of congenital and genetic disorders is 
common in all the countries due to a lack of skilled professionals and limited 
laboratory services to confirm diagnoses. This results in an underestimation of the 
birth prevalence, prevalence and burden of disease of congenital and genetic 
disorders. 
 
The GenTEE partner MoD in collaboration with South African GenTEE partner A. 
Christianson documented, in the 2006 MoD Global Report on Birth Defects25, global 
attention to this data deficit. In order to close the knowledge gap they provided 
modeled estimates of birth prevalence of congenital disorders, of genetic or partly 
genetic origin (multifactorial congenital disorders), for 193 countries. These data 
demonstrate the global impact of congenital disorders.  
 
This is detailed pictorially for the eight GenTEE nations in Figure 3.2 below. The 
major difference between nations that contributes to higher birth prevalence of 
congenital disorders is the birth prevalence of infants with autosomal recessive 
disorders, particularly conditions with intellectual disability, sickle cell disorder (SCD) 
and thalassaemia. High levels of consanguinity exacerbate the situation as 
                                                        
24
 www.nnfi.org (accessed May 16, 2013) 
25
 http://www.marchofdimes.com/downloads/birth_defects_report-pf.pdf (accessed April 9, 2013) 
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evidenced in Egypt, India and Oman. The birth of infants who develop complications 
secondary to genetic risk factors, essentially Rhesus incompatibility between the 
parents but especially the presence of Glucose-6-phosphate dehydrogenase (G6PD) 
deficiency are another factor contributing to high birth prevalence (In Oman 28% of 
males and 12% of females have G6PD deficiency but only very small proportion 
(0.1%) of newborns have complications. There are more than 80 types of G6PD 
deficiency, most are A+ and B+ types which are innocent. Only a few Mediterranean 
types lead to haemolysis and neonatal jaundice in newborns). 
 
Figure 3.2 Minimum global estimates of birth prevalence of congenital disorders of 
genetic or partly genetic origin 
 
 
Figure 3.2 demonstrates that Egypt, India and Oman are particularly affected by a 
high birth prevalence of congenital and genetic disorders. It is estimated that India 
probably has the largest number of affected infants in the world. Below an estimate of 
the birth prevalence of selected congenital and genetic disorders has been made for 
the GenTEE survey based upon hospital-based data (Box 3.5). 
 
 
 
March of Dimes (MoD), Birth Defects Foundation White Plains, New York, 2006 (Appendix B) 
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Impact of congenital and genetic disorders: challenges for national health 
services in GenTEE countries 
 
India probably has the largest number of carriers for haemoglobinopathies in the 
world. The need for a national haemoglobinopathies care and prevention programme 
has been on the agenda of the public debate in India for decades but yet needs to be 
addressed by the government of India. The implementation of such a programme on 
a nationwide scale is met by daunting challenges as outlined in Box 3.6 below. 
 
 
 
 
 
Below an estimate of the birth prevalence of congenital and genetic disorders has been 
made based on published reports. 
 
Disorder   Estimated prevalence/ Number of births/year, 
    1,000 live births  estimates 2010 
Cong. malformations  20    545,400 
Down syndrome  1.25    34,000 
Metabolic disorders  0.83    22,700 
ß-thalassaemia + SCD  0.37    10,100 
CH    0.4    11,000  
DMD    0.2    5,450 
SMA    0.1    2,700 
 
Data provided by Ishwar C. Verma, Centre of Medical Genetics, Sir Ganga Ram Hospital, Rajender 
Nagar, New Delhi, India. 
Box 3.5 Burden of congenital and genetic disorders, national estimate 
for the birth prevalence of selected disorders for India 
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Epidemiology: The prevalence of carriers varies from 1 - 17% in different ethnic groups 
with an overall estimate rate of carriers of 3 - 4% (35 - 45 million carriers). 
 ~10,000 - 20,000 affected babies are estimated to be born annually. 
 ~ 100,000 affected children are estimated to be in the country. National 
survival data are not available. 
More than 65 mutations have been characterized in the population, 7 of 
these mutations account for ~85 - 90% of all mutations identified.
1
 
 
Treatment & care: The majority of affected children have severe symptoms and receive sub-
optimal treatment and clinical management and most of them are not 
receiving regular blood transfusions and iron chelation. This is mainly due 
to resource poor clinical settings, limited availability of facilities in the public 
domain and because the majority of families’ lack of financial resources.
2,3
 
Bone marrow transplantation is available at few centres but is unaffordable 
by most families. 
 
Prevention, barriers 
and constraints: Although haemoglobinopathies pose a major health problem and health 
professionals and parent/patient organizations have lobbied for decades for 
a “National Haemoglobinopathies Control Programme”, a national 
programme is still lacking. India is faced with the challenge how to reach 
out to a multi-ethnic population of more than 1.2 billion people where the 
vast majority (> 70%) live in rural areas, only 65% (of the females) and 82 
% (of the males) are literate
4
. India is home to 22 scheduled and several 
hundred other spoken languages
5
 and there are 4,693 endogamous 
communities including 427 tribal groups  
 The lack of economic and financial resources and insufficient health care 
infrastructure in the public domain is coupled with a lack of awareness 
about thalassemia in the public and among health professionals. 
Reluctance to take up screening offers due to fear of stigmatization has 
been reported from high risk tribal populations.
6,7
 
 
Introducing services 
in a gradual way: In the absence of a national haemoglobinopathy care and prevention 
programme the ICMR has taken the lead and funded extensive regional 
multi-centre studies to determine the prevalence of ß-thalassaemia and 
sickle cell anaemia and to assess the feasibility to establish centres for 
screening and counselling in medical centres and other institutions where 
thalassemia facilities are lacking. It is expected that pilot programmes will 
be implemented in Delhi, Chandigarh and Punjab and that eventually the 
programme will be integrated into the public health care system in all 
states. 
 
1 
Colah, R: Control, Strategies for Hemoglobinopathies in India. 1st Pan-Asian Conference on 
Haemoglobinopathies, country reports. Thalassemia Report 2012; 2 (s1), p.1-2. 
2 
Mohanty D et al.: Prevalence of ß-thalassemia and other haemoglobinopathies in six cities in India: a 
multicentre study. Journal of Community Genetics, October 2012, 4:33-42. 
3
 Madan et al.: Frequency of ß-thalassaemia trait and other hemoglobinopathies in northern and western India. 
Indian Journal of Human Genetics, 2010 Jan-Apr; 16(1): 16-25. 
4 
Population Census India 2011. Online available at http://www.census2011.co.in/literacy.php (accessed May 
2, 2013) 
5 
Verma IC, Saxena R, Kohli S: Past, present & future scenario of thalassaemic care & control in India. Indian 
Journal of Medical Research 134, October 2011, pp. 507-521. 
6
 Mohanty D, Das K: Genetic counselling in tribals in India. Indian Journal of Medical Research 134, October 
2011; pp. 561-571. 
Box 3.6 ß-thalassaemia in India 
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Oman has enough empiric national data of birth prevalence for congenital and 
genetic disorders to assist it in planning future medical genetic health services. Using 
this and modeled birth prevalence data the country has developed projections of 
annual costs of treating common disorders such as haemoglobin disorders in the 
absence of primary prevention (Box 3.7). 
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In just three decades Oman has successfully controlled and eradicated major 
communicable diseases. Whereas in the past the problem of congenital and genetic 
disorders was hidden in the high mortality rate because most affected infant died before 
being diagnosed, today more and more infants are diagnosed and provided with the best 
possible care. In the absence of primary prevention, an increasing number will move into 
adolescence and adult life in the next years, with important service implications. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Oman: projected births of infants with congenital and genetic disorders, 
2001 fertility rates
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Figure 3.4 Oman: projected annual 
costs of treating 
haemoglobin disorders in 
Oman  
Figure 3.5 Oman: projected 
numbers of patients with 
sickle cell disorders or 
thalassemia 
Figures modeled by B. Modell based on data provided by Anna Rajab, Genetic Unit, Directorate General of Health Affairs, 
Ministry of Health, Muscat, Sultanate of Oman 
Box 3.7 Projected birth prevalence of congenital and genetic disorders and its 
impact in Oman 
 
Figure 3.3 Oman: projected births of infants with congenital and 
genetic disorders, 2001 fertility rates 
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      %   year 
 Argentina 24.7   2011 
 Brazil    19.3   2010 (congenital anomalies only) 
 China    unknown/data not available 
 Egypt    unknown/data not available 
 India    estimate 5.8  2007 (neonatal deaths) 
 Oman    39   2008 (hospital-based 
         perinatal deaths) 
 Philippines   11.3   2005 (neonatal deaths) 
 South Africa   unknown/data not available 
Congenital and genetic disease burden: infant deaths and under-5 mortality 
 
The data presented in Box 3.7 below highlight the limited availability and paucity of 
national data on infant deaths due to congenital disorders in most GenTEE countries. 
In addition, they demonstrate differences in the national ascertainment of data and 
the structural weakness in data ascertainment on the impact of congenital/genetic 
disorders in general. This makes the comparison of data difficult. The table below 
shows that India and the Philippines present the percentage of infant deaths due to 
congenital/genetic disorders as percentage of neonatal deaths. Whereby India is 
probably underreporting deaths considering the World Health Organization (WHO) 
estimates of 8% of neonatal deaths due to congenital disorders (Box 3.8). China, 
Egypt and South Africa cannot provide national data and Oman26 can only provide 
data on hospital-based perinatal deaths which include stillbirths. 
 
 
References 
Argentina Report of the Dirección de Estadística e Información de Salud of the Ministry of Health of Argentina (2011), 
p. 35, available at www.deis.gov.ar (accessed May 16, 2013) 
Brazil Brasil (2013), Ministério da Saúde, Departamento de Informação e Informática do SUS – DATASUS, 
Sistema de Informações de Saúde. Mortalidade infantil (menores de um ano) 
http://tabnet.datasus.gov.br/cgi/tabcgi.exe?sim/cnv/inf10uf.def (accessed January 29, 2013) 
India Data provided by Ishwar C. Verma, Centre of Medical Genetics, Sir Ganga Ram Hospital, Rajender Nagar, 
New Delhi, India. 
Oman  2009 Annual Health Report of Ministry of Health prepared by Department of Health Information & Statistics. 
Philippines Department of Health Statistics 2006. available at http://www.doh.gov.ph/kp/statistics/infant_deaths.html 
(accessed May 16, 2013) 
 
 
 
                                                        
26
 In Oman stillbirth rate in Ministry of Health institutions where 95% of national deliveries take place is 7.9 per 
100 births 
Box 3.8 Best available national data on infant deaths due to 
congenital/genetic disorders 
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The higher percentages of infant deaths attributed to congenital/genetic disorders in 
Argentina and Brazil are also attributable to the countries having advanced well 
through epidemiological transition, thus having adequate neonatal care with reduced 
numbers of deaths from prematurity and infection, with resulting exposure of the 
deaths due to congenital/genetic disorders. This would also be an issue in Oman, 
were the deaths due to congenital/genetic disorders differentiated. 
 
 
The countries with the highest percentage of deaths due to congenital disorders 
namely Argentina, Brazil, Egypt and Oman are the countries that have advanced 
the most through epidemiological transition. This is indicated in Figures 1.1 & 1.2 
which indicates in 2010 their infant mortality rates were ≤20 per 1,000 live births, and 
the life expectancy was >70 years. The percentage of deaths due to congenital 
disorders would be expected to be high in these countries. The number of deaths 
due to infectious diseases and malnutrition would have dropped significantly in the 
preceding decades whilst deaths due to ‘congenital anomalies’ would have remained 
constant, thus increasing the percentage of deaths due to congenital disorders. 
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The best available international data (country estimates) on under-5 mortality have 
been published by WHO. 
 
Figure 3.6 WHO data (country estimates) on congenital “anomalies”27 as cause of 
deaths in children under-5 in GenTEE countries (2008, 2010)28 
 
 
 
Figure 3.6 confirms the increase of the percentage of deaths due to congenital 
“anomalies” (disorders) in children under 5 in all GenTEE countries between 2008 
and 2010. The data suggest in all countries a temporal trend of an increasing 
percentage of childhood deaths due to congenital “anomalies”, indicating they are 
currently all experiencing positive epidemiological transition. The highest percentages 
are reported for Oman (2008: 25%, 2010: 28%) and Argentina (2008: 25%, 2010: 
27%), followed by Egypt (2008: 18%, 2010: 21%) and Brazil (2008: 16%, 2010: 
19%). 
Oman and Argentina are nearing the percentages reported in Western countries on 
congenital “anomalies” as cause of deaths in children under-5.29 
 
In contrast, the relatively low percentage of deaths due to congenital disorders in 
India (2008: 3%, 2010: 7%), the Philippines (2008: 6%, 2010: 10%) and South 
Africa (2008: 4%, 2010: 8%) could have two reasons. Firstly, and this is particularly 
true for India and South Africa, while congenital and genetic disorders have become 
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 The term „anomalies“ is employed by WHO. 
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 The WHO data are country level estimates of child deaths under 5 years of age by cause for Member States for 
the years 2008 and 2010. They represent the best estimates based on the evidence available to it up to the end 
of 2009 rather than the official estimates oft he Member States. Underlying causes of deaths are defined 
according to the International Classification of Diseases (ICD). For China a model was developed to assign the 
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2001-2003. (WHO: Child mortality by cause, available at http://apps.who.int/gho/data/view.main.gbdc-
CH15?lang=en, accessed May 16, 2013)  
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 Western countries with low under-5 deaths (3%) such as Finland, Japan and Norway reported in 2010 36%, 
40% and 33% of under-5 deaths due to congenital „anomalies“ respectively. 
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a major disease burden, the number of under-5 year deaths due to infectious 
diseases and malnutrition remain high.30 Secondly, there is probably underreporting 
of deaths due to ‘congenital anomalies’ due to poor universal clinical diagnostic 
services and inadequate surveillance and reporting systems. Nevertheless, also in 
these countries the percentages of deaths due to congenital anomalies are rising 
significantly albeit from a relatively low percentage. 
 
Congenital and genetic disorders and their impact on paediatric hospital 
admissions 
 
Data on hospital admissions due to congenital/genetic disorders are scarce in 
GenTEE countries. Only India and Brazil have some hospital-based data. The data 
ascertained by the Sir Ganga Ram Hospital 31 , New Delhi, in 2006, show an 
admission rate of 8% to its paediatric unit (Table 3.1). Representing the following 
disorders: 67.3% congenital malformations, 12.2% inborn errors of metabolism, 
10.2% single gene disorders and 10.2% chromosomal disorders. 
 
 
Table 3.1 Genetic disorders/congenital malformations/inborn errors of 
metabolism: Neonatal Intensive Care Unit, Sir Ganga Ram Hospital,  
New Delhi, 2006 
Disorder Total no. % 
Total 1222  
All genetic disorders 98 8.0 
Malformations 66 67.3 
Inborn errors of metabolism 12 12.2 
Single gene disorders 
(G6PD 7, CAH 1, Albinism 1, Muscle disease 1) 
10 10.2 
Chromosomal disorders 10 10.2 
Data provided by Ishwar C. Verma, Centre of Medical Genetics, Sir Ganga Ram Hospital, Rajender Nagar, New Delhi, India. 
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 The highest percentage of under-5 deaths in South Africa in 2010 was 28% due to HIV/AIDS and 24% in India 
due to Pneumonia. 
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 Sir Ganga Ram Hospital is a 650-bed multi-specialty private hospital in New Delhi, India. It provides 
comprehensive medical services to patients from Delhi and neighbouring states. The hospital has a strong 
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to the poor and needy patients. All development activities of the hospital are financed from internal resources, 
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20% of the beds are available free for admission (including boarding, lodging, investigations, medicine and 
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For Brazil, admission rates for ages 0-19 years for all hospitals are 2.46% for 
congenital anomalies. However, in tertiary care hospitals, where collection of data is 
more specific, of the three main diagnoses coded upon admission congenital and 
genetic disorders accounted for more than one third of total paediatric 
admissions.32,33 
 
For Oman, only an expert estimate of 50% could be provided for admission rates due 
to congenital and genetic disorders to the Royal Hospital, Muscat – a tertiary care 
hospital. 
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Birth prevalence of selected country specific “common” recessive single gene 
disorders and distribution of single gene disorders in ethnicities/geographical 
clusters 
 
GenTEE countries do not have nationwide studies that provide data that would allow 
the estimate of selected country specific common recessive single gene disorders. 
 
However, in countries such as Argentina, Brazil and the Philippines where national 
newborn screening programmes detect specific autosomal recessive disorders, data 
about the birth prevalence are available although data may only account for specific 
regions as coverage varies (Box 3.4, Underreporting of cases; Box 3.5).  
 
In Argentina there are no country specific common recessive single gene disorders. 
Newborn screening detects three autosomal recessive conditions: 
Phenylketonuria (PKU) 1/30,000, cystic fibrosis (CF) 1/9,000 and congenital adrenal 
hyperplasia (CAH) 1/15,000. 34  Geographical clusters of single-gene disorders, 
usually due to founder effects, have been described but are rare.35 Two of the most 
conspicuous are Sandhoff disease in Cordoba province 36  and oculocutaneous 
albinism in La Roja province.37 ß-thalassaemia is a common recessive disease as 
Italian ancestry is reported by close to 50% of the population however, there are no 
birth prevalence data, and no clusters have been described.38 
 
In Brazil, newborn screening detects PKU, sickle cell (Hb AS) and CF. The 
prevalence of sickle cell trait (Hb AS) is 4% (2-8%) among the general population and 
6-10% among Afro-descendants. Estimated population prevalence would be around 
7,200,000 Hb AS individuals, 25,000-30,000 with sickle cell disease and 3,500 new 
cases diagnosed each year.39 CF is officially screened for in only three Brazilian 
states, if the birth prevalence considers exclusively births in such areas, it can be 
estimated as 1/10,000. The demographic composition in these states includes 
descendants from European immigration (Italy and Germany) and does not reflect 
Brazil as a whole. Regarding PKU, estimated birth prevalence by the screening 
programme is 1/23,000 births, although birth prevalence also varies among regions.18 
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2007 report) http://portal.saude.gov.br/portal/arquivos/pdf/INDICADORES_TRIAGEM_NEONATAL.pdf (accessed 
May 16, 2013) 
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Presently there are some clusters under investigation, as for instance a very high 
concentration of mucopolysaccharidosis type VI in an isolated region of the state of 
Bahia. 
 
In the Philippines, the Newborn Screening Reference Center (NSRC) documents 
the following prevalence at birth rates (from 1996 to 2011/ 3,106,938 newborns 
screened): CAH 1/10,604, Congenital hypothyroidism (CH) 1/3,004 and G6PD 
deficiency 1/50. 40  Data on the distribution of single gene disorders in 
ethnicities/geographical clusters are not available for the Philippines. 
 
China, Egypt, India, Oman and South Africa have data based on single or 
multicentre studies or hospital-based data.  
 
In China, data are available from studies that have been conducted among local 
hospitals. These studies show that the provinces of Guangdong, Guangxi and 
Hainan are probably the most affected by thalassaemia with an estimated carrier 
frequency of more than 20% in these areas. The birth prevalence of G6PD deficiency 
varies in regions and ethnic groups. Again, the birth prevalence seems to be high in 
southern China, mainly in the provinces of Hainan, Guangdong and Sichuan. The 
data also show that the prevalence of G6PD deficiency varies among five ethnic 
groups (Han, Zhuang, Yao, Dai and Jinou). Higher rates were found among the 
Zhuang, Yao, Dai and Jinou minorities as compared to the Han majority. 
 
In Egypt, studies carried out by the Ministry of Health & Population (MoH&P) 
Children with Special Needs Department in three different governorates to assess the 
frequency of ß-thalassaemia carriers among secondary school students showed that 
frequency rates varied among the governorates. The highest frequency was found in 
Cairo (1.95%), the lowest in Qaliobia (0.87%). 
 
In India, regional studies conducted under the aegis of Indian Council of Medical 
Research (ICMR) showed that the carrier frequency of the gene for ß-thalassaemia 
varies in different regions and in different communities. On the average it is estimated 
that 3-4 % of people in India are carriers of the ß-thalassaemia gene (i.e. one in 
30/45 people in India are carriers of ß-thalassaemia). This will calculate to 35-45 
million carriers. The frequency is higher in north and western India, and less in south 
India. In high risk states the carrier frequency is about 5 %. This will calculate to a 
birth prevalence of ß-thalassaemia major to be 0.63 per 1,000 live births (1/1,600). 
 
The prevalence of Hb E varies among the different caste/ethnic groups in India and 
the carrier frequency may be as high as 30-40% in tribal communities.  
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 Padilla CD, de la Paz, EM: Genetic services and testing in the Philippines. Journal of Community Genetics. 
Online first. July 22, 2012. Online available at http://link.springer.com/content/pdf/10.1007%2Fs12687-012-0102-
4.pdf (accessed May 2, 2013) 
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According to a recent report presented by R. Colah: “sickle cell anemia is a major 
problem in central India and the tribal belts in the west, east and south especially in 
the states of Madhya Pradesh, Chattisgarh, South Gujarat, Maharashtra and Orissa. 
Although it is mainly seen among tribal population groups it is also present in some 
non-tribal communities. The prevalence of sickle cell carriers is as high as 30-40% in 
some of these population groups. Estimates indicate that more than 5000 babies with 
sickle cell anemia would be born each year.”41 
 
The information collected from the various genetic centers shows that common single 
gene disorders, in addition to thalassaemia, are spinal muscular atrophy (SMA), 
sensorineural deafness, albinism, CAH, Wilson disease, mucopolysaccharidosis, 
galactosemia and CF.42,43,44 
 
For Oman, hospital data including 420,000 live births are available.45 These data 
show that autosomal recessive disorders are common in Oman. Although most of 
these autosomal recessive disorders are rare, they add up to a large number when 
these rare disorders are totaled together. 
 
In South Africa, studies showed that inherited autosomal recessive conditions of 
unusual prevalence were found among Blacks (SMA, oculocutaneous albinism, 
Fanconi anemia (FA)), Black immigrants (sickle cell anaemia), Ashkenazi Jews 
(Gaucher disease, Tay Sachs disease), White (CF), Greek and Indian immigrants 
(thalassaemia) and Afrikaners (Polycystic kidney disease, FA). 
Clustered geographic distributions of single gene disorders were reported by six 
countries (Box 3.9). Ethnic clusters were reported by China, India and South Africa. 
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(i) Geographical clusters 
Country disorder 
  Argentina Sandhoff disease (Cordoba province) 
 Oculocutaneous albinism (La Rioja province) 
  
  Brazil2 Albinism, undefined type (Ilha dos Lençois region) 
 Achondrogenesis-Grebe (southern Bahia region) 
 Acheiropodia (southeast Minas Gerais region) 
 Spastic Paraplegia, optic atrophy and neuropathy - SPOAN – MIM 609541 (Serrinha dos Pintos – Rio 
Grande do Norte – northeast Brazil) 
 Neural tube closure defects (NTD) and hydrocephaly not related to NTD (São José do Pantano – Minas 
Gerais) 
 Gaucher Disease (Tabuleiro do Norte – Ceará) 
 Mucopolysaccharidosis type VI, Phenylketonuria, Congenital Hypothyroidism and Cystic fibrosis 
(Monte Santo – Bahia) 
  
  Oman6 Congenital adrenal hyperplasia, galactosialidosis, Robinow syndrome (Al Batinah) 
Bardet-Biedl syndrome, Congenital generalized lipodystrophy (Al Dakhiliyah) 
Carbohydrate-deficient glycoprotein syndrome (Al Dhahirah) 
Ellis-van Creveld syndrome (Al Sharqiyah) 
Meckel-Gruber syndrome (Al Wusta) 
Schwartz-Jampel syndrome (Muscat) 
 
(ii) Geographical and ethnic clusters 
Country Disorder 
 China 
 
 
 
G6PD deficiency (Dai, Jinuo, Yao and Zhuang minorities that live in autonomous regions in the Yunnan, 
Guangxi and Guizhou Provinces) 3 
G6PD deficiency and thalassaemia exhibit huge geographical variation. The China Ministry of 
Health (MOH) has not published national birth prevalence or prevalence of these disorders. The 
prevalence is much higher in southern China (Guangxi, Hainan, Yunnan, Guangdong and Guizhou 
province). Many studies have shown the carrier frequency of G6PD deficiency and thalassaemia are 5% 
or more in southern China (Table 4). In some areas the carrier frequency can exceed 20%. Due to 
extensive geographic size and variety of ethnic backgrounds, birth prevalence varies from the northern 
to southern areas of the country. Thalassaemia and G6PD are the most common genetic conditions in the 
provinces of Guangdong and Guangxi on the south coast of China.  4 
 
 India5 ß-thalassaemia and SCD (Central India and the tribal belts in the west east and south, especially in 
Madhya, Pradesh, Chattisgarh, South Gujarat, Maharashtra and Orissa) 
Van der Knaap Cystic megalencephaly (Aggarwal community north India) 
Spinocerebellar ataxia type 12 (Aggarwal community north India) 
Butyryl cholinesterase deficiency (Vysa community south India) 
Laron dwarfism (western India and Sindh area of Pakistan) 
 
(iii) Ethnic clusters and prevalence in at-risk populations 
Country Disorder 
  South    
         Africa7 
 
Fanconi’s anaemia (Afrikaans 1/26,000, Black 1/40,000) 
Polycystic kidney disease: autosomal recessive type (Afrikaans 1/26,000) 
Galactosemia (Black 1/18,000) 
Duchene muscular dystrophya (Indian 1/14,000) 
Oculocutaneous albinism (Black 1/3,900) 
Cystic fibrosis (White 1/3,000) 
Tay Sachs disease (Ashkenazi Jewish 1/3,000) 
Spinal muscular atrophy (Black 1/2,000) 
Gaucher disease (Ashkenazi Jewish 1/1,600) 
Sickle cell anaemia (Black immigrants <1/10,000) 
Thalassaemia (Greek (β), Indian (α and β) >1/10,000) 
Porphyria (Afrikaans 3/1,000) 
Hypercholesterolemia (Afrikaans 10/1,000) 
 
Box 3.9 Clustered distribution of single gene disorders in GenTEE countries 
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Birth prevalence of selected common chromosomal disorders 
 
Most countries (Argentina, China, Egypt, India, Oman and South Africa) were 
able to provide national data based on regional studies on the prevalence of Down 
syndrome (Box 3.10). The highest prevalence at birth was found to be in Oman 
where 2.6 births with Down syndrome per 1,000 live births were reported from 2000 
to 2008. For this time period, the ascertainment of Down syndrome in the Sultanate 
was almost complete. In 90% of cases, the cytogenetic diagnosis was performed 
within 6 months after birth. Based on a case-control study, advanced maternal age 
was identified as a significant risk factor for Down syndrome. Some 40% of mothers 
giving birth to Down syndrome children in Oman are younger mothers. Thus over 
60% of infants with Down syndrome are born to mothers of advanced maternal age. 
Currently the high prevalence of Down syndrome is considered to reflect the longer 
reproductive period in older women due to limited use of family planning and birth 
spacing. Consanguineous marriages were higher among parents of Down syndrome 
children than in the Omani population in general. The identification of possible 
additional risk factors for Down syndrome in Oman is presently being studied.46 
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Country Disorder Birth prevalence (live births) 
  Argentina Down syndrome 1:510 
  China2 Down syndrome 1:550 
  Egypt3 Down syndrome 1:787 
  India4 Down syndrome 1:800 
  Oman5 Down syndrome 1:380 
  South Africa6 Down syndrome 1:525 
1 Campaña H, Pawluk MS, López Camelo JS (2010) ECLAMC Study Group. Birth prevalence of 27 selected congenital 
anomalies in 7 geographic regions of Argentina. Arch Arg Pediatr 108 (5):409-417. 
2 Zhu J (2011) Genetic counseling and birth defect prevention. Paper presented at the National conference on early 
pregnancy and prenatal screening and birth defect prevention, Kunming, Yunnan Province, China 
3 Ezzat S. El-Sobky and Solaf M. Elsayed (2004): Down syndrome in Egypt. The Egyptian Journal of Medical Human 
Genetics, Vol. 5, (2): 67-78. 
4 Data provided by Ishwar C. Verma, Centre of Medical Genetics, Sir Ganga Ram Hospital, Rajender Nagar, New Delhi, 
India. 
5 Rajab A, Patton M (2012): Genetic Diseases in the Sultanate of Oman. In: Genomics and Health in the Developing 
World. Oxford monographs on medical genetics by Dhavendra Kumar. Chapter 54, pp. 678-693. 
6 Kromberg J et al. (2012): Genetic services and testing in South Africa. Journal of Community Genetics. Online first 19 
June 2012. 
Box 3.10 Prevalence at birth of Down syndrome (GenTEE countries with best 
available national data) 
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Prevalence of “late-onset” disorders 
 
There are no data available on the prevalence of hereditary “late-onset disorders” in 
the GenTEE countries. Only Brazil was able to access estimates published in the 
official cancer report by the National MoH (2006)47, citing an estimate of 2,400 to 
4,800 new cases per year for hereditary breast cancer and 1,250 to 2,500 new cases 
per year of hereditary non-polyposis coli cancer. 
 
In conclusion 
 
All the GenTEE countries have limited available empirical epidemiological data. Several 
reasons underpin this problem including: 
 
 poor or absent congenital disorder surveillance,  
 lack of congenital disorder registries,  
 lack of clinical diagnostic capability of health care practitioners especially in 
primary healthcare where most of these children present,  
 home births,  
 lack of access to appropriate care and  
 underreporting. 
 
This will limit any middle- and low-income country’s ability to initiate and develop 
medical genetic services according to their health needs. Such data is essential to 
assessing those needs. The WHO recognized the inadequacy of epidemiological data in 
middle-and low-income countries, and its causes, as a barrier to developing medical 
genetic services in 1999. 48
, 49  It reiterated this in the recent World Health Assembly 
resolution A63.17 in May 201050 that prioritized services for the care and prevention of 
congenital disorders, particularly in middle- and low-income nations. It further 
recommended that countries take steps to remediate the problem. 
 
Acquiring such data in the short term will be difficult, time consuming and expensive. 
Some middle-and low-income countries may initially use modeled epidemiological data 
from the MoD Global Report on Birth Defects for health needs assessment for medical 
genetic services. Then part of the development of these services can be the acquisition 
of empirical epidemiological data. This approach was undertaken by the IR Iran in 
developing its medical genetic services.
51 
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IV Availability of genetic services 
 
Genetic service development 
 
All GenTEE countries have embarked on the initiation and development of genetic 
services. Most countries have begun this process with limited or no empirical national 
data on the epidemiology of congenital and genetic disorders. The concern is that 
informed service development may be hampered by the lack of data. 
 
“Early starters” like Argentina, Brazil, China and South Africa started genetic 
services in the 1950s and 1960s. Whereas the Philippines and Oman are relatively 
“late starters”, initiating services in the 1980s and 1990s respectively. In Egypt and 
India services started in the 1970s52. Regardless of the onset, the development of 
services was “champion driven” in each GenTEE country. This means developed 
initially by a few physicians, many of them trained abroad.  
 
Services in all countries were started at tertiary care institutions, mostly at 
university based hospitals and academic departments and accompanied by the 
introduction of laboratory services. 
 
The development of services was often funded by research means or donation 
funds (and were at that time free-of-charge to the patient) and depended on the 
priorities chosen by individual academics acting in their country as early 
innovators and driving forces. Thus at the onset genetic services development was 
fragmented, characterized by “enthusiasm based” decision-making by individuals or 
institutions, resulting in unplanned service “silo” development. 
 
Services are unregulated or regulations are often not enforced in some GenTEE 
countries as for instance in Argentina, “where DNA laboratories are certified by a 
state agency, participation in quality assessment programmes is voluntary and 
regulation very lax. Further, while in theory most of these laboratories must have in-
house and external quality control programmes, there is little government oversight 
on these issues.”53 (Part 6) 
 
In some GenTEE countries, for instance in the Philippines, genetic service 
development slowed down markedly when champions retired or died. 
 
The diffusion of services into secondary and primary care has been top-down 
and dependent on the health care systems willingness to fund the necessary 
infrastructure and to pay for services. Thus in all the countries these services are 
limited, often resulting in fragmented public services. 
                                                        
52
 First department of medical genetics established in India in Pune in 1972. 
53
 Penchaszadeh VB, Aguiar MJB. (2009). Regulatory Issues in Clinical and Laboratory Genetics in Developing 
Countries. Examples from Latin America. In: Quality Issues in clinical genetic services. Eds Kristoffersson U, 
Cassiman JJ, Schmidtke J. Heidelberg: Springer Verlag, 2009. 
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In all countries the need for integrating genetic services into the public health care 
sector or strengthening public health care services was or still is not regarded as a 
health priority, resulting in understaffed, underfunded and fragmented services in 
the public health sector and the lack of basic infrastructure facilities in peri-
urban and rural areas. However, recently some countries such as Argentina and 
Oman have started to implement national programmes in order to strengthen genetic 
services in the public health sector (Box 4.1). 
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Box 4.1 National policies to strengthen genetic services in GenTEE countries 
 
In 1999 and the 2000s six out of eight GenTEE countries started to develop national policies to 
strengthen their genetic service infrastructure: 
 
In 1999, the MoH in Oman developed a “National Programme for the Control of Genetic Blood 
Disorders” based on a community genetic model for controlling haemoglobin disorders by offering 
screening and counselling. 
Since 2005, Oman has embarked on a systematic planned national development of genetic services 
outlined in the MoH’s 5-year-plans. 
 
In 2001, the National DoH in South Africa published “Policy Guidelines for the Management and 
Prevention of Genetic Disorders, Birth Defects and Disabilities”. The document provides 
recommendations for the integration of genetic services in South Africa. However, the effects on the 
health services imposed by the HIV/AIDS pandemic and other problems have severely limited the 
implementation of these guidelines.1 
 
In 2002, the Egyptian MoH&P established a national committee for community genetics leading to the 
development of 11 genetic counselling clinics in different Egyptian governorates. 
 
In 2006, Argentina appointed a national commission on genetic health services that has formulated a 
plan for strengthening genetic services in the public sector which was adapted by the National MoH as 
a national policy for strengthening the network of genetic services in the public sector and for 
supporting training activities in medical genetics addressed to primary health professionals in 
disadvantaged areas of the country. Recently, following the EU funded CAPABILITY project (2007-
2009), special initiatives by national and provincial ministries of health have been started to improve 
genetic service delivery by increasing coordination and regionalization. 
 
In 2009, the Brazilian National MoH published a decree which proposes the creation of a “Política 
Nacional de Atenção Integral em Genética Clinica no SUS” (National Policy for Comprehensive Care in 
Clinical Genetics at SUS). However, the decree is still awaiting implementation. 
 
In 2010, the government of India established a National Institute of Biomedical Genomics in Kalyani, 
West Bengal.2 This institute is likely to fill up the gaps in data on genetic disorders that exist at present. 
In February 2013, the National Rural Health Mission of the Ministry of Health and Family Welfare 
(MoHFW) launched a new initiative of Child Health Screening and Early Intervention Services to provide 
comprehensive screening and care to all children. The purpose of these services is to improve the 
overall quality of life of children through early detection of congenital disorders, diseases, deficiencies, 
development delays including disability. A set of thirty common conditions has been identified for 
screening and further management. An estimated 270 million children in the age group of 0-18 years 
are expected to be covered in a phased manner. Early intervention centres will be set up in all districts 
providing management for referred cases and will also link these cases with tertiary level health 
services in case of surgical management.3,4 
_________________ 
1 www.doh.gov.za/docs/policy/humangenetics.pdf (accessed May 16, 2013) 
2 www.nibmg.ac.in (accessed May 16, 2013) 
3 http://www.newswala.com/Health-News/Launch-of-National-programme-for-Universal-Screening-of-Children-29206.html 
(accessed May 16, 2013) 
4 Ministry of Health and Family Welfare: Rashtriya Bal Swasthya karyakram launched - country’s future depends on children’s 
health. February 6, 2013. Online available at http://pib.nic.in/newsite/erelease.aspx?relid=92045 (accessed April 9, 2013) 
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Private sector development 
 
Congenital and genetic disorders have not yet been recognized as a health priority 
by national health policy makers in any of the GenTEE countries. Due to this neglect, 
the private sector in several countries has stepped in during the last decade and 
increasingly provides genetic services not available in the public sector, and services 
covered or not covered by private health insurance or services for which long waiting 
times exist in the public health care sector. 
 
The development of services in the private sector is opportunistic and mostly 
technology and market driven. Oft times testing services in the private sector are 
more or less unregulated and are offered regardless of their proven clinical validity or 
utility. Out-of-pocket expenses for services provided either by the commercial health 
sector (Argentina, Brazil, Egypt, India, the Philippines, South Africa) or by 
government-owned services (such as China where for instance all genetic molecular 
tests provided by regional government owned secondary and tertiary care hospitals 
have to be paid for out-of-pocket) tend to be the norm for genetic services in most 
GenTEE countries, except in Oman where genetic services provided by the 
government are free for Omani nationals. However, in Oman, being a late starter in 
the development of genetic services, its scope of currently available services is 
limited but steadily increasing. 
 
 
Political and cultural influences on genetic service development 
 
Although being “early starters” the development of genetic services was halted in 
Argentina and China by political developments. Many geneticists left Argentina in 
the mid-seventies because of the military dictatorship and in China, when medical 
schools and universities were closed for 5 years, during the “Great Cultural 
Revolution” genetic services were suspended. In South Africa the further 
development of genetic services was halted in the late 2000s by the consequences 
of the HIV/AIDS epidemic. 
 
Cultural traditions and population policies also shaped the development of services. 
In India and especially in China (due to the Chinese one child policy implemented in 
1979), the establishment of PND services and related cytogenetic laboratories paved 
the way for implementing and diffusing genetic services into secondary and primary 
care. This development was supported by the willingness of the population to pay 
out-of-pocket for PND services.54 
 
                                                        
54
 In China, PND services are affordable to many Chinese couples because „6 persons (4 grandparents, 2 
parents) cover the cost for one child” (personal communication N. Zhong, Director, Peking University Center of 
Medical Genetics, Peking University Health Science Center, Beijing, P. R. China) 
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In countries with a strong Catholic tradition, such as Argentina, Brazil and the 
Philippines, where termination of pregnancy after a positive PND result is not legally 
permitted, the availability of PND and PGD services is very limited in the public 
sector. However, in these countries the private sector often steps in and offers 
services that are not funded by the state or by insurances and also provides services 
that are not strictly legal (see “Availability of key genetic services”). 
 
In Muslim countries like Oman and Egypt the relative high frequency of rare single 
gene disorders due to consanguineous marriages, tribal structures of the rural 
population and the high prevalence of haemoglobin disorders furthered the 
development of genetic services including counselling services and establishment of 
hospital-based data registries.  
 
Oman responded so far to this marriage pattern, deeply rooted in its culture, by 
offering voluntary premarital counselling and premarital screening services for 
haemoglobin disorders with current 10% uptake. 
In 1999 the “National Programme for the Control of Genetic Blood Disorders” was 
established as a community genetic programme. It operates in all regions through 
regional teams providing care, high-risk population screening, premarital counselling 
and education (primarily for haemoglobin disorders). 
 
In a recent population based survey on morbidity and mortality, funded by the Oman 
Research Council (TRC), the percentage of consanguinity (including first 
cousin/second cousin marriages) was 40.4%. When marriages among more distant 
relatives (marriages within same tribe) were included, consanguinity was well over 
50% (53.1%) (Figure 4.1). 
 
Figure 4.1 Consanguinity in Oman 
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In Egypt a recent hospital-based study showed that among those cases diagnosed 
with congenital or genetic disorders the overall parental consanguinity rate was 
55%.55 
 
In south India Hindus practice consanguinity (30 to 36 %), with preferred marriage 
being between uncle-niece. However in the rest of India the Hindus do not marry 
consanguineously. Whereas Muslims throughout India marry consanguineously. A 
multinational study of over 600,000 pregnancies and live births, in which 10 of the 38 
populations studied were from India and nine were from Pakistan). The analysis 
showed that, from approximately the sixth month of pregnancy to a median age of 10 
years, deaths in first-cousin progeny exceeded mortality in nonconsanguineous 
progeny by an average of 44/1000 births.56,57 
 
Milestones in genetic service development in GenTEE countries 
 
Table 4.1 provides a condensed overview of the service development during the last 
60+ years. Service development in GenTEE countries is accompanied by 
 
 professionalization of genetics through the establishment of professional 
bodies and scientific societies’ development of qualification standards; 
 
 recognition of medical genetics as a medical specialty in seven out of eight 
countries; 
 
 increasing number of genetic units and available testing services primarily in 
the private sector or at tertiary care level; 
 
 development of national policies for strengthening genetic services in the 
public domain in five (Argentina, Brazil, Egypt, Oman and South Africa) out 
of eight countries (however, policies not yet implemented in Brazil or severely 
limited in South Africa). 
 
                                                        
55
 Afifi HH et al.: The most encountered groups of genetic disorders in Giza Governorate, Egypt. Bratisl Lek Listy 
2010; 111 (2), 62-69. 
56
 Bittles AH. The impact of consangunity on the Indian population. Indian J Human Genet 2002; 8:45-51. 
57
 Bittles AH. and Neel JV. 1994 The costs of human inbreeding and their implications for variations at the DNA 
level. Nature Genet. 8, 117–121. 
 
Table 4.1  Milestones in genetic service development in GenTEE countries 
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Availability of key genetic services 
 
Availability of PGD and PND services and follow-up services 
 
Figure 4.2 Availability of PGD and PND services and follow-up services (2011) 
 
 
 
 
In Argentina, reproductive genetic service and MToP are not available in the public 
domain due to the illegality of abortion. This legal restriction has prevented the 
development of PND, PGD and MToP services in the Argentinian public domain. 
However, PND and MToP are widely practiced in the private sector and seem to be 
“tolerated” by the system (Figure 4.2).  
 
In Brazil – although abortion is illegal – court orders allow MToP in cases of severe 
congenital malformations58, in particular if incompatible with life. PND services for 
monitoring pregnancies at risk have been established in some public settings. 
However, PND is most easily accessible in the private sector in Brazil where PGD is 
available as well. 
 
In China and India, prenatal genetic diagnosis paved the way for genetic service 
development. The geographical distribution of PND centres in China shows a distinct 
pattern (Figure 4.3). PND services diffused into secondary and tertiary care services 
and are more widespread than other medical genetic testing services. PND services 
cluster in the more affluent eastern and southern-eastern regions of China. In the 
poorer western and northern region, less medical genetic services are available. But 
if services are available they tend to be PND services. 
                                                        
58
 In cases of anencephaly there is now a decision from the supreme court allowing pregnancy termination. 
(Horovitz D et al (2012) Genetic services and testing in Brazil. J Community Genet. Online available at 
http://link.springer.com/content/pdf/10.1007%2Fs12687-012-0096-y (accessed February 15, 2013) 
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Figure 4.3 The geographical location of medical genetic centres and PND centres in 
China 
 
Overview provided by Zhong N, Zhao X: Peking University Center of Medical Genetics, Beijing, People’s Republic 
of China. 
 
 
In India, PND is available in all care settings and India is the only GenTEE country 
where PND services are also provided by non-governmental organisations (NGOs).  
 
The Philippines is the only country where MToP services are not provided not even 
by the private sector. 
 
In all countries with PGD services, PGD services are only available in the private 
sector or, as in China, PGD is provided by “entrepreneurial” hospitals owned by the 
government/regions and has to be paid for out-of-pocket.  
 
In Oman, PGD is in the first stages of development. 
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Availability of newborn screening services 
 
Mandatory national newborn screening programmes have been implemented in all 
but one GenTEE country (Figure 4.4). South Africa still has no national newborn 
screening programme and all newborn screening tests in South Africa have to be 
purchased in the private sector. 
In India newborn screening is being provided by a number of government hospitals 
as well as private hospitals and stand-alone laboratories. The state of Goa has had a 
newborn screening in all the government hospitals for three years. In Gujarat 
newborn screening has recently been started in some government hospitals. 
Newborn screening for SCD has been initiated in Gujarat, Chattisgarh and 
Maharashtra both in tribal and non-tribal groups. A cohort of affected babies is 
followed up regularly and given early intervention care. The newborn screening 
programme has resulted in greater risk awareness among the parents of 
homozygous babies who are opting for PND in subsequent pregnancies. 
China and India are the only GenTEE countries where NGOs provide newborn 
screening services in some areas. This is an indicator that they are covering service 
needs not provided by the state. 
 
 
Figure 4.4 Availability of newborn screening services (2011) 
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Country Biotin. CAH CF CH Chaga
s 
Congenital Congenital Galactosemia G6PD PKU Retinopathy SCA Thal. 
 Def.     deafness syphilis    (preterm)   
Argentina              
Brazil 
 
  2 3        
4  
China
5
         
6    
5 
Egypt
7
              
India9      8
 
 
  
10  
Oman              
Philippines        
 
    
 
Abbrevations: 
Biotin Def. Biotin Deficiency 
CAH  Congenital adrenal hyperplasia 
CF  Cystic fibrosis 
CH  Congenital hypothyroidism 
G6PD Glucose-6-Phosphate Dehydrogenase deficiency 
PKU  Phenylketonuria 
SCA  Sickle cell anaemia  
Thal.  Thalassaemia 
 
_______________________________ 
1 No national/regional newborn screening programme available in South Africa. 
2 CF is only screened for in 3 states 
3 CH is only screened for in 27 states 
4 SCA is only screened for in 14 states 
5 Not available in Tibet. 
6 Screened for in southern China 
7 Newborn screening for PKU and Galactosemia are still in pilot testing phase 
8 High risk newborns 
9 For Biotin deficiency, cystic fibrosis, galactosemia and PKU available in private hospitals, and on demand in commercial sector. 
10 In Gujarat, Chattisgarh and Maharashtra both in tribal and non-tribal groups. 
However, the scope of disorders covered by national screening programmes differs 
substantially among countries and within countries (especially in Brazil, China; 
Table 4.2). Argentina’s programme covers 10 disorders whereas the Omani 
programme, so far, covers only one disorder. 
In the Philippines there are plans to expand newborn screening by 2013. Coverage 
will extend from 5 disorders to more than 20 disorders, including haemoglobin 
disorders, amino acid disorders, organic acid disorders, and endocrine disorders. 
 
Table 4.2 Disorders for which newborns are screened in GenTEE countries59 by 
national programmes (2011) 
 
 
 
 
 
 
                                                        
59
 No national/regional newborn screening programme available in South Africa. 
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Coverage of national newborn screening programmes differs also between urban 
and rural areas. For instance, in Argentina, in one third of jurisdictions providing 
newborn screening, coverage is less than 50%.60 The highest coverage (close to 
100%) occurs in the City of Buenos Aires. 
 
In China, the national wide newborn screening programme covers more than 90% of 
the newborn population in the affluent eastern provinces, falls well below 30% in the 
western provinces and is not available in Tibet. The national coverage in 2007 was 
40%.61 
 
In Egypt, where newborn screening for CH was implemented as a preventive public 
health programme in 2000, screening for CH is available in all 29 governorates 
(>90% coverage). 
 
In India many hospitals provide newborn screening for hypothyroidism, CAH and 
G6PD deficiency, while some hospitals provide further tests using tandem mass 
spectrometry (TANDEM MS). Screening for biotinidase deficiency, galactosemia, 
PKU and CF are available in commercial laboratories.  
 
The mandatory national newborn screening programme in the Philippines started in 
2004 with the “Newborn Screening Act”. Based on this act, newborn screening 
evolved from 24 hospitals in 1996 to more than 3000 newborn screening facilities 
today being available throughout the country. As of the end of 2011 newborn 
screening had an overall coverage of 42%. 
 
In most GenTEE countries with mandatory screening programmes, the private sector 
offers screening for additional disorders. 
 
Availability of genetic screening62 and carrier testing services63 
 
It is mainly the Catholic GenTEE countries that do not have genetic screening and 
carrier testing. 
Genetic screening tests are not available in Argentina, Brazil and the Philippines. 
Carrier testing is not available in Argentina and the Philippines.  
 
                                                        
60
 Argentina, 2009b. Ministerio de Salud, Departamento de Estadística e Información de Salud. Online available 
at http://www.deis.gov.ar/ (accessed May 16, 2013) 
61
 Zhong N: Clinical Genetics in China: Genetic Disorders and Current Status. 2007, presentation available at 
www.capabilitynet.eu (accessed May 16, 2013) 
62
 Newborn screening not included.,Screening is defined in the survey as a test that is systematically offered to 
the general population or part of it 
63
 Heterozygote carrier for a autosomal-recessive condition 
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Figure 4.5 Availability of genetic screening and carrier testing services (2011) 
 
 
In the Philippines, most of the country’s peoples are Roman Catholics, Protestants 
or Muslims, and in the Philippines, all these religions oppose abortion for any 
purpose. 
 
Brazil does not have genetic screening, however carrier testing is available in the 
private sector. 
 
Conditions screened for: 
 
In Brazil, carrier screening is not performed on a population basis, but on a one on 
one basis, usually in the private sector when requested by the family or carrier. 
Carrier screening is performed in research projects linked to a specific disorders (e.g. 
in the region of Bahia for mucopolysaccharidosis VI cluster). 
 
In India genetic screening services as well as carrier testing are available on request 
in the government hospitals, the commercial and private sector as well as not-for 
profit hospitals. Large scale screening for thalassaemia and SCD has been carried 
out in Gujarat by the Indian Red Cross Society from 2004 to 2010. 64  An ICMR 
initiated project has been completed in six cities with a high prevalence of 
haemoglobinopathies in six different states screening pregnant women and school 
children. 65 , 66  Although useful lessons how to implement carrier screening 
                                                        
64
 Indian Red Cross Society (IRCS), Gujarat State Branch. Annual Report 2009-2010. Ahmedabad; IRCS, Gujarat 
State Branch, 2010. 
65
 Colah R, Surve R, Wadia M, Solanki P, Mayekar P, Thomas M et al.: Carrier screening for beta-thalassemia 
during pregnancy in India: a 7-year evaluation. Genet Test 2008; 12 : 181-5. 
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programmes have been learned from these studies, a coordinated national 
thalassaemia prevention programme has not yet been established in India. However, 
plans are currently afoot to start screening and control programmes for thalassaemia 
in the high risk states including Delhi, Chandigarh and Mumbai67 (see also Box 3.6 
above). 
 
In Oman: SCD, ß-thalassaemia and G6PD deficiency are screened for in the 
population. In the next 5-year plan it is expected that genetic screening will be 
introduced for more autosomal recessive disorders. 
 
In South Africa: In the private sector newborn screening is available and carrier 
screening for CF. In the tertiary health care sector there is carrier screening for 
individuals on request for numerous recessive disorders tested in the public health 
sector laboratory (includes CF, ß-thalassaemia, sickle cell anaemia, SMA etc.). 
Genetic screening for the Ashkenazi Jewish population (Tay-Sachs, CF, Canavan 
disease, FA, familial dysautonia, Niemann-Pick disease, Glycogen storage disease 
type 1a, Bloom syndrome, and mucolipidosis IV). Gaucher disease screening is 
available on request. 
 
 
                                                                                                                                                                             
66
 Mohanty D, Colah R, Gorakshakar. Jai Vigyan S & T Mission Project on community control of thalassemia 
syndromes – Awareness, screening, genetic counselig and prevention. New Delhi: Indian Council of Medical 
Research; 2008. 
67
 Verma IC, Saxena R, Kohli S: Past, present & future scenario of thalassaemic care & control in India. Indian J 
Med Res 134, October 2011, pp. 507-521. 
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Availability of genetic testing services68 
 
In all GenTEE countries molecular diagnostic testing is available at the tertiary care 
level (mostly university based). University based services are depending in part on 
research funds (especially in Brazil, China and Egypt) and may be free of charge 
and are limited by the availability of these funds. 
 
In India molecular genetic testing is established and available for a large number of 
disorders varying from thalassaemia, Duchenne muscular dystrophy (DMD), SMA, 
fragile X syndrome, albinism, deafness, Wilson disease, Huntington disease (HD) 
and spinocerebellar ataxia and others. Many government sector laboratories offer 
molecular testing at subsidized rates. Laboratories in private institutions extend the 
range of disorders for which molecular testing is provided. Next generation 
sequencing (NGS) is available in a limited number of laboratories. Microarray 
analysis for cytogenetic studies are increasingly being used, being provided by 
several private laboratories and some government institutions. 69  A website 
(geneticsindia.org)70 lists the genetic tests and services that are currently available in 
various laboratories in India. The Indian Genetic Disease Database (IGDD) lists 
mutations observed in various genetic disorders.71 
 
Figure 4.6 shows that genetic testing services are mainly available in the tertiary 
health care sector and the private sector. In China, Egypt and India NGOs are 
offering testing services in order to facilitate access to diagnostic testing services in 
many underserved areas. 
                                                        
68
 Diagnostic testing in a symptomatic individual to confirm or exclude a genetic condition 
69
 In India there are many cytogenetic testing laboratories country-wide, in secondary and tertiary care settings, 
and in government and the private sector. Many of them also provide PND, FISH studies and QF PCR analysis. 
70
 http://www.geneticsindia.org/ (accessed April 12, 2013) 
71
 http://www.igdd.iicb.res.in/IGDD/home.aspx (accessed April 10, 2013) 
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Figure 4.6 Availability of molecular genetic testing services (2011) 
 
 
 
In Oman molecular diagnostic testing is provided free of charge by the MoH for: 
SCD, α-thalassaemia and ß-thalassaemia. Genetic tests for haematological cancer 
patients with tumour markers and minimal residual disease diagnostics are provided 
by the MoH’s genetic laboratories. 
 
In all GenTEE countries the basic testing required to diagnose congenital and genetic 
disorders, chromosomal analysis, including FISH, and molecular diagnostic 
technology are available. Except for Oman and the Philippines this includes the 
ability to undertake predictive testing for late-onset monogenic disorders. Newer 
molecular genetic technologies such as microarray and NGS have been introduced 
for diagnostic service purposes in four countries (Brazil, China, India and Oman, 
Table 6.3, “Availability of different genetic testing techniques in GenTEE countries”). 
 
Pharmacogenetic testing has been introduced in all countries except the 
Philippines. 
 
 
 
 
 
 
 
 
 
Molecular diagnostic testing for infectious diseases 
Molecular diagnostic testing for infectious diseases is available in all the countries. This 
underlines the recognition and acceptance by the GenTEE countries of molecular 
genetic diagnostic testing in disciplines outside medical genetics. 
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Availability of genetic counselling services 
 
Genetic counselling services have been established in all GenTEE countries (Figure 
4.7). 
 
Figure 4.7 Availability of genetic counselling services (2011) 
 
 
However, in the Philippines and South Africa genetic counselling services are 
exclusively available in tertiary care settings and in the private sector. This means 
that patients either need to travel to (mostly university based) urban counselling 
centres or must have the means to purchase genetic counselling in the private 
sector. Only three countries (Brazil, China and Oman) provide counselling services 
at primary care level. However, in Brazil and China these services are only available 
in some regions and are not ubiquitous. 
 
In four countries (Brazil, China, Egypt and India), NGOs provide genetic counselling 
services in some areas, indicating that they are covering counselling needs that are 
not met otherwise in these countries. In Brazil, counselling provided by NGOs will 
only relate to a specific disease such as SCD. Usually in Brazil genetic counselling is 
performed by physicians in secondary or tertiary care settings. 
 
Egypt (Box 4.2) and Oman have started to develop community genetic services 
based on counselling centres at primary, secondary and tertiary care. 
 
In India, genetic services were first established in Delhi, Pune, Hyderabad, Mumbai 
and Lucknow and included genetic counselling. When more genetic centres were set 
up in Bangalore, Chennai, Amritsar and other cities, they included genetic 
 51 
counselling services as well. More recently the requirement for genetic counselling 
centres has been felt in the private sector, and a number of services have been set 
up in corporate hospitals.72,73 
 
In South Africa in the 1990s an ambitious approach trying to offer medical genetic 
services including counselling services to the public through primary care was 
pioneered and policy guidelines established. However, implementing the guidelines 
and establishing a primary care counselling infrastructure was thwarted by the 
HIV/AIDS epidemic which forced the National Department of Health (DoH) to shift 
priorities. 
 
 
 
 
 
                                                        
72
 Puri RD, Verma IC. Genetic services in India : A model for developing countries. In “Genomics and Health in 
the Developing World.’ Edited by Kumar D. Oxford University Press, Oxford. 2012. pp 927-35. 
73
 For profit proprietary hospitals in India generally owned by a corporate system. 
Box 4.2 Development of counselling services: Egypt (2012) 
 
In 2002 a national committee for community genetic services was established by the Egyptian 
government. Its main objective was to develop policy guidelines for the prevention and 
management of genetic disorders. The committee recommended the necessary establishment 
of a national programme for genetic services delivery. At the end of 2002 the Minister of Health 
responded to the request of the committee and signed an approval on a proposal presented by 
the MoH&P’s Children with Special Needs Department that included an action plan and time 
frame for the implementation of a genetic counselling programme. The programme started 5 
years ago with the establishment of one counselling clinic in Giza governorate. 
 
Today (2012) there are 11 counselling clinics in different governorates in Egypt. 
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Availability of genetic testing services and follow-up services in urban/rural 
areas 
 
Overall genetic testing services in the GenTEE countries are predominantly available 
in urban areas (Figure 4.8). In South Africa, genetic services are exclusively 
available in urban areas. The current situation in South Africa is that most genetic 
services are either provided at urban tertiary care institutions, mostly universities, or 
in the private sector services that cater for the affluent urban upper middle and upper 
classes.  
Figure 4.8 clearly indicates that the rural population is underserviced in most 
GenTEE countries and demonstrates the lack of basic infrastructure facilities in rural 
areas. In countries with national newborn screening programmes, services are also 
available in rural areas – however, coverage rates may differ between urban and 
rural areas. China and India are the only countries where MToP services are 
available in rural areas indicating the importance that is ascribed to PND services in 
these countries and the common practice of selective abortion. 
In India private laboratories have extended the availability of genetic testing services, 
by appointing agents who collect the appropriate samples and send them onwards to 
the central laboratory for analysis. The expense for the service is borne by the 
patient. 
 
Figure 4.8 Availability of genetic testing services and follow-up services in 
urban/rural areas (2011) 
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The geographical distribution of genetic services in Brazil (Figure 4.9) illustrates the 
disparities in the provision of services between urban and rural areas and between 
south, the eastern and north and western states. The majority of medical genetic 
services in Brazil are located in the south-east or in state capitals, the state of São 
Paulo being a noticeable exception, with services also available in the interior of the 
state. There are no genetic services in the states of Amazonas, Amapá, Roraima, 
Rondônia and Tocantins. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Clinical care facilities in genetics 
 Outpatient consultations in clinical genetics 
 
Overview provided by Dafne Horovitz, Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente 
Fernandes Figueira/Fundação Oswaldo Cruz, Rio de Janeiro, Brazil. 
 
 
 
 
 
 
 
 
 
Availability of genetic services at different care levels 
Genetic services in all GenTEE countries are dominantly available at tertiary care level 
and/or in private sector services concentrated in main cities. Oman provides 
community genetic services available in rural areas providing genetic screening and 
carrier testing services and genetic counselling primarily for haemoglobin disorders. 
 
 
Figure 4.9 Geographical distribution of medical genetic services in Brazil (2010) 
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Patients or samples sent abroad/purchase of genetic testing services from 
abroad/provision of genetic testing services for foreign countries 
 
The increasing trend of genetic tests crossing national boundaries can also be 
observed in GenTEE countries (Figure 4.10). 
 
Purchasing genetic testing services from abroad – private sector dominated 
 
Genetic services are not purchased from abroad by the public sector in most 
GenTEE countries (Figure 4.10). Only the Oman national health service purchases 
DNA based testing and biochemical testing services for mutation analysis for SMA, 
osteopetrosis, athrogryposis and TANDEM MS 74  screening for inborn errors of 
metabolism. This is changing as diagnostic capability increases in Oman. 
 
 
Figure 4.10 Patients or samples sent abroad/purchase of genetic testing services from 
abroad/provision of genetic testing services for foreign countries (2011) 
 
 
It is the private sector in most GenTEE countries (Argentina, Egypt, India75, the 
Philippines, South Africa) that drives the trend to purchase testing services from 
abroad (Box 4.3, “Purchasing genetic testing services from abroad – the examples of 
Egypt and the Philippines”). 
In China and Egypt it is forbidden to send samples abroad for testing, exemptions 
need official approval from the government (Box 4.3).  
                                                        
74
 In Oman neonatal screening with Tandem MS is available in Sultan Qaboos University Hospital. Other tertiary 
hospitals purchase diagnostic services abroad. 
75
 For molecular or biochemical tests not available in India, samples are sent abroad. For example, biochemical 
tests for diagnosis and prenatal diagnosis of Maple Syrup Urine disorder and some other biochemical disorders 
as well as molecular diagnosis of many diverse disorders. 
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The scope of testing services regularly obtained from abroad by the private sector in 
the Philippines exemplifies the extent to which the private sector uses the 
availability of overseas services. These services, which are easily accessible and 
increasingly becoming more competitively priced, are used to test for disorders that 
are not tested for within the country, thereby increasing the range of tests available. 
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Box 4.3 Purchasing genetic testing services from abroad – the examples of Egypt 
and the Philippines (2012) 
 
Egypt 
At a public authority level it is forbidden to send any human biological specimen abroad. It can be done 
sometimes for research purposes (with many restrictions) and for quality control. However, many private 
hospitals and laboratories send samples abroad for testing after getting official permission and obtaining the 
consent of the parents or patients for the following conditions: extended screening of newborns who were born 
in a private hospital, laboratory diagnostic and follow-up tests for metabolic conditions, chromosomal and 
genetic disorders, molecular testing for genetic disorders and diagnosis and predictive testing for some chronic 
illnesses including cancer. The most renowned external laboratory that private laboratories and hospitals 
regularly purchase genetic testing from is Bioscientia/Germany. 
 
 
The Philippines 
The private sector sends samples abroad for molecular, biochemical and cytogenetic testing for: 
 
Molecular Genetics       Cytogenetics 
α-thalassaemia carrier testing       CGH-array 
Ataxia w/ oculomotor apraxia       M-FISH 
Bullous Congenital         Microarray cytogenetics 
Ichthyosiform Erythroderma 
Congenital Lipodystrophy 
Cornelia de Lange Syndrome 
Cystic Fibrosis  
Fragile X carrier 
Fragile X  
Freeman-Sheldon Syndrome  
Gaucher disease   
Glycogen Storage Disease  
Goltz Syndrome 
PORCN gene analysis   
Hereditary Spastic Parapesis   
Holoprosencephaly   
Huntington Disease 
Hypercoagulable state   
Lynch Syndrome   
mtDNA disorder   
Neonatal Diabetes 
Leber's Hereditary Optic Neuropathy (LHON)  
Pompe disease   
Progeria    
Rett Syndrome    
XDP      
XSCID 
   
Biochemical Genetics 
Acylcarnitine and Amino Acid Profile (Expanded Newborn Screening) by Tandem Mass Spectrometry, 
Acylcarnitine Profile for Fatty-Acid Oxidation Defects, 
Amino Acid Quantification Analysis, 
Biotinidase Screening, 
7-Dehydrocholesterol Analysis, 
Lysosomal Enzyme Assay, 
DNA analysis of 6-Pyruvoyl Tetrahydropterin Synthase Deficient, 
Hyperphenylalaninemia and Urine Pterins, 
Transferrin Isoforms, 
Phytanic Analysis, 
Plasmalogen Analysis, 
Very-Long Chain Fatty Acid for Peroxisomal Disorders, 
Enzyme Assays for Lysosomal Storage Disorders [i.e. Gaucher’s Disease, Niemann-Pick Disease, Pompe’s Disease, Mucopolysaccharidosis 
(MPS) Enzyme Assay with Glycosaminoglycan (GAG) Screening]. 
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Affluent patients who can afford the expense of travelling abroad to obtain genetic 
tests not available in their home countries are referred to other (mostly Western) 
countries for genetic testing services (e.g. PGD).  
 
In Oman, patients may be referred by the Oman national health services for PND 
services not available in the country. The national “Treatment Abroad Expert 
Committee” makes decisions on funding treatments and tests abroad for nationals in 
cases where such treatments and tests are unavailable locally. 
 
 
 
 
 
 
 
 
Testing for rare disorders76 
 
Testing for rare disorders meets specific problems all over the world and no country 
is able to provide genetic testing for all such conditions. In the GenTEE countries 
testing for rare disorders is often only available from specialist research laboratories 
abroad and often the international community of senior scientists collaborates to 
provide the test and covers costs through research funds. 
 
Providing testing services for other countries 
 
Private laboratories in Brazil, China, Egypt, India and South Africa are providing 
services for other countries, mostly for neighbouring countries with a less developed 
testing service infrastructure. India manufactures some kits for molecular testing and 
exports them. 
Palau uses the national newborn screening programme in the Philippines. 
 
 
                                                        
76
 Rare disorders are defined by the Council of the European Union as affecting no more than 5 per 10000 
persons. „It is estimated that between 5 000 and 8 000 distinct rare diseases exist today, affecting between 6 % 
and 8 % of the population in the course of their lives.“ (Official Journal of the European Union: Council 
Recommendation of 8 June 2009 on an action in the field of rare diseases (2009/C 151/02). Available at 
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2009:151:0007:0010:EN:PDF (accessed July 11, 
2012) 
Purchasing genetic testing from abroad 
Although the private sector contributes to the global movement of patient samples in 
GenTEE countries and helps affluent patients to gain access to testing services, the 
quality of services received by affluent patients from abroad may be impaired due to 
the lack of consistent enforcement of quality controls in the private sector. 
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Availability of national/regional preconception care programmes 
 
Preconception care services available in the GenTEE countries are limited and are 
mainly community based services (Figure 4.11). Family planning is available in all 
the GenTEE countries. Folic acid fortification of staple foods is available in 6 
countries (Egypt and the Philippines excluded) and iodised salt is available in all 
countries. 
There is limited availability of iron (Argentina, Oman, the Philippines) and vitamin A 
(Oman, the Philippines, South Africa) food fortification. In India iodinisation of salt 
is mandatory and an ambitious programme has begun to administer iron and folic 
acid twice weekly to adolescent girls. Education regarding the adverse effects of 
alcohol and tobacco is limited to Argentina, Brazil, India and the Philippines. 
Notably, South Africa, with the highest documented community based birth 
prevalence of Foetal Alcohol syndrome has no universal education regarding alcohol. 
Rubella vaccination is not available in China and South Africa whereas in Oman 
vaccination coverage for measles and rubella is over 95%. Preconception care 
services for individuals, limited to the services described for public and private 
services for genetic counselling are available in India, Oman and South Africa. 
 
 
Figure 4.11 Availability of preconception care (2011) 
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V Access to genetic services 
 
Genetic services are highly inequitable in most GenTEE countries. The 
accessibility of available genetic services is compromised due to a number of inter-
related barriers. 
 
Cost and reimbursement systems for key genetic services 
 
Coverage of genetic services by the public health care system or by compulsory 
social insurance or by private insurance is limited or often not available in GenTEE 
countries.  
 
In Argentina, patients with genetic disorders find it very difficult to get insurance 
coverage for their conditions and usually have to go to court to obtain it.  
In India both social and private insurances usually deny coverage of genetic 
services on the grounds of “pre-existing condition”. 
 
In Brazil, the majority of the population is served by the public Unified Health System 
(“Sistema Único de Saúde” or SUS) which proposes to ensure full, universal and free 
of charge medical access for the entire Brazilian population. However, genetic tests 
are often not available within the public health system due to insufficient number of 
services and scarce funding. For those who have private insurance it has 
become progressively easier to have genetic testing covered. 
 
In China, public hospitals provide most health care services which can be directly 
accessed by patients who know their way into the system.77 Government-owned 
hospitals form the backbone of the health care system and account for most of the 
provision of health care services. With the start of economic reforms in China in 
1978, the financial responsibility for providing health care services was decentralized. 
The responsibility for the provision of health care services shifted from the central 
national government to the local governments resulting in sharp inequalities between 
affluent urban areas and regions and poor rural areas/regions. Reducing government 
financial support meant that the government-owned providers in the health sector 
were forced to earn profit. Ownership of health services remained public but financing 
was gradually privatized, forcing health care facilities to rely more on the sale of 
profitable services. As a consequence, by the economic reforms government 
financial support was replaced by out-of-pocket spending (see also Table 1.2) and 
public hospitals came to function more like for-profit services 78 . There is 
comparatively little development of private hospitals and private hospitals are 
relatively rare.79 However, backed by Western capital in the mid-2000s a private 
                                                        
77
 there are no GPs acting as gate keepers 
78
 Blumenthal D and Hsiao W (2005): Privatization and Its Discontents — The Evolving Chinese 
Health Care System, New England Journal of Medicine 353;11, page 1166. 
79
 „Currently, private hospitals are relatively rare, and private health care as an important component of the health 
care system in China has received little policy attention.“ (Huang C. et al: The Emerging Role of Private Health 
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medical sector has emerged to provide special services mainly in the Beijing, 
Shanghai and Guangzhou area. Health insurance coverage introduced in the 1990s 
has increased during the last decade. In 2005, 29% of the Chinese population were 
covered by a health insurance.80 Since 2009, the Chinese central government has 
embarked on plans to provide universal coverage to all urban and rural residents by 
2020. 81  Genetic counselling, prenatal screening, ultrasound examination, 
karyotyping, biochemical tests and treatment for congenital disorders may be to a 
certain extent covered by insurance. However, most cytogenetic tests are not 
covered in China. Molecular genetic tests are new to the insurance authority 
and thus are exclusive. Overall in China personal affluence is a critical predictor 
of access to genetic testing services. 
 
In Egypt, genetic services provided by the private sector have to be covered mainly 
by out-of-pocket payments. The coverage of genetic tests by the public sector is 
limited and services for poor people may be covered by donations from NGOs or 
individual charity. 
 
In Oman, the health system is characterized by its universal coverage for both 
citizens and governmental or public sector expatriates. The health system is financed 
mainly by the government and accounts for about 80% of the total health 
expenditure. Services purchased by private sector vary according to services. Health 
care is directly provided and operated by the government, with the MoH being the 
main health care provider. The MoH is also responsible for ensuring the availability of 
health policies and plans and monitoring the implementations. Although Oman has a 
growing health care sector, Oman still heavily depends on imports and there is a 
rising need for locally sourced health care products and services and locally trained 
health professionals. A large part of Oman’s healthcare workforce comprises 
expatriates. This is changing due to the government’s Omanization policy which 
encourages native doctors to pursue specialized courses outside the country.82 
Genetic services are provided mostly by an Omani national workforce (95% Omanis). 
 
Genetic services are free for Omani citizens (universal coverage), however, the 
scope of currently available testing services is limited. With the establishment of 
the National Genetic Centre, Oman aims at improving availability of and access to 
genetic services. 
 
In the Philippines, only newborn screening is covered by insurance, all other 
genetic services and testing have to be paid for out-of-pocket. 
 
                                                                                                                                                                             
Care Provision in China. Asia Health Policy Program working paper series #10. Stanford University, Asia Health 
Policy Program, 2009: http://asiahealthpolicy.stanford.edu, accessed May 16, 2013) 
80
 Blumenthal D and Hsiao W (2005): Privatization and Its Discontents — The Evolving Chinese 
Health Care System, New England Journal of Medicine 353;11, page 1167. 
81
 WHO (2010): The world health report: health systems financing: the path to universal coverage. 
82
 Sultanate of Oman Healthcare Report August 2012 
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In South Africa, patients have to pay a fee for genetic testing services which is 
determined by a means test. Those patients, who access genetic services in private 
practice, generally have medical insurance and are reimbursed (depending on 
scheme and plan). For example, the cost of a genetic counselling session is set, 
approximately, at the accepted medical aid rate for such a consultation and therefore 
is largely refunded to the patient by the medical insurance. 
 
 
 
 
 
 
 
 
 
 
 
Significant barriers that affect access to medical genetic services in GenTEE 
countries 
 
Although all factors shown below in Figure 5.1, geographical barriers, financial 
barriers, no timely access due to skill gaps, insufficient referral structures and 
implicit rationing of services, operate in all GenTEE countries the proportion of 
each is likely to vary. For example in India the financial barrier is greater than others. 
However it is beyond the scope of this survey to assess the contribution of each 
factor. 
 
Figure 5.1 Factors reported to affect access to medical genetic services in GenTEE 
countries  
 
Coverage of genetic services 
The GenTEE survey clearly indicates that the unwillingness to cover genetic tests by 
both public health care and (private) insurance companies stalls the 
comprehensive clinical integration of genetic testing services into routine health 
care. However it has to be kept in mind that coverage and reimbursement decisions 
worldwide take time and are often hampered by a lack of available data evaluating the 
cost-benefit of genetic tests and by the costs incurred by the evaluation of new 
technologies. 
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Barriers that affect access to medical genetic services 
 
 Geographical accessibility of services: In all GenTEE countries genetic 
services are concentrated in the main cities, impacting the ability of the 
poorer rural and peri-urban population to physically reach the services. 
Public transportation to services may be inadequate, transport costs may be 
prohibitive, the time it takes to undergo a consultation may take a day or more 
resulting in the individual patient/parents losing time from work and thus 
valuable pay. The distance for specimens to be transported may also be great 
resulting in time delays that can affect the viability of specimens, in particular 
specimens for cytogenetic analysis. In order to overcome geographical 
barriers, in some countries such as Argentina, India and the Philippines 
genetic centres in tertiary hospitals run telemedicine programmes for genetic 
consultations accessible to secondary and primary care hospitals located in 
distant regions. In India telemedicine is being introduced in certain regions 
and free educational telemedicine conferences are organized for medical 
geneticists. 
 
 Affordability of services: Out-of-pocket payments in the private sector 
tend to be the norm for genetic testing services, and mostly the affluent 
upper-middle and upper classes can afford services. The major barriers to 
equitable access in most GenTEE countries are the lack of universal coverage 
and the dependence of genetic service provision on direct payments. The 
majority of patients and families cannot afford out-of-pocket funding in 
countries such as Argentina, China, Egypt, India and the Philippines. 
 
 Adequacy of services: In most GenTEE contries fragmented, underfunded 
and understaffed public health sector services are unable to deliver the 
volume of required services. This results in crowded services, excessive 
waiting lists that implicitly lead to non-transparent prioritization and rationing of 
services. All GenTEE countries are in need of better referral system 
development. In GenTEE countries genetic services are available at 
specialized hospitals at secondary or tertiary care level and routine points of 
entry to genetic service at primary care level are very limited. 83  Lack of 
expertise and skill gaps in recognizing congenital and genetic disorders 
by primary care providers impedes the route through necessary 
diagnostic, care and prevention services for patients and their families. 
Community genetic services near to patients and their families throughout the 
country are rare and can only be found to a certain extent in Oman, yet with 
restricted scope of services. 
 
                                                        
83
 Mandatory newborn screening programme may be the only exception for which in some countries exist entry 
points at primary care level. 
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VI Current state of genetic services 
 
Human resources and training 
 
Integration of medical genetics into the medical schools' curricula 
 
In Argentina, genetics knowledge of physicians is poor as most medical schools do 
not include meaningful teaching in genetics in their curricula.  
 
In Brazil, genetics is part of the curricula in several health related graduate schools, 
either as a structured discipline or among one of the major themes such as cell 
biology. It is classically taught within the basic disciplines of the courses with little, if 
any, integration with practice. Few medical school curricula include practical training 
in genetics. The genetics content in almost all medical schools does not cover even 
the needs of a general medical education. Therefore, most physicians do not 
recognize the genetic basis of diseases with which they are dealing and/or do not 
know how to refer to genetic services and/or do not give the deserved importance to 
the process of genetic counselling.  
 
In China, approximately 100 universities/colleges are qualified for giving 5-8 years 
professional education for the students wanting to be medical doctors (MDs). All 
these universities/colleges have genetics as compulsory, less than 10 universities, 
including Peking University, Tshinghua University and Zhejiang University, have 
specially designed medical genetics instead of genetics. None of these set up 
separate course for medical genetics. In China, medical genetics or overall genetics 
usually is taught in the 2nd year of all medical undergraduate (including the courses 
for doctors, nurses, medical test technicians, public health personnel, medical 
administration personnel) as compulsory before the beginning of medical practice.“84  
 
In Egypt, medical genetics is integrated in the medical faculties’ curricula for 
undergraduate students but not as a separate specialty. It is taught as part of the 
paediatric curriculum.85 
 
In India, genetics is presently taught under various specialities like anatomy, 
physiology, pathology, paediatric s and internal medicine, as there is no separate 
department of genetics in the majority of medical schools. Although the Medical 
Council of India (MCI) has incorporated medical genetics in the medical curriculum, 
most medical schools are considered ill-prepared for medical genetics.86  
 
In Oman, genetic courses are taught in genetic biotechnology and biology at Sultan 
Qaboos University (SQU) (Medical Laboratory Scientific Officers (MLSO) and College 
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 Zhong N. GenTEE Report on People’s Republic of China, 2010, p. 21. 
85
 Randa Kamal A. Raouf (2010): GenTEE Report on Egypt, p. 35. 
86
 Aggarwal SS: Medical Genetics in India – What needs to be done? Indian J Med Res, 130, October 2009, pp. 
354-356. 
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of Medicine and Health Science). Medical school courses include basics of human 
genetics, chromosomal and molecular inheritance. Clinical genetics are taught in 5th-
7th year of medical paediatrics and internal medicine. 
 
In the Philippines, genetics is taught primarily in medical school as topics integrated 
in biochemistry, paediatrics, internal medicine and obstetrics (Commission on Higher 
Education (CHED) 2006). The Philippine Paediatric Society has included genetics as 
a core topic in its paediatrics curriculum for all medical schools. 
 
In South Africa, four medical schools in the country have medical genetics 
professionals on their staff, and medical genetics is integrated into the undergraduate 
student curricula to a varying extent. Medical students are also trained at three other 
universities, but medical genetics teaching at these universities is limited and often 
falls to clinicians in various non-genetic specialties, particularly paediatrics.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Impact of unsatisfactory integration of medical genetics into medical schools’ 
curricula 
Due to typically unsatisfactory integration of medical genetics into their undergraduate 
medical training, it is fair to assume that most physicians in GenTEE countries, do not 
recognize the genetic basis of diseases of their patients, do not know how to refer to 
genetic services, if available, and do not give due importance to genetic counselling. 
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Medical genetics recognised as a specialty in medicine  
 
Although medical genetics is recognized as a specialty in all GenTEE countries but 
China, GenTEE countries are underserved and the number of genetic specialists is 
insufficient in regard to the recommendations from from the UK Clinical Genetics 
Committee of the Royal College of Physicians87 (Table 6.1). 
 
Table 6.1 Recognition of medical genetics, estimated numbers of certified 
medical geneticists (2011) 
Country Specialty officially 
recognized 
Certified medical 
geneticists 
Per million 
population 
 
 Argentina 
 
1991 
 
~120 
 
2.8 
 Brazil 1983
88
/1993
89
  ~200 1.0 
 China recognised as a sub-
specialty 
- - 
 Egypt yes, date not provided ~ 100-150
90
 1.12-1.74 
 India 1982 (super specialty)
91
 60 0.06 
 Oman 2000
92
 5 2.5 
 Philippines 2000 7 0.07 
 South Africa 2007 11 0.22 
 
 
Argentina: The specialty of medical genetics is recognized by the National MoH 
since 1991. The Argentine Society of Genetics, in conjunction with the National MoH, 
has certified about 120 clinical geneticists who staff 41 clinical genetics units 
throughout the country or work in private practice, providing genetic consultations 
and counselling.  
 
Brazil: In 1983, medical genetics was recognized as a medical specialty by the 
Conselho Federal de Medicina (CFM, Federal Council of Medicine). Since then, 
several new residency programmes were created, totalling 11 programmes, and 
vacancies for 23 new physician trainees yearly. Expertise in a medical specialty in 
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 A report from the Clinical Genetics Committee of the Royal College of Physicians suggests that two medical 
geneticists and four genetic counsellors are required to provide an adequate genetic service to every one million 
people.(Harper PS, Hughes HE and Raeburn JA: Clinical genetics services in the 21
st
 century. The Royal College 
of Physicians of London, London, 1996. Online available at 
http://www.rcplondon.ac.uk/sites/default/files/documents/clin_gen_21c.pdf (accessed May 6, 2013) 
88
 Federal Council of Medicine 
89
 Board Certification Brazilian Medical Association 
90
 Data provided by Prof. Mona Mohamed Hassan El Ruby, Clinical Genetics, NRC, Egypt. 
91
 Doctor of Medicine (DM) in Medical Genetics is a three-year super-specialty course offered only by a few 
medical colleges in India and only a single government -run medical college offers this course. http://entrance-
exam.net/government-colleges-for-dm-in-medical-genetics/ (accessed April 12, 2013) 
92
 Presently there are five clinical geneticists in Oman qualified in clinical genetics from UK and Canada. In 
genetic laboratories currently there are 5 PhD Scientists, 10 senior genetic scientists with master degree and 30 
genetic laboratory scientists 
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Brazil is not based solely on the titles coming from medical residencies and 
recognized by the Ministry of Education. Another form of professional recognition 
comes from board certification, awarded by the societies of medical specialties and 
recognized by the Associação Médica Brasileira (AMB, Brazilian Medical 
Association) and the CFM. Board certifications in medical genetics are held annually 
since 1993 by Sociedade Brasileira de Genética Médica (SBGM) and involve a 
theoretical test, analysis of curriculum and interviews. In 2010, around 200 physicians 
had been awarded with board certificates. 
 
China: Medical genetics is currently recognized as a sub-major in medical school but 
a sub-specialty in prenatal practice in the country. In most of cases, the medical 
genetics professional in medical school has nothing to do with clinical genetic 
services. Genetic testing and genetic counselling are run independently in hospital, 
and generally are not combined and considered as the term of “medical genetics”. 
Clinical staffs who undertake the role of “medical geneticists” are normally 
obstetricians, gynaecologists, paediatricians, and various other medical specialties. 
In some small local genetic posts even genetic laboratory technicians may play the 
role of “genetic counsellor”, due to the lack of professional staff, although it is illegal. 
 
Egypt: Medical genetics is a recognized specialty in the country. The number of 
practicing medical geneticists is estimated to be 100-150. 
 
India: Medical genetics is recognized as a super specialty but the MCI has not made 
it mandatory that every medical school should have a department of medical genetics 
for training purposes. There are only ten medical schools/institutions that provide 
postgraduate training in clinical genetics. There is only a single government-run 
institute in India offering a three-year postgraduate training course in medical 
genetics (DM in medical genetics93, Department of Medical Genetics, Sanjay Gandhi 
Postgraduate Institute of Medical Sciences 94 ). However this institute has a MCI 
approved intake capacity of just two students per year. For seeking admission to the 
DM in medical genetics, candidates must have completed their Medical Doctor (MD) 
in paediatrics or general medicine or candidates with MD/ master of science (MSc) in 
obstetrics & gynaecology are also eligible to apply for this course. Postgraduate 
training in medical genetics is also being introduced in three more institutions. At 
least six other institutions provide training in medical genetics without a formal 
degree. 
 
Oman recognizes a specialty in medical genetics obtained abroad. 
 
In the Philippines there are only seven trained medical geneticists, five of whom are 
in Metro Manila while two are practicing in the provinces. To date, all clinical 
geneticists are paediatricians. Medical genetics is a recognized specialty since year 
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 http://entrance-exam.net/government-colleges-for-dm-in-medical-genetics/ (accessed April 12, 2013) 
94
 http://www.sgpgi.ac.in (accessed April 11, 2013) 
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2000. The Department of Paediatrics, Philippine General Hospital (PGH) offers a 2-
year fellowship programme in clinical genetics. It is designed to provide broad clinical 
exposure to areas of dysmorphology, biochemical genetics, cytogenetics, molecular 
genetics, and neonatal screening programmes. Components of the training 
programme are genetics and metabolic clinics, ward rounds and participation in 
regularly scheduled pre- and post-clinic conferences. Experience in genetic 
counselling and training in laboratory procedures for the diagnosis of genetic 
disorders are likewise included.95 
 
South Africa: Medical genetics was initially recognised as a subspecialty, and in 
1999 nine medical geneticists were registered, through a grandfather clause, under 
this system. Subsequently nine more medical specialists (mostly paediatricians) 
undertook the newly introduced 2-year medical genetics training and were registered 
as sub specialist medical geneticists. However, in 2007, medical genetics was 
recognised as a primary specialty in medicine in South Africa. Specialist training 
(over 4 years) towards a postgraduate medical degree and fellowship of the College 
of Medical Geneticists (FCMG(SA)) is currently offered at four universities. At 
present, there are 11 medical geneticists, registered with the Health Professions 
Council of South Africa (HPCSA), of which ten are in academic practice. Seven 
registrars are in specialist training. 
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 Padilla CD. Overview of Genetic Health Services at UP Manila. Acta Medica Philippina. 2008; 42 (2): 7-10. 
Impact of limited availability of medical geneticists 
Especially in Brazil, China, India, the Philippines and South Africa there is an urgent 
need for expansion and capacity building in medical genetics. The limitation in 
available medical geneticists not only severely hampers the ability of these countries to 
diagnose and manage hereditable disorders but also their ability to incorporate the 
benefits of genetic/genomics research into mainstream medicine. 
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Postgraduate training programmes available for biochemical, cytogenetic and 
molecular geneticists  
 
Argentina: There are postgraduate training programmes in biochemical, cytogenetic, 
and molecular genetics for PhD professionals, but these are highly variable in scope 
and the number of graduates unknown. 
 
Brazil: The postgraduate programmes in genetics have been collaborating with the 
training of professionals for teaching and research in medical genetics. Although the 
primary purpose is to train professionals for universities and research centres, a 
reasonable proportion become trained in the specific areas of medical genetic 
laboratory investigation including cytogenetics, biochemistry, and molecular biology. 
The non-medical professionals whose undergraduate or postgraduate training 
enables them to perform within medical genetics, or even those who enter the area 
by the practice, may obtain qualification through their associations, although few opt 
to do so. 
 
China: Postgraduate training programmes for biochemical, cytogenetic and 
molecular geneticists are not available. 
 
Egypt: No postgraduate degree for any of the genetic laboratory specialties exists, 
thus physicians receive either a master in genetics or in clinical pathology, while 
pharmacists and scientists receive a master degree in molecular biology or master of 
biochemical science. To become qualified as genetic laboratory specialists, they get 
extensive training for one year and then on-job training for a second year in any of 
the genetic laboratories in the university or the National Research Center (NRC). 
There are also postgraduate specialized training courses in molecular genetics, 
cytogenetics or biochemical genetics that are done regularly twice per year, in the 
genetic division of the NRC. 
 
India: Postgraduate training programmes for biochemical, cytogenetic and molecular 
geneticists are available in many universities. Many departments of biotechnology 
have been opened in universities, providing training in molecular genetics, but also 
biochemical and cytogenetics. Due to the numerical availability of laboratories in 
India, employment of trained personnel is assured and there is no shortage of 
scientists trained in molecular techniques. Biochemists are mostly pursuing molecular 
based research. 
 
Oman: Master degrees in molecular genetics, molecular biology, biotechnology, and 
biochemistry are available at the SQU. Professional training in cytogenetics has been 
provided at the national cytogenetic laboratory.  
Molecular cytogenetics (FISH) training was provided by visiting consultants. 
A PhD programme in biochemical and molecular genetics is available at SQU. 
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The Philippines: Formal postgraduate training programmes for molecular genetics 
are available. A MSc in molecular biology and biotechnology and a PhD in molecular 
biology and biotechnology are currently offered at the University of the Philippines 
(UP) Diliman; a MSc in molecular medicine is currently offered in St. Luke‘s Medical 
Center (SLMC); at the UP Manila College of Medicine, there is a MD-PhD 
programme with a focus on PhD on molecular medicine. However, formal 
postgraduate training programmes for biochemical genetics and cytogenetics are not 
yet available. Collaborations with hospitals abroad are available for further training of 
clinical geneticists. In-house trainings and seminars are carried out by the faculty and 
senior laboratory scientists of the Institute of Human Genetics-National Institutes of 
Health (IHG-NIH). 
 
South Africa: Medical scientists can be trained in human genetics if they complete a 
bachelor of science (BSc) (Honours) degree in a biological science and a 2-year 
internship, in a recognised human genetics setting, and become registered by the 
HPCSA.96 
Similarly, medical technologists need to complete a 3-year national diploma or BSc 
degree in biomedical technology and a 1-year internship, and then register with the 
HPCSA. 
Medical scientists have the option of undertaking further study towards obtaining MSc 
or PhD degrees. 
South Africa has training programmes sufficient to train the numbers needed to 
undertake the work required to develop medical genetic services. The problem lies 
with the national and provincial health departments lacking the will, commitment and 
finances to support this training and make posts available for those trained. 
 
                                                        
96
 Health Professionals Council of South Africa (2010). Professional boards. Medical technology. Available from: 
http://www.hpcsa.co.za/board_medtech_education.php (accessed May 16, 2013) 
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Availability of postgraduate programmes 
 
With the exception of China and Egypt (where postgraduate training is more on a CME 
basis) postgraduate programmes for laboratory geneticists are available in the GenTEE 
countries. They are variable regarding scope and capacity, and limited to an extent in 
some, for example in the Philippines and South Africa, by lack of resources. Countries 
have, and still do, send scientists overseas for training, but as a country’s capacity 
grows, doing this, at least for basic training, has become less necessary. 
 
The availability of postgraduate programmes is impacted by: 
 
Lack of training infrastructures 
In the Philippines, there is a lack of diagnostic and treatment facilities. Added to this is 
the scarcity of geneticists who could oversee trainings and make consultations at the 
same time.  
With all the developments in the field of genetics, especially in research, and the 
growing number of patients, it is more cost-effective for some countries to send people 
abroad for training (Oman, the Philippines). However, Oman is in transition and is 
setting up more own training capacities. 
 
Lack of political commitment and resources 
South Africa has training programmes to train the necessary staff to undertake the 
work required to develop medical genetic services. The problem is the necessary 
national and provincial health departments’ will, commitment and lack of finances to 
undertake this training and make posts available for those trained. 
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Genetic counsellors as a recognised and registered profession 
 
Genetic counsellors are a registered profession in South Africa only. 
 
In the other GenTEE countries genetic counselling is mostly provided by clinical 
geneticists and by various other medical professions: 
 
Argentina: Non-physician genetic counsellors are not a recognized or registered 
profession, and there is no formal postgraduate training in genetic counselling. 
Genetic counselling is a physician responsibility and is provided by clinical geneticists 
or other physicians with genetics training.  
 
Brazil: Despite the involvement of many professionals in care regarding genetics, 
clinical evaluation and genetic counselling are delivered predominantly by physicians, 
with few exceptions (for instance, nurses counsel patients with inherited cancer in 
some reference centres; genetic information regarding sickle cell trait after newborn 
screening is given in primary care settings). Genetic counselling is not a recognized 
health profession. 
 
China: Genetic counselling is not a recognized and registered health profession. 
Genetic counselling is normally carried out by various medical specialties, such as 
obstetricians, gynaecologists, and paediatricians. 
 
Egypt: Genetic counselling services are provided by physicians and genetic 
counselling is not a recognized health profession. 
 
India: Genetic counsellors are not recognised and registered as a health profession. 
However formal postgraduate training in genetic counselling has been initiated in four 
institutions. Genetic counselling is provided by medical geneticists as well as other 
health care professionals.  
 
Oman: Medical genetic counselling is not yet officially recognised as a profession. 
However a PhD programme in genetic counselling is being planned and master 
degree students in genetic counselling are currently training in the UK. 
Genetic counselling is provided by clinical geneticists and paediatricians. Other 
health care professionals who provide genetic counselling services for haemoglobin 
disorders within the community genetic programme include medical and nursing staff 
from primary and secondary health care. 
 
The Philippines: Genetic counselling is currently primarily a responsibility of the 
clinical geneticists. A MSc in genetic counselling programme was started in 2011-
2012 at UP-PGH, presently with eight students in the first batch, and six in the 
second. This MSc in genetic counselling at the UP-PGH caters for nurses, doctors 
and other allied health professionals. The MSc will train personnel to support services 
provided by a scarcity of clinical geneticists. The objective is to provide 1 genetic 
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counsellor in each of the 81 provinces of the country. Medical genetics is being 
taught by clinical geneticists and visiting genetic counsellors from abroad and 
includes lectures on the conditions included in the newborn screening panel of 
disorders. 
 
South Africa: Genetic counselling is a recognised and registered health profession 
with formal postgraduate training at the master’s degree level (requiring 2 years of 
fulltime formal teaching and clinical training, a research project, and a 2-year 
internship) and registration with the HPCSA. There are 16 registered genetic 
counsellors and another four who will become available at the end of 2013. However 
there are five posts currently available in the country and should any of those posts 
be vacated they will be frozen and lost. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Genetic counsellors as registered profession 
 
South Africa is the only GenTEE country currently that has non-MD genetic 
counsellors, educated and trained following the model developed in the UK and in the 
USA, which is now increasingly being implemented in Europe and elsewhere.  
 
Oman and the Philippines have initiated training programmes for non-MD genetic 
counsellors.  
 
Not having genetic counsellors as part of medical genetic services places an increased 
workload and severe strain on the limited number of physicians available in low- and 
middle-income countries. Genetic counsellors can alleviate a considerable portion of 
this workload.  
 
However, genetic counsellors are only part of the solution to the problem. Countries 
need to train staff in the primary health care (PHC) setting to be able to extend genetic 
counselling from the tertiary environment into PHC. In South Africa, clinical geneticists 
suggested training nurses and this worked well. Due to lack of commitment and 
financial support this programme has become redundant. 
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Education programmes in medical genetics and genetic counselling available 
for non-genetic health professionals 
 
In all GenTEE countries there are education programmes in medical genetics 
available for non-genetic health professionals. However, initiatives to provide such 
training courses depend heavily on the engagement of clinical and other geneticists. 
In countries such as China, India and South Africa governmental support for 
educational programmes is provided. However, in South Africa this is very limited 
and considered to be inadequate to achieve its purpose. 
 
Argentina: There are education programmes in medical genetics and genetic 
counselling available for non-genetic health professionals. Short courses directed at 
primary care health professionals and general physicians are conducted in urban and 
rural settings.  
 
Brazil: The Sociedade Brasileira de Genética (Brazilian Society of Genetics, SBG) 
has been conducting certifications in human cytogenetics and in human molecular 
genetics since 1999, through an agreement with the Federal Councils of Biology, 
Biomedicine and Pharmacy.  
 
China: There are several nationwide conferences held by the Central MoH or by the 
China Medical Association (CMA) on the topic of medical genetics and perinatal 
health care. Major hospitals and institutions also provide short term professional 
training for non-genetic health professionals. 
 
Egypt: Training courses on the detection of congenital and genetic disorders and 
referral to the community genetic clinics are available for nurses and physicians, in 
cooperation between the Ain Shams University Department of Paediatrics and the 
NRC. Physicians working in the community genetic clinics receive condensed 
practical training courses of two months and can attend specialized courses, for 
example dysmorphology, premarital counselling, genetic laboratory results 
interpretation, and prenatal testing and diagnosis. 
 
In India, courses and CMEs are organized by various professional groups. Funding 
agencies such as the ICMR, the Council of Scientific and Industrial Research (CSIR), 
the government of India Department of Science and Technology (DST) and 
Department of Biotechnology (DBT) have task forces in genetics and provide liberal 
support for educational activities in genetics. 
 
Oman: Professional training in genetic counselling for nurses is organised by 
consultants in clinical genetics for nursing staff. Training seminars in genetic 
counselling for haemoglobin disorders are offered to primary health care (PHC), 
maternal and child care workers and physicians within the National Programme for 
the Control of Genetic Blood Disorders. 
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The Philippines: As mentioned in the previous section, the MSc in genetic 
counselling programme provides CME on genetic counselling to nurses, doctors and 
other allied health professionals (such as biologists, behavioural scientists). Health 
professionals from non-genetic fields are accepted for postgraduate training in 
molecular biology and biotechnology in UP Diliman, and in molecular medicine in 
SLMC. The MD PhD programme of the UP College of Medicine offers a PhD in 
molecular medicine. 
 
South Africa: The National DoH provides very limited finances for medical genetics 
education for nurses and doctors working in PHC. In 2005 a standardised syllabus for 
this programme was developed by medical genetics professionals. The programme 
consists of a four month distance learning section (using a specially compiled manual 
on birth defects97), four contact days of lectures and tutorials, and an examination. 
Candidates who pass the examination can then undertake four more training days on 
developing clinical skills, including dysmorphic examination, and counselling skills. 
Medical geneticists and genetic counsellors give occasional lectures to non-genetic 
health professions students and qualified health professionals, such as medical 
specialists and registrars in various medical fields, general practitioners, 
physiotherapists, occupational therapists, speech therapists, social workers, 
pharmacists, and nurses, as well as medical insurance personnel. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                        
97
 Birth Defects: Counselling and caring for children with birth defects. Developed by the Perinatal Education 
Programme in collaboration with the South African Department of Health, SAIDA and the March of Dimes, EBW 
Healthcare, 2010. Online available at http://scribd.com/doc/31657154/Birth-Defects-Free-Online-Edition 
(accessed April 22, 2013) 
Education programmes in medical genetics for non-genetic health professionals 
 
The clinical and counselling workload of physicians in medical genetic services in 
middle-and low-income countries, in addition to being assisted by genetic counsellors, 
can be further alleviated by training physicians in other disciplines and PHC workers. 
 
It appears that the need for education of non-geneticists in genetics has been 
recognized widely, but it is also apparent that there is no uniform pattern of 
programme structures, likely due to variable needs in all GenTEE countries. 
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Brain drain/migration of health care personnel working in medical genetics 
 
Argentina: There is some brain drain/migration from Argentina to developed 
countries of health care personnel working in medical genetics but the magnitude is 
not known. The causes are the same as for brain drain of health care personnel in 
general, namely low pay, lack of opportunities for advancement, and poor quality of 
life. 
 
Brazil: External brain drain has not been a problem in Brazil. Many experts go 
abroad, especially to the USA and Europe for training, but usually for a limited time. 
When returning to the country, often new technology is implemented and many 
services are “upgraded”. The absence of medical genetics as a formal medical 
specialty in the SUS, however, has been leading to a different modality of internal 
“brain drain”, where trained geneticists have no job positions available. Such fact 
leads trained specialists to other practices / medical specialties where they can earn 
a living, and many never return to medical genetics again. 
 
China: The brain drain/migration of health care personnel working in all fields of 
medical services is a big problem for China, as foreigners with a medical degree 
awarded by overseas university are not accepted by the National MoH and therefore 
are not allowed to practice medicine. A number of Chinese-American medical 
geneticists, who previously studied and were trained in the USA, are involved in 
teaching and research, but rarely get into clinical practice. 
 
Egypt: Brain drain or migration abroad, either temporary or permanent, of medical 
geneticists is not a significant problem in Egypt. Only a small proportion of former 
staff work outside Egypt, typically in Gulf States where salaries are much higher 
compared to the small salaries physicians receive in Egypt. The main problem in 
Egypt is the inequity in the distribution of genetic specialists in the country, because 
internal migration to semi-rural, rural and remote areas is not attractive to the majority 
of physicians with an interest in genetics.  
 
India: PhD students from institutions recognised internationally on graduation often 
migrate to the West. However it is not possible to quantify the number. 
 
Oman: The brain drain/migration of mostly non-Omani 98  health care personnel 
working in medical genetics is a problem in the Sultanate of Oman. Around 30% of 
resignations are due to finding better opportunities elsewhere, the advantage of 
doing so probably being financial. This impacts negatively on medical genetic health 
services as it results in insufficient staff numbers.  
 
                                                        
98
 In Oman, the majority of the heatlh care workfocr comprises expatriates. However, this is slowly changing due 
to the „Omanization Policy“ of the Omani government. Omanization means that skilled occupations hold by 
expatriates should be filled by trained Omani nationals. Still, many Omani physicians and lab personnel have 
obtained their training abroad and not in Oman. 
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The Philippines are strongly affected by brain drain. The majority of the original staff 
of the IHG-NIH have been absorbed by genetic laboratories overseas, and Philippine 
students going for PhD work overseas do not return. 
 
South Africa: The brain drain/migration of health care personnel working in medical 
genetics is a problem in the country. Four out of the nine medical geneticists trained 
in the country between 2000 and 2008 have left the country or the profession. A 
further three are working part-time and no posts are available at present for future 
graduates. Around 15% of genetic counsellors have emigrated. Several counsellors 
are working in part-time positions, including the three who are working in the western 
Cape. Staffing National Health Laboratory Service (NHLS) laboratories in the public 
sector is problematic since medical scientists, once qualified, may leave to the private 
sector for better wages or emigrate. Vacated posts are frozen due to cost constraints. 
In this way the Division of Human Genetics, NHLS and University of the 
Witwatersrand (WITS) in Johannesburg, between 2007 and 2010 lost 30% of its 
laboratory staff. Thus, the country is very short of trained personnel, staff numbers in 
the field are decreasing instead of increasing, and development in the field is being 
retarded. Medical scientists in research also leave to gain experience overseas and 
many do not return. 
 
 
 
 
 
 
 
 
 
 
Import of specialists from abroad to provide medical genetic services 
 
Import of foreign genetic specialists is not an issue in GenTEE countries except in 
Oman where foreign genetic specialists are acting as temporary consultants. This is 
either because, as in Egypt, enough genetic specialists are available or, as in China 
and South Africa, there are difficulties in obtaining registration and low salaries are a 
deterrent. 
Brain drain/migration 
 
External (migration) or internal (leaving the field of medical genetics altogether) brain 
drain due to unsatisfactory career and salary conditions is a problem in all GenTEE 
countries  
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Workload 
 
Availability of service and extent of integration of genetic services targeted and 
designated for public health care into the health care system 
 
In Argentina, there are 41 clinical genetic units in the public sector, as part of a 
national network of 1,319 public hospitals (with a total of 76,885 beds) and 6,290 
PHC centres. Some hospital genetic services perform outreach to health centres 
within their area of influence, but all too often patients affected with genetic 
conditions must find their own way to a tertiary hospital for genetic services. Some of 
the few comprehensive genetic centres in tertiary hospitals run telemedicine 
programmes for genetic consultations accessible to secondary and primary care 
hospitals in the provinces. 
 
Brazil: The Brazilian National MoH published a decree in 2009, which proposes the 
creation of a “Política Nacional de Atenção Integral em Genética Clinica no SUS” 
(National Policy for Comprehensive Care in Clinical Genetics at SUS).99 The process 
that led to acknowledge the need to establish such a policy began in 2001. Some of 
the conclusions highlighted that most Brazilian regions were hardly prepared for the 
clinical genetics practice. Thus, with basic problems of infrastructure and 
shortcomings in the area, the challenge is to establish a minimum organizational 
structure, from which strategic actions would be applied to ensure comprehensive 
care in genetics.  
 
China: Clinical genetic services, although limited, are integrated into the public health 
system, in and around the academic centres of the universities and hospitals. Most 
genetic counselling clinics are held in public hospitals, especially maternal & child 
health hospitals. The medical genetic staff hardly undertake outreach visits due to the 
limited resources, the majority of the population still remain underserviced. An 
efficient hierarchical maternal & child health care network has been established from 
small towns to metropolitan cities. The right of frequent medical 
examination/screening during pregnancy is protected by the Law of the People’s 
Republic of China on Maternal and Infant Health Care (MIHCL)100 enacted in 1995. 
Facilities for general prenatal screening, karyotyping, biochemical tests, 
ultrasonography screening, microbiological tests are present in all level hospitals; 
PND is only available in qualified centres in major cities.  
 
Egypt: Genetic services are integrated into the primary, secondary and tertiary 
health care. The community genetic counselling clinics are a referral site between 
primary and tertiary care. The clinics work through a system of referrals from primary 
                                                        
99
 Brasil (2009a), Ministério da Saúde, portaria GM no. 81, 20 de janeiro de 2009 – Institui, no ambito do Sistema 
Único de Saude (SUS), a Politica Nacional de Atenção Integral em Genetica Clinica. Diário Oficial da União 
21/01/2009 
100
 The Law of the People's Republic of China on Maternal and Infant Health Care. Online available at 
www.asianlii.org (accessed May 13, 2013) 
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care to secondary care then tertiary care level of services. The early detection of 
genetic and congenital disorders is done at PHC level, and then cases are referred to 
the genetic counselling clinics in the catchment area where diagnostic services, 
counselling and follow-up are provided by secondary care physicians. Investigations, 
treatment and rehabilitation services are provided by the health insurance 
organization, and then cases are referred again to the clinics for follow-up. 
The general population has also a direct access to a tertiary level of medical genetic 
care through the genetic departments, centres, and units at university level and the 
NRC. Nevertheless, at that level there are no service networking activities between 
the different universities. 
 
India: Most genetic centres are part of hospitals providing comprehensive care. 
Many of the hospitals are in the government sector, and thus represent tertiary care 
referral centres for primary and secondary health care. There are some laboratories 
which are quaternary centres, national laboratories that obtain specimens from 
throughout the country, and not linked with hospitals.  
 
Oman: Services for haemoglobin disorders have been integrated into the PHC 
system. 
 
The Philippines: In 2004 newborn screening was integrated into the public health 
delivery system. All newborn screening laboratories are considered public health 
laboratories. Guidelines and accreditation are run by the DoH. Aside from newborn 
screening, the clinical genetics unit of the department of pediatrics, PGH, receives 
consultations and referrals for genetics-related cases from all over the country. The 
Telegenetics Referral System (TRS) is undergoing pilot implementation in 10 
hospitals all over the country, with the aim of providing genetic services in remote 
areas of the country. 
 
South Africa: Clinical genetic services, although limited, are integrated into the 
public health system, in and around the academic centres of the universities of Cape 
Town, Free State, Stellenbosch, WITS and formerly KwaZulu Natal. Most genetic 
counselling clinics are held in public hospitals, associated with academic hospitals 
and the genetic services are available through referral from other hospitals and 
clinics. The medical geneticists and genetic counsellors also undertake outreach 
visits both within and outside their provinces, although, with the limited resources, the 
majority of the population still remain underserved.  
Community education of health care professionals, at many levels from PHC to 
tertiary settings, is also undertaken in order to increase awareness and integrate the 
services into the healthcare system. At present, a limited number of nurses in PHC 
are receiving basic in-service training in medical genetics, and paramedical 
professionals, such as physiotherapists and occupational therapists, receive some 
teaching during their training. 
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Extent of integration of genetic services into the public health care system 
 
Clinical genetic services are integrated – although to a limited extent – into the public 
health care system in the GenTEE countries. Most of these services are available at 
secondary or tertiary care level in urban areas. In the rural areas, the availability of 
genetic services is still scarce. 
 
While genetic services appear to be integrated into the health care system, the majority 
of genetic patients are clearly underserviced in all GenTEE countries. 
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Number, location and regional distribution of medical genetic 
departments/medical genetic units/centres 
 
Table 6.2 Number of “genetic units”101 and laboratories in GenTEE countries 
(2010) 
 
country genetic units laboratories/integrated laboratories 
   
Argentina 41
102
 (public domain) 
 
29 public 
3 private 
Brazil 66 47 public 
50 private, of these 25% are exclusively 
genetic laboratories 
   
China - 9 university bound medical 
genetic centres 
- 2 reproductive centres (Jiangsu, 
Yunan) 
- unknown number of PND 
centres at major provincial 
hospitals 
75 public 
number of private laboratories unknown 
(mainly in the  
Beijing, Shanghai and Guangzhou area) 
   
Egypt 11 genetic counselling clinics 
5 genetic departments in 
university hospitals & a genetic 
division with 8 departments at the 
NRC 
8 public 
10 private 
   
India 54
103
 10 public 
35 private 
   
Oman
104
  
 
2 MoH services 
5 SQU 
3 public (2 MoH 1 forensic) 
5 university bound (Ministry of Education) 
   
Philippines 1 
(Clinical genetics Unit, 
Department of Pediatrics, PGH) 
4 Newborn screening (3 public, 1 private) 
3 Molecular (1 public, 2 private) 
1 Biochemical (1 public) 
4 Cytogenetics (2 public, 2 private) 
4 DNA analysis (paternity testing, 3 public, 
1 private) 
   
South Africa 4
105
 
 
8 public 
5 private 
 
                                                        
101
 Definition of “genetic unit”: A genetic unit is a clinical entity staffed by clinical geneticists and provides access 
to laboratory diagnoses. 
102
 Of these only 5 genetic units conform with the notion of “comprehensive genetic centre”. 
103
 Cytogenetic investigations are being undertaken by 45 centers, biochemical investigations at 28 centers, PND 
by 45 centers, and genetic counselling at 45 centers. Delhi has 6 centers, each of which serves 2.3 million 
people. 
104
 Genetic service units and laboratories in the public domain. 
105
 Division of Human Genetics laboratory at the NHLS and the University of the Witswatersrand, Johannesburg, 
University of Cape Town, Division of Human Genetic laboratory and Groote Schuur Hospital, University of 
Stellenbosch/Tygerberg Hospital laboratory, University of the Free State, Human Genetic laboratory 
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Location and regional distribution of genetic services 
 
In all GenTEE countries considering their populations, there are not sufficient medical 
genetic units available. 
 
For instance only 54 genetic units are presently running in different parts of India. This 
is considered insufficient for a large country like India, where some capitals of the 28 
states do not have genetic services. 
 
Genetic units are nearly always based in tertiary care at university hospitals and thus 
are likely to serve the more affluent urban middle and upper classes and to a lesser 
extent the rural population. 
 
In the Philippines only PGH (the largest tertiary government hospital in the country) 
has a clinical genetics unit. Most of the geneticists in the country are located in the 
Manila area, particularly in PGH. There are efforts to change this now, through the TRS. 
However, this system does not involve setting up more genetic units. Laboratories are 
also mainly at UP Manila. Samples from all over the country are received here. There 
are private laboratories but their services cannot be afforded by the less affluent 
population. 
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Access to genetic testing and most common referrals for genetic testing 
 
In all GenTEE countries except Oman there is a mix of private and public laboratory 
service distributed over the country, but with a focus on big cities and poorer access 
in rural areas. The laboratories offer a broad range of genetic laboratory techniques 
to cover the needs for clinical diagnosis.  
 
In Brazil, China, India and Oman all established laboratory techniques and NGS 
technology are available to support diagnostic services within the country (Table 6.3). 
 
Table 6.3 Availability of different genetic testing techniques in GenTEE 
countries (2012) 
 
Technique Argentina Brazil China Egypt India
106
  
(2010) 
Oman Philippines South 
Africa
107
  
(2007) 
Conventional 
Cytogenetic Techniques 
constitutional 
        
Conventional 
Cytogenetic Techniques 
acquired 
        
mFISH 
 
        
iFISH 
 
        
MLPA 
 
        
PCR/ sequencing 
 
        
QF-PCR 
 
        
RT-PCR 
 
        
Southern Blotting 
 
        
Microarray 
 
     108    
Metabolic Biochemistry      109   
NGS (Next Generation 
Sequencing) 
     110   
 = available 
 
 
 
 
 
 
                                                        
106
 Sir Ganga Ram Hospital, Center of Medical Genetics: Directory of Genetic Tests, 2010. Available from: 
http://geneticsindia.org/FullTestList.aspx?lab_id=1 (accessed May 16, 2013) 
107
 Department of Health, South Africa (2007). Diagnostic Genetic Tests. Available from: 
www.doh.gov.za/docs/index.html (accessed May 16, 2013) 
108
 At Sultan Qaboos University 
109
 Available at university hospital  
110
 From 2012 
mFiSH Multicolor fluorescence in situ hybridization 
iFiSH Interface fluorescence in situ hybridization 
MLPA Multiplex ligation-dependent probe amplification 
PCR Polymerase chain reaction 
QF-PCR Quantitative fluorescent polymerase chain reaction 
RT-PCR Reverse transcription polymerase chain reaction 
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The most common referral for a genetic investigation is dysmorphology in all 
countries except Oman (Table 6.4).This is probably a reflection of the inherited 
disease pattern of the country; haemoglobin disorders being the most common 
inherited disorder in the country. Compared to the other GenTEE countries, Oman 
has a slightly different pattern for referring to genetic testing also reflecting the 
structure of the genetic burden in the society. 
 
Table 6.4 Ranking (1-10) among GenTEE countries of the ten most common 
indicators for issuing a genetic test (estimates by the GenTEE consortium) 
 
Example for common 
indicators 
Argentina Brazi
l 
China Egypt India Oman* Philip
pines 
South 
Africa 
Nonsyndromic Mental 
Retardation 
3 2 3 3 1 5 2 2 
Neuro-Muscular Disorders 2 6 4 8 5  4 3 
Haemoglobin disorders  9 7 6 2 1 5 8 
Congenital 
Malformations/Dysmorphi
c 
1 1 1 1 3 2 1 1 
Cancers (familial) 7 4 9 9 9 3
111
  7 5 
Infertility, including 
recurrent miscarriage 
4 8 5 4 4 4 6 7 
Profound Deafness 
(Childhood) 
8 7 6 7 7  9 10 
Family History, including 
Premarital Counselling, 
excluding cancers and CF 
5 5 2 5 6  8 6 
CF 9 10 10 10 8 10 10 4 
Failure to Thrive 6 3 8 2   3 9 
*Additional ranking of disorders not included in the table for Oman: 
Repeated Stillbirth 6 
Growth failure in a child, delayed puberty or ambiguous genitalia 7 
Chromosomal fragility testing 8 
Premature ovarian failure 9 
Multiple affected birth with spinal muscular atrophy, Osteopetrosis, cystic fibrosis 10 
 
 
                                                        
111
 Hematological cancer 
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Quality assurance of medical genetic services 
 
Availability of quality assessment schemes and existing regulatory frameworks 
for genetic services 
 
In GenTEE countries the healthcare systems are multifaceted and there is neither 
official framework for assessing new genetic tests that become available nor 
any formal system for approving which tests may be used in a clinical setting. 
Accreditation of clinical laboratories is not mandatory in most of the countries.  
 
Clinical laboratories are accredited by special agencies of the ministries of health in 
Argentina. Except for laboratories that perform newborn screening, there are no 
official agencies that control or monitor the analytical validity of tests. Quality 
assessment of laboratory results relies mostly on the voluntary decision of the 
laboratories directors to participate in a quality control programme, usually of 
an international agency. Chromosome and DNA studies are performed in the 
laboratories of public hospitals, mostly teaching hospitals, or by private laboratories. 
While these laboratories are certified by a state agency, participation in quality 
assessment programmes is voluntary and regulation very lax. Further, while in 
theory most of these laboratories must have in-house and external quality control 
programmes, there is little government oversight on these issues.  
 
In Brazil, there is no specific regulation for medical genetics services. All other 
medical services are regulated and supervised by the National MoH and its specific 
agencies, particularly the Agência de Vigilância Sanitária (ANVISA)112. Some quality 
assessment programmes are available for laboratories, so that they comply with 
international standards. Most private laboratories tend to undertake it voluntarily, 
not specifically for genetics, but for all testing offered. 
 
In China, quality assessment schemes are available and the centres in hospitals are 
exposed to regular peer reviews. All clinical laboratories offering genetic 
diagnosis are required to meet the standards of the Central MoH’s Centre of 
Clinical Testing. Some private laboratories may also comply with ISO15189 
(Accreditation Criteria for the Quality and Competence of Medical Laboratories) 
and obtain accreditation from College of American Pathologists (CAP).  
 
There are quality assessment schemes for genetic laboratories in Egypt, either 
internal from within the laboratory itself or external, through a protocol of agreement 
with an external laboratory from another country, e.g. the CDC quality assurance for 
the MoH&P central health laboratories, especially for neonatal screening tests. 
 
                                                        
112
 ANVISA, 2010. Agencia Nacional de Vigilância Sanitária 
http://portal.anvisa.gov.br/wps/portal/anvisa/home/servicosdesaude (accessed August 29, 2010. 
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In India the National Accreditation Board for Testing and Calibration of Laboratories 
(NABL) inspects and accredits the laboratories for genetic tests. The quality 
assurance programme involving exchange of samples is not done by this board. A 
quality assurance programme for thalassaemia and haemophilia is run by the 
Department of Haematology Christian Medical College, Vellore. Some laboratories 
also enrol in the European Molecular Genetics Quality Network (EMQN) programme 
of the EU for molecular tests. Many centres performing newborn screening tests are 
enrolled in the quality control programme run by CDC. 
 
The human genetic laboratories of the MoH in Oman follow the quality assurance for 
cytogenetic testing of blood, bone marrow and amniotic fluid available from the 
Cytogenetic European Quality Assessment (CEQA) 113  since 2009, but quality 
assessment schemes are not available locally. 
 
The Philippines follow both internal and external quality assessment schemes, like 
the CEQA. The newborn screening laboratories have been participating in the 
proficiency testing of the CDC since 1997 while the cytogenetics laboratory started 
only last 2011. 
 
In South Africa, some quality assessment schemes are available and the academic 
departments of human genetics are exposed to regular peer reviews. NHLS 
laboratories in academic and tertiary settings, doing genetic testing, can be 
monitored and accredited by the South African National Accreditation System 
(SANAS) so that they comply with international standards. However, this process is 
not mandatory. Private laboratories are not subjected to such scrutiny but tend 
to undertake it voluntarily. The NHLS laboratory at WITS University participates in 
biannual quality assurance programmes and obtains accreditation for testing 
proficiency through the CAP. It is in the process of moving into new accommodation 
and when this is complete it will undertake SANAS accreditation. Further, biological 
medical scientists follow a set syllabus and intern programme laid out by the HPCSA 
and only HPCSA registered medical scientists may work in the public and private 
sector laboratories. 
 
Due to the variability of health care systems in the GenTEE countries it appears that 
the flexible European quality assurance systems could serve as an optimal model for 
emerging economies. 
 
 
 
 
 
 
 
                                                        
113
 http://www.eurogentest.org (accessed May 16, 2013) 
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Documentation of process and outcome data 
 
The documentation and process of outcome data, takes place frequently at the level 
of each institution providing the service and no national data are available, like in 
Argentina and Brazil, China, Egypt, South Africa.  
 
In Argentina, the documentation of process and outcome data on medical genetics 
services takes place at the level of each institution providing the service and no 
national data are available. Each medical centre keeps the records and data they 
require for their internal assessments and/or annual reports and there is no national 
policy or coordination of data for the whole country. 
 
Brazil has a good quality and data control in the newborn screening programme. All 
newborn screening centres have to undergo an initial accreditation and are only 
promoted to the more complex phases (more diseases screened) based on quality 
standards for uptake and results. The National MoH has a permanent commission for 
the follow up of this programme.  
 
In China, only the centres in hospitals are required to submit annual report to 
Maternal & Social Health Section, Central MoH, but national data are not accessible 
for the public. Each academic centre keeps the records and data in their own 
database, and there is no policy to update the records to administration units.  
Harmonization of quality assurance through international networking 
 
In Europe, quality assurance within genetic testing laboratories is guided largely by a 
network of external quality assurance (EQA) providers, which provide laboratories 
with genetic test samples and feedback based on the laboratory's analysis of the 
sample, both in the form of individual reports and group feedback that can lead to 
standardized guidelines. These providers vary in the number of tests schemes 
(programmes that test laboratory proficiency by examining testing results on a 
standardized sample) available and geographical scope The EMQN and the Cystic 
Fibrosis Thematic Network are among the largest providers, and both have received 
funding from the EU. Additionally, it may be beneficial in the longer term for other 
jurisdictions, such as the Latin American countries, and the other GenTEE countries to 
participate in similar harmonization activities, as they may benefit more from this 
model than from one developed for a single country (e.g. the United States), because 
Latin American countries face similar challenges regarding the sufficient availability of 
testing samples. It may be possible as well to preliminarily include developing 
countries to join in under the umbrella of a European cross-national quality assurance 
plan. Indeed, the EMQN welcomes countries outside Europe within it schemes. Given 
multiple regional or continental networks of quality assurance, international groupings 
can themselves interact to produce a truly worldwide harmonization of quality. 
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In India, accreditation by the NABL involves lot of documents that are to be 
submitted to the board before the physical inspection. Most genetic centres maintain 
registers of the patients with genetic disorders seen by them. 
 
In Egypt, each genetic laboratory or genetic department or centre (either academic 
or private) has its own records and annual data that is not shared on a national level 
and the MoH&P does not have a direct authority to have access to those records. 
 
In Oman, yearly reports to the MoH have to be prepared on: clinical consultations, 
laboratory performance, quality measures and training activities. 
 
In the Philippines, all newborn screening centres undergo an initial accreditation 
and re-accreditation every three years. The accreditation team consists of both local 
and international experts. 
 
For South Africa, each academic centre keeps the records and data they require for 
their internal assessments and/or annual report and there is no national policy or 
coordination of data for the whole country. 
 
 
Availability of national guidelines and recommendations for the provision of 
medical genetic services including ethical guidelines 
 
National guidelines or recommendations for the provision of medical genetic services 
are rare in GenTEE countries. Argentina and Egypt have no national guidelines, the 
Philippines have guidelines for the provision of newborn screening.114 
 
In Brazil, aiming to assist in medical decision making and thus optimize the care of 
patients, the AMB and the CFM in 1999 triggered a process with the specialty 
societies for the development of medical guidelines based on scientific evidence 
currently available. Since 2000, the SBGM contributed seven guidelines: (i) Clinical 
Genetics Evaluation of the Newborn, (ii) Familial Cancer, (iii) Female Sterilization: 
Statement, (iv) Male Sterilization: Indications, (v) Laboratory Tests for Diagnosis of 
Symptomatic Diseases, (vi) Turner Syndrome: Diagnosis and Treatment, and (vii) 
Predictive Testing (CFM projeto diretrizes). In 2010, the SBGM started working 
intensively in elaborating more than 40 guidelines, especially in regard to diagnostic 
tests and new treatments115. Official government documents are rare, but in the last 
decade some important initiatives are being taken. In 2001, the National MoH 
established a commission to discuss and propose recommendations related with the 
access and use of the human genome. This resulted in a document published in 
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 Newborn Screening Act of 2004 (RA 9288) 
115
 data obtained by Dafne Horovitz by personal communication 
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2003116 with recommendations about genetic tests and the ethical use of genetic 
information. The document recommends that: 
 
 diagnostic genetic tests, predictive or not, performed in the context of research 
involving humans, are voluntary, after proper guidance, and always preceded 
by the signing of informed consent (except tests of public health programmes, 
as neonatal screening, and those that aim to reduce personal risk to health or 
health of third parties); 
 tests that are performed with a medical purpose in order to diagnose and 
establish appropriate schemes of therapy and prevention should not be 
indicated before its sensitivity, specificity and efficacy have been scientifically 
substantiated;  
 it is forbidden to request genetic tests as a prerequisite for job admission, 
except as provided in specific legislation, or granting benefits, by any public or 
private institution, or that the personal genetic information is used in a 
discriminatory manner in such institutions; 
 it is prohibited to disclose genetic test results to any person other than the 
individual himself/herself or his/her legal representative; 
 genetic testing, both diagnostic and predictive, can only be performed on 
medical request and 
 that education for health professionals and for the population is highly 
recommended, in order to clarify the benefits and risks of information obtained 
from genetic tests. 
 
 
In China, the MIHCL provides recommendations for the provision of genetic services. 
In 2001, the China State Council published a State Council Order (No. 308) on the 
implementation of the MIHCL. The law and the council order provide a detailed 
guideline for the development of maternal & child health care, especially in the area 
related to the “detection and control” of genetic disorders.117 
 
The Central MoH has published a list of regulations, these include: 
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 CAGH (2003) - Comissão sobre Acesso e uso do Genoma Humano- Informação genética- Testes genéticos e 
recomendações (2003). Ministério da Saúde, Secretaria de Ciência, Tecnologia e Insumos Estratégicos. 
Departamento de Ciência e Tecnologia. Online available at 
http://www.ghente.org/temas/informacao/testes_geneticos.pdf (accessed May 6, 2013) 
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 For the controversy surrounding the MIHCL and its subsequent development see: 
Hesketh T, Wei XZ: Maternal and child health in China. BMJ 1997;314:1898. Online available at 
http://www.bmj.com/content/314/7098/1898?view=long&pmid=9224139 (accessed May 13, 2013) 
Guo SW: China: The Maternal and Infant Health Care Law, Fundan University Shanghai, China. Abstract 
available online at http://onlinelibrary.wiley.com/doi/10.1002/9780470015902.a0005201.pub2/abstract (accessed 
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 implementation of human Assisted Reproductive Technology (ART); 
 management of human ART; 
 specifications for human ART; 
 principle consideration of ethical issues in ART; 
 basic standards for human sperm bank;  
 sperm bank management practices; 
 technical specifications of sperm bank. 
 
 
The right for people to access genetic services is legally protected, professional 
regulations are monitored by the Central MoH and services (including newborn 
screening, cytogenetic testing and PND) have been established in most regions (see 
Figure 4.3 above) at provincial level. All the service centres (including both university 
and hospital-based ones) are registered by the Central MoH. The quality of services 
is monitored once every two years. 
 
 
In India, the government has become very strict and has mandated that all 
institutions carrying out research should have an ethics review board. 
The ICMR has issued Ethical Guidelines for Biomedical Research on Human 
Participants in 2006118. 13 pages cover ethical guidelines for genetic research. These 
include: general guidelines, pedigree studies, participant requirements, informed 
consent, and confidentiality of data and defines risk and benefits. There is a separate 
section on genetic screening that includes prenatal testing, screening in newborns, 
screening of children and anonymous testing. Another section covers therapeutic 
trials including gene therapy, the human genome project, DNA and cell 
banking/repository and DNA diagnosis and PND. There are special regulatory bodies 
that are tasked to ensure the review, approval and monitoring of all research projects 
in the field of stem cell research.119 
 
 
In Oman, the MoH adopted the WHO “Proposed International Guidelines on Ethical 
Issues in Medical Genetics and Genetic Services”120 in 1998, omitting the topics of 
MToP and PND. 
 
In South Africa, National Policy Guidelines for the Management and Prevention of 
Genetic Disorders, Birth Defects and Disabilities, were initially drawn up with 
contributions from all major stakeholders (from academic and government 
departments) and a document was published in 2001 by the National DoH121. The 
document provides recommendations for the provision of genetic services and has 
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 http://icmr.nic.in/ethical_guidelines.pdf (accessed May 7, 2013) 
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 http://www.westerncape.gov.za/text/2003/humangenetics.pdf (accessed May 2, 2013) 
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sections on general ethical guidelines for medical genetics (modified from the WHO 
Hereditary Disease Programme, 1996, document122) and on ethical principles for 
genetic professionals.123 This policy document is still available and it has not yet been 
superseded. 
Some ethical guidelines, for genetic research purposes, were drawn up, around the 
same time, by the Medical Research Council (MRC) and a committee was set up for 
the purpose. These guidelines appeared in a booklet entitled: Guidelines on Ethics 
for Medical Research: reproductive biology and genetic research.124  This booklet 
followed on from a booklet on the general principles of ethics for medical research.125 
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Setting international standards 
 
GenTEE countries face a similar situation as the USA and many European countries. 
These countries, despite their relatively advanced state in developing and 
coordinating the various institutions involved in setting standards at different levels of 
the process, have yet to succeed in fully integrating what continues to be a somewhat 
fragmented structure. The OECD, the EC and the WHO have been working together in 
recent years to develop consensus around international standards and best practices 
for ensuring the quality of genetic services in their member countries. There remains 
much work to do to finalize and implement their recommendations. 
 
A number of bodies have made recommendations relating to quality assurance in 
healthcare, and specifically in the provision of genetic services. Many calls have been 
made for the creation of an independent and autonomous national level body assigned 
the task of institutionalizing a quality assurance process across an entire country. The 
WHO has also recommended that a national health laboratory policy should be 
developed, emphasizing quality assurance and the networking of laboratories. Such a 
policy should be backed by legislation and overseen by a broad based group 
comprising a range of stakeholders, recognizing that a successful system must take 
into account the widely differing perspectives and motivations of the stakeholders 
involved. 
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National policies and legal frameworks 
 
Existing national policies, guidelines and planning activities for the provision 
of medical genetic services 
 
In most GenTEE countries, the development of national policies, guidelines and 
planning activities for the provision of medical genetic services started in the 2000s, 
reflecting the advances in genetic technologies and genetic sciences development. 
 
 
Argentina: There are no national guidelines or recommendations for the provision of 
medical genetic services, including ethical guidelines. The national policies and legal 
frameworks regarding medical genetics are within the responsibility of the National 
MoH. In turn, the National MoH has been influenced by experts in medical genetics 
from the Pan American Health Organization (PAHO). Since 1982, PAHO has 
sporadically been convening regional consultations of experts in medical genetics, 
which in turn issued recommendations to member countries, including 
Argentina.126,127 ,128,129,130,131 A special consultation took place in Argentina in 2003, 
in which specific recommendations were issued by the consultant, including the 
appointment of a blue ribbon National Commission on Genetics and Health that 
would have the task of surveying the status of medical genetics services in the 
country and pointing needs for development. 132  This National Commission was 
created in 2006 and has since conducted a countrywide survey of genetic services 
and formulated a plan for their strengthening and coordination. 133  Currently, the 
National MoH has adopted as a national policy this report of the National 
Commission and has been strengthening the network of genetic services in the public 
sector as well as developing a nationwide registry of congenital anomalies, which has 
already started in the northeastern provinces of the country.134 
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Brazil: The Brazilian National MoH published a decree in 2009, which proposes the 
creation of a “Política Nacional de Atenção Integral em Genética Clinica no SUS” 
(National Policy for Comprehensive Care in Clinical Genetics at SUS).135  
 
The process that led to acknowledge the need to establish such a policy began in 
2001 and was partly influenced by the announcement of the sequencing of the 
human genome. The ethical, political, legal, and administrative matters related to the 
access to human genetic material became an issue in most countries, and the 
national Comissão sobre Acesso e Uso do Genoma Humano (Committee on Access 
and Use of the Human Genome) was created136. 
 
During the period 2004–2006, there were several meetings and two regional 
workshops (south/ southeast and north/northeast/center-west). Representatives of 
the National MoH also participated in inserts during clinical genetic conferences. 
This process resulted in a proposal that ultimately led to the ordinance No. 81 of the 
National MoH in January 20th 2009, which established the “Política Nacional de 
Atenção Integral em Genética Clinica no SUS” (National Policy for Comprehensive 
Care in Clinical Genetics at SUS)137, and also designated the strategies for actions 
that must be taken into account in its regulation.  
 
The existence of a published policy for genetics constitutes an important historical 
milestone for Brazil. By the time this text was written, however, no supplementary 
ordinance, which would be absolutely essential to organize and regulate this policy, 
had been published. Since January 2009, the Aliança Brasileira de Genética 
(Brazilian Genetic Alliance)138, several patient–parent organizations and the SBGM 
have been trying to pressure the National MoH to implement the policy. In 2012 a 
commission for the elaboration of a policy for rare diseases was constituted, as a 
result from pressures from these organizations. It is expected that the policy will be 
instituted in 2013. 
 
 
China: The MIHCL legally guarantees that every Chinese national registered at birth 
has the right to have access to health care. One part of national policy prioritises 
services for the prevention of congenital disorders. Guidelines for preconception and 
pregnancy health care services were approved by the Central MoH in 2011. The 
guidelines clearly outline the standard of services required prior to conception, during 
pregnancy, at birth, in infancy and childhood and the way in which these services 
could be delivered at various levels from primary to tertiary health care settings. 
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The use (including for research purposes) of blood products, tissue, stem cells and 
gametes and zygotes in humans are regulated. Any use or research of these 
materials requires a written application to and permission from a local ethics 
committee. 
  
In 2002, the National Population and Family Planning Commission, Ministry of 
Health, and State Food and Drug Administration jointly issued a “Regulation of the 
prohibition of foetal sex determination and pregnancy termination for non-medical 
purposes“. The regulation defines the conditions and procedures to be adhered to 
when determining the sex of the foetus and when inducing a sex-selective 
termination of a pregnancy. Foetal sex determination and sex-selective induced 
abortion for non-medical purposes are illegal and violations are subject to criminal 
sanctions and loss of license to practice. Parents and medical professionals are not 
allowed to use foetal sex for the termination of a pregnancy for reasons other than 
medical purposes.139 Termination of pregnancy is prohibited for any reason after 28 
weeks of gestation. 
 
In addition to the legislation set out above there is a guideline for the use of informed 
consent document (issued by the Central MoH) to protect autonomy and privacy. 
 
 
In Egypt, policies and planning activities related to the provision of genetic services 
are included under the MoH&P five-year plan for the prevention and early 
intervention of disabilities: 
The MoH&P five-year plan addresses the following dimensions: 
 
 an integrated system for treatment and rehabilitation by implementing 
registries; 
 
 a prevention and early detection programme by establishing 
 
(i) a national premarital care counselling programme; 
 
(ii) a safe motherhood programme which covers antenatal care, childbirth care, 
neonatal care and post-natal care (focusing on congenital anomalies, 
jaundice and early detection of causes of mental retardation)140; 
 
(iii) a national newborn screening programme for CH141; 
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and 
 
(iv) a programme monitoring child growth and development, immunization, 
nutrition and care; 
 
 rehabilitation through supporting rehabilitation centers and introduction of 
community-based rehabilitation (CBR). 
 
 
India: There are no national policies guidelines in planning activities for provision of 
medical genetic services in India. Guidelines for research have been issued by the 
ICMR and theses are enumerated below. There are also guidelines for ART. 
As PND was (and still is142) often used for the diagnosis of foetal sex for non-medical 
purposes and abortion of female foetuses the government promulgated a law entitled 
“Pre-Natal Diagnostic Techniques (PNDT) Act”, in 1994. The PNDT Act was 
implemented in 1996143 and was amended in 2002 bringing IVF and ART within the 
framework. The amended bill was entitled “Pre-Conception and Pre-Natal Diagnostic 
Techniques (Prohibition of Sex Selection) Act”. A further amendment in 2003 brought 
all ultrasound examinations during pregnancy also under its ambit. Every ultrasound 
machine had to be registered. After numerous complaints from radiologists the range 
of indications for which ultrasound examinations were permitted were listed. 
The ICMR has issued the following guidelines: 
 
 ART (Regulation) Rules144; 
 National Guidelines on the Management of Retinoblastoma145; 
 Guidelines for Good Clinical Laboratory Practices146; 
 Guidelines for Stem Cell Research and Therapy147; 
 Guidelines for Management of Type 2 Diabetes148; 
 Guidelines for International Collaboration/Research Projects in Health 
Research149; 
 Ethical Guidelines for Biomedical Research on Human Participants150; 
 Intellectual Property Rights Policy151; 
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 National Guidelines for Accreditation, Supervision and Regulation of. ART 
Clinics152. 
 
 
Oman: The MoH of The Sultanate of Oman has recognized the need for appropriate 
medical genetic services and genetic technologies to control congenital/genetic 
disorders. The National Committee for the Prevention of Genetic Diseases was 
established in 2004 and includes representatives from the Ministries of Health, 
Education, Social Affairs, Information and National Economy. 
In 2005, the MoH published its 7th Five-Year Plan for Health Development (2006-
2010)153 which included a national strategic plan on genetic diseases in order to 
reduce the morbidity and mortality. 
 
Its objectives were 
 
(i) improving the management of patients affected by congenital/genetic 
disorders (especially for congenital blood diseases, mental retardation 
including Down syndrome and physically impairing conditions), and providing 
effective preventive measures; 
 
(ii) developing molecular genetic technology expertise capable of supporting local 
care and prevention programmes; 
 
(iii) providing premarital services to inform about increased risks for 
congenital/genetic disorders including risk assessment; 
 
(iv) providing public health education on genetic risks for the Omani population. 
 
 
To achieve its objectives, the National Genetic Centre was established to provide 
clinical and laboratory diagnostic services, care services and prevention programmes 
and to conduct training activities and research in the field of medical genetics was 
enacted. The National Genetic Centre has been endowed with a budget of 5.2 million 
R.O. (~ 10,288,000 €/13,467,000 US$ in April 2013). 
 
The demand on national manpower development was appreciated and a number of 
Omani nationals are currently training in the Sultanate and abroad in the field of 
genetic medicine and genetic laboratory technologies. 
 
                                                                                                                                                                             
151
 http://www.iitr.ac.in/ipr/IPR%20Policy.pdf (accessed May 8, 2013) 
152
 http://icmr.nic.in/art/Prilim_Pages.pdf (accessed May 8, 2013) 
153
 Ministry of Health, Sultanate of Oman (2005) 7th Five-Year Plan for Health Development (2006-2010). 
Available at http://www.moh.gov.om/en/nv_menu.php?o=fiveyearplan/fiveyearPlan.htm&SP=1 (accessed 17 
October, 2012) 
 97 
Existing national policies are within a framework of Muslim Law (Sharia) which 
forbids the interruption of pregnancies after 12 weeks gestation exempt for cases 
where there is danger to the mother’s life or where ultrasound reveals structural 
anomalies incompatible with life such as hydrocephaly, anencephaly, renal dysplasia. 
The rising number of surviving disabled children with congenital and genetic 
disorders is creating awareness and concern about the increase of families with 
disabled children. The national policy for prevention is to avoid marriages between 
carriers and in correspondence with this policy premarital screening for carriers and 
appropriate counselling are available. 
 
 
The Philippines: The only policies that can be related to genetics are: 
 UNICEF/UNDP/World Bank/WHO Special Programme for Research & Training in 
Tropical Diseases154; 
 Operational Guidelines for Ethics Committees Reviewing Biomedical Research155; 
 Ethical Guidelines for Genetic Research with a Section on Stem Cell Research. 
(issued by the Philippine Council for Health Research and Development)156; 
 The Intellectual Property Code of the Philippines (Republic Act No. 8293)157. 
 
 
South Africa: The National Policy Guidelines for the Management and Prevention of 
Genetic Disorders, Birth Defects and Disabilities 158  document provides 
recommendations for the provision of genetic services. It has sections on general 
ethical guidelines for medical genetics and on ethical principles for genetic 
professionals.159  
Ethical guidelines for genetic research purposes are available.160  In the National 
Policy Guidelines for the Management and Prevention of Genetic Disorders, Birth 
Defects and Disabilities the priority medical genetic services are described. These 
include services offered prior to conception, during pregnancy, at birth, in infancy and 
childhood, and in adolescence and adulthood. The way in which these services could 
be delivered at various levels from primary to tertiary health systems, is covered. The 
education of learners at schools and the training of genetic health professionals is 
addressed. Recommendations that medical geneticists’ and genetic counsellors’ 
posts should be provided, urgently, in every province in the country, in order to offer 
the services, have not yet been acted upon, and most provinces still have no posts at 
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all. Interventions are described, including strategies for prevention, such as genetic 
counselling, preconception and prenatal methods of prevention (e.g., PND), postnatal 
diagnosis and population screening. There are recommendations regarding: the 
integration of medical genetics laboratory services into the NHLS, which has been 
partially achieved, although co-ordination is still poor and duplications and 
inconsistencies still exist; the composition and functions of a Medical Genetics 
Advisory Board (it was suggested medical genetics professionals as well as a lawyer 
should be included); and the evaluation of human genetics programmes.  
 
International conventions and directives, such as the European Convention on 
Human Rights, acknowledge that there are basic human rights for patients with 
genetic conditions and that everyone is entitled to basic health care.161 In line with 
these international standards the South African Constitution of 1996 provides not 
only for fundamental rights such as the right to life (Section 11 of the constitution), to 
equality (Section 9), dignity (Section 10) and privacy (Section 14) but also provides, 
in Section 27, that everyone has the right to have access to health care, sufficient 
food, water and social security.  
 
In terms of the National Health Act (NHA) of 2003162 the State is obliged to provide 
free health care services to pregnant and lactating women and children under the 
age of 6 years. Furthermore, free PHC services must be provided to all those who 
are not members of medical aid schemes. Section 4 of the NHA also provides 
authority for women to have access to free termination of pregnancy, subject to the 
Choice on Termination of Pregnancy Act 92 of 1996. This act provides the conditions 
and procedures to be followed for a person to obtain a termination of pregnancy. It 
states that a woman may obtain a termination upon request in the first 12 weeks, and 
thereafter, in consultation with a medical practitioner, where the health of the mother 
or the foetus may be at risk. The NHA (2003) has clear provisions in section 7 for 
consent to medical treatment and, with a few exceptions, a health care service may 
not be provided without informed consent. Further, section 8 of the NHA deals with 
the control of the use of blood products, tissue, and gametes and zygotes in humans 
and prevents the reproductive cloning of human beings. 
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Specific cultural and social issues pertaining to medical genetic services 
 
Argentina: The main cultural and social issues pertaining to medical genetic services 
stem from the lack of genetic literacy among the population and the health 
professionals and the paucity of genetic services available throughout the 
country. 
 
Furthermore, coverage for genetic services by private and social insurance is 
very poor, which leads to discrimination and stigmatization of people with 
genetic disabilities. 
 
The lack of prenatal genetic services in the public sector and the prohibition of 
abortion for foetal reasons increase the stress and suffering of families 
affected with genetic conditions.  
 
Low social class, low education level, and adherence to conservative religious 
precepts are associated with a high emotional burden from genetic defects. 
 
 
Brazil: Poverty and lack of knowledge and understanding of genetic services, 
their purposes and what they can offer are the basic issues. 
 
Abortion is not viewed as an option by many, due to cultural and religious 
attitudes. However, some women do not consider the termination of a pregnancy of 
a malformed and non-viable foetus an abortion; thus abortion for specific medical 
indications would be acceptable to many. 
 
Predictive and prenatal testing is culturally complicated, as the public is not used to 
taking the responsibility for decisions related to their own health and treatment. Many 
physicians who work in prenatal settings do not seem to understand the 
meaning of informed choice and autonomous decision making, and often make 
decisions for their patients.  
Participation of patients and informed autonomous decision making regarding 
health care is not a tradition in Brazil. Physicians are still viewed as holding all 
information regarding health, and for a long time, people have accepted being told 
what to do in this area. People making informed autonomous decisions about their 
health care has been changing in the last decade or so with the spread of access to 
communication and the internet supported by general education of the public. 
However, Brazil is still way behind in general medical education compared with other 
countries.  
 
The importance of medical genetics and its integration into public health and 
prevention is not understood by most physicians, health authorities, public 
officials, and policy makers. Nor is the specialty of medical genetics known by 
many, who believe genetics will always be linked to very rare disorders, research, 
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laboratories, and high cost. Such beliefs are common amongst the lay public and 
health professionals. In consequence many patients/families are not referred to 
specialized services or only arrive in genetic services after recurrences, which could 
have been avoided. 
 
 
China: There are a several specific cultural and social issues relating to genetic 
services in China. China consists of 56 ethnic minorities who differ in language, 
lifestyle, belief and culture. The distribution of congenital and genetic disorders may 
differ among specific groups and geographic locations. 
 
(i) Language – the official language of China is mandarin, but only 53.1% 
Chinese can fluently communicate by mandarin. 86.4% are using the 
language with one of seven very distinct accents.163 53 ethnic groups have 
their own language. Most of the languages for small ethnic groups have 
distinct linguistic patterns, are rich in words for daily life, but lack scientific 
words. 
(ii) Lifestyle – lifestyle of people also differs between ethnic groups. 
(iii) Faith– Buddhism, Christianity and Islam are present in China and Taoism 
represents also a large faith group. Some ethnic groups may also have their 
own faith.  
(iv) Traditional Chinese medicine – Chinese herbal medicine is deeply rooted 
in the Chinese culture. Thus most Chinese still consult both Western medical 
health professionals and traditional Chinese herbal medical practitioners. 
 
 
All these issues can affect the ways in which genetic services are delivered and 
received, the communication and interactions in genetic counselling sessions and the 
choices people make. 
 
Egypt: In general, there is still lack of awareness concerning the importance of the 
services for early intervention and prevention of genetic and congenital disorders.  
 
Misconception about some services include the mistaken idea by some that 
antenatal genetic testing is merely a step used by women to obtain abortion for a 
unwanted pregnancies.  
 
Fixed cultural and social beliefs and fear of stigmatization are common issues 
that prevent people from asking for such genetic services.  
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 Data provided by Nanbert Zhong, Peking University Center of Medical Genetics, Beijing, People’s Republic of 
China. 
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This is especially common among the rural population, mainly the rural communities 
of the southern part of Upper Egypt. This might be attributed to the high prevalence 
of illiteracy and customary consanguineous marriages amongst these people.  
There is a great discrepancy between rural and urban population as regards 
their perception of intervention and preventive approaches to congenital and 
genetic disorders. Changing such attitudes in rural populations (57% of the total 
population) is difficult, but modifying their to date fixed cultural and social beliefs will 
be essential to enable rural populations to gain maximum advantages from utilizing 
available community genetic services. 
 
India is a vast country with great social, cultural, religious and ethic diversity. 
Consanguineous marriages are practiced by most communities in south India, the 
frequency ranging from 20 – 30 % of unions. This occurs both among the Muslim and 
Hindu communities. In north India consanguineous marriages are practised mostly 
by Muslims. 164  However in the rural areas a small number of consanguineous 
marriages, 3-5 %, are seen in the Hindu community.165 
In addition, throughout India, many people marry within their own ethnic group 
(endogamy), although not consanguineously. This results in the presence of founder 
mutations.  
These practices result in a higher birth prevalence of autosomal recessive disorders 
and numerous founder mutations in the Indian population. Many disorders are 
common among certain communities (Box 3.9). 
 
Stigmatization of those carrying mutant genes (especially women). The stigma 
associated with being a thalassaemia minor carrier has been well documented by 
social studies. For instance, a study conducted in Bengal observed “that blood is 
deeply valued in the Bengali Kinship system and this genetic mutation is perceived to 
be corrupting the blood. Being a thalassaemia carrier (i.e. having thalassaemia 
minor) renders an individual unfit as a suitable marriage partner because of beliefs 
related to purity of blood, its association with the continuity of the lineage, and 
subsequent transmission of desirable traits to future generations. The risk of non-
marriage affects women disproportionately, and parents are not inclined to test their 
daughters because of the possibility of not being able to marry them off to eligible 
suitors.”166 
Such data highlight the need for genetic counselling to take into account the 
perception of the tribal communities and to develop anthropological tribal oriented 
approaches to avoid stigmatization. 
 
The possibility of stigmatization of women found to be carriers of X-linked disease 
also needs careful consideration in genetic counselling consultations. 
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New Delhi, India. 
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Med Res 134, October 2011, pp. 507-521. 
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Oman: The custom of consanguineous and arranged early marriages in Muslim 
communities is deeply rooted in Arab culture. The balance of opinion in the Middle 
East still remain in favour of consanguinity irrespective of increased risk of autosomal 
recessive diseases, congenital malformations and mental retardation. 
Recent data suggest that there is a reduction in the frequency of consanguineous 
marriages particularly in urban areas of Oman.  
The present policy to address the issue includes premarital identification of carrier 
risk by genetic screening and counselling of carriers to afford them the opportunity of 
deciding not to marry. 
 
The Philippines: Several cultural and social issues affect the delivery of genetic 
services. 
 
(i) Termination of pregnancy is illegal: termination of pregnancy is not 
available and is considered illegal by law; this is due to a largely Catholic 
influence in the country. 
(ii) Religious beliefs and traditional practices affect the way people view health 
and the causes of disease. Those living in far-flung provinces would still seek 
help from traditional faith healers rather than consult a medical professional.  
(iii) Lack of education and understanding of basic genetic concepts: 
Although genetic awareness is rising among the Filipinos, the lack of 
education and understanding of basic genetic concepts, also contribute to the 
misconceptions about genetics. 
(iv) Infections remain to be the top priority of the DoH. The majority of 
programmes and strategies are designed to combat communicable diseases. 
With the increasing awareness among Filipinos of the different genetic 
disorders, the demand for genetic services however has increased throughout 
the Philippines. 
(v) Provision of basic genetic healthcare services to every region remains 
the biggest challenge. While it would be preferable to have at least one 
geneticist and one genetic counsellor in each region, this is currently not 
possible. There are only a few geneticists with clinical practices, available 
only in the major urban areas such as Manila, Cebu, and Davao. In response 
to this critical lack of specialists, the DoH and the NSRC offer scholarships 
for fellowships in clinical genetics for paediatricians committed to practicing 
clinical genetics in regions currently without services. In addition, a MSc 
programme in genetic counselling was established in 2011 (see “Genetic 
counsellors as a recognised and registered profession”). 
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South Africa: There are a several specific cultural and social issues relating to 
genetic services in South Africa167: 
 
(i) Systems of thought, prevailing fatalistic attitudes, communal decision-
making, the indistinct line between life and death, and belief in the power of 
ancestral spirits. 
(ii) Beliefs and myths about the causes of genetic disorders.  
(iii) The tendency, in the majority of people, to consult both western medical 
health professionals and traditional healers.  
(iv) The custom of consanguineous marriage, common practices and taboos. 
(v) Language and communication, since in most local languages there are no 
terms for words such as genes and chromosomes. 
 
 
All these issues can affect the ways in which genetic services are delivered and 
received, the communication and interactions in genetic counselling sessions and the 
choices people make. They are integral to an issue prevalent in other countries, 
namely a lack of genetic literacy among the population and the health professionals 
and the paucity of genetic services available throughout the country. 
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Population of Southern Africa. In Clarke A, Parsons E (eds). Culture, Kinship and Genes. London, Macmillan, 
147-157. 
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Assessment of the attention given to medical genetic services by the national 
government/policy makers as compared to other health issues 
 
In Argentina, genetic services do not receive sufficient attention by national 
government/policy makers as compared with other health issues. 
 
Brazil: Genetic services are not well recognized both by the general public and 
the medical profession. Education and literacy for the public and medical 
profession in genetics is needed. 
 
 
China: The central government has given a great deal of attention to maternal and 
child health since the founding of the People’s Republic in 1949. In the last two 
decades, China has made substantial progress in reducing maternal, infant and 
under-five mortality. Most of the policies related to medical genetics were developed 
for birth defect control by the maternal & child health division of the Central MoH. For 
example, the policy of providing free folic acid for the prevention of neural tube defect 
renewed in 2010, the regulation of technology for foetal chromosome karyotyping 
issued in 2008. However, there is no regulation regarding molecular genetic 
diagnosis. 
 
 
Egypt: To date not much attention has been given to the genetic services from 
health policy makers. Providing genetic services is not a priority in the new health 
reform system (HRS). The key priority in the HRS is to achieve universal insurance 
coverage for all Egyptians.  
The MoH&P has focused on other health issues including the avian flu and H1N1 flu 
(Swine Flu). Most of the attention was directed to these two top priority health crises. 
Budgets were reallocated and even health care professionals were relocated to 
participate in surveillance and prevention of the epidemic infection. 
Currently the family planning programme, the expanded childhood immunization 
programme, HIV, Hepatitis C and cancer prevention and treatment are the main 
interest of the MoH&P and are priority health issues. 
 
 
India: The national government has shown great interest in non-communicable 
disorders, such as cardiovascular diseases, diabetes mellitus, stroke, chronic lung 
disorders and cancer. The pilot phase of the National Program for Prevention and 
Control of Cancer, Diabetes, CVD and Stroke (NPCDCS) for these disorders was 
launched in January 2008, with an outlay of Rs. 1660 crores (~233 million €/ 305 
million US$ in April 2013) in the 11th 5-year plan.168 Unfortunately the NPCDCS 
programme does not include congenital and genetic disorders. Although talks 
for initiating a nationwide programme for the care and prevention of 
                                                        
168
 http://health.bih.nic.in/Docs/Guidelines-NPCDCS.pdf (accessed April 30, 2013) 
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haemoglobinopathies have been ongoing for several decades, no concrete national 
programme has yet been started by the government. The ICMR has now taken the 
lead to start a “National Haemoglobinopathies Control Programme”.169 It will start in 
Delhi, Chandigarh and Punjab as a pilot study (see Box 3.6). The ICMR has also 
taken the initiative to establish five additional regional haemoglobinopathy centres at 
medical colleges in Maharashtra, Gujarat, West Bengal, Karnatakar and Punjab for 
molecular and prenatal diagnosis.  
In February 2013, a new health initiative “Rashtriya Bal Swasthya Karyakram” was 
launched by the government. The initiative is set to provide comprehensive health 
care “and improve the quality of life of children through early detection of congenital 
disorders, diseases, deficiencies, development delays including disability”.170 
 
 
Oman: Increasing attention has been given to medical genetic services in the past 
years. Since the implementation of the 7th Five-Year Plan for Health Development 
(2006-2010) by the MoH, the Sultanate of Oman has a national strategic plan on 
congenital and genetic diseases. (see “Existing national policies, guidelines and 
planning activities for the provision of medical genetic services“) 
 
 
The Philippines: Aside from newborn screening, the DoH has supported (financially) 
the Philippine Birth Defects Surveillance (PBDS) Project171, the TRS Project and the 
Preconception Health (PH) Project, in collaboration with the IHG-NIH-UP. The PBDS 
is currently implemented in 18 sentinel sites (different political/geographical regions) 
with 82 health facilities and communities. The TRS is currently implemented in 10 
sites, and the goal is to make genetics services accessible to all patients with 
congenital and genetic disorders through the use of a web-based referral system. 
Aside from these projects, there is very little attention provided for the other aspects 
of medical genetic services. 
The future of genetic services is dependent on a variety of factors. Limited attention 
is provided by government since the focus is still on eradication of infectious diseases 
that predominate the top ten causes of infant mortality and infant morbidity. 
 
Learning from the developed countries where eradication of infections eventually 
paved the way to improvement of genetic services, the Philippines must prepare 
now by giving more attention (in terms of budget and programme planning) to 
congenital and genetic disorders. 
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South Africa: The national policy regarding medical genetic services, which was set 
out in the National Policy Guidelines for the Management and Prevention of Genetic 
Disorders, Birth Defects and Disabilities, was developed before the impact of the HIV/ 
AIDS pandemic became apparent. That epidemic together with other problems, 
including the increasing incidence of tuberculosis (TB), poor governance and 
difficulties in health service delivery, has resulted in medical genetic services having 
diminished priority compared with the 1990s. It is hoped that this situation will 
improve consequent on the recognition, by the WHO, that congenital and genetic 
disorders present major health problems, and, in 2010, their recommendation that 
services for the care and prevention of congenital and genetic disorders in 
developing countries should be prioritised.172 
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In conclusion 
 
With the probable exception of Oman the national governments of the other GenTEE 
countries have only given limited attention to legislation and regulation of services 
for the care and prevention of congenital and genetic disorders and still need to 
develop strategies to strengthen their genetic services and to enable their primary 
care services to use the services for the benefit of their patients. It is obvious that in 
large countries like India, the introduction of services for population screening 
programmes (e.g. for haemoglobinopathies) will be a gradual process.  
 
Despite most of GenTEE countries progressing well through epidemiological transition 
the realisation that this increases the public health significance of congenital and 
genetic disorders has not been fully recognized. Genetic testing services for chronic 
diseases with subgroups with significant genetic risk components non-
communicable chronic diseases such as: heart disease, stroke, cancer and 
diabetes are hardly available. The WHO has indicated over the last decade the need 
for middle- and low-income countries to consider the need for medical genetic services. 
Congenital and genetic disorders and services for their care and prevention were 
confirmed as a global priority, particularly in middle- and low-income nations by the 
WHO’s World Health Assembly in 2010. 
 
South Africa is a special case. The Constitution and laws protect the rights of the 
disabled and at the turn of the 21st century it had put in place very progressive thinking 
national guidelines for genetic services. However, for several reasons, including a 
change of priorities because of the HIV/AIDS and the TB epidemics, the policies still 
wait for full implementation. 
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VII Research priorities in genetics/genomics 
 
Argentina 
 
In Argentina, biomedical research has a long tradition in academic centers. 
 
The Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET, National 
Council for Scientific and Technological Research173) has existed for over 50 years, 
albeit with changing roles. Its main function today is to fund and administer a 
researcher career. CONICET, in turn, is part of the Argentinian Ministry of Science, 
Technology and Productive Innovation, which in 2009 started a concerted effort to 
develop public-private partnerships for research and development in genomic 
approaches in biotechnology and biomedicine. Most scientific and technical research 
is conducted at Argentinian (public) universities with public and private funds. 
 
The National MoH has a lesser role in genetic/genomic research.174 
 
Genetics/genomics research is conducted in several centres, such as the:  
 
 Department of Molecular Biology of the University of Buenos Aires175; 
 Instituto de Investigaciones de Ingenieria Genetica y Biologia Molecular176; 
 Fundacion Leloir177; 
 Instituto Multidisciplinario de Biología Celular178, and the 
 Instituto de Biología Molecular y Celular of the Universidad Nacional de 
Rosario179. 
 
Specific areas of genetics/genomics research are:  
 
 basic molecular genetics; 
 immunogenetics; 
 molecular population genetics; 
 forensic genetics; 
 genome sequencing (the Trypanosoma cruzi genome was sequenced by a 
multinational team in which Argentine geneticists from two separate 
institutions played a key role); 
 gene therapy; 
 cancer genetics and  
 stem cell research. 
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Research in clinical genetics is concentrated in dysmorphology–cytogenetics, 
selected single-gene disorders such as skeletal dysplasias, muscular dystrophies, 
fragile X syndrome, CF, thalassaemia, congenital deafness, and cancer.180 
 
In 2009 the National MoH convened a large group of geneticists conducting research 
to discuss priorities in genetics research. However, the results of this exercise have 
not been disseminated nor acted upon. 
 
Research funding by private parties in Argentina 
 
Research funding for genetics by private parties is very scarce in Argentina. 
 
Known co-operations with international funding agencies in Argentina 
 
There are a number of research projects in basic genetics that have received funding 
from several international bodies, such as the USA National Institutes of Health 
(NIH), Fogarty Center, CDC, Howard Hughes Foundation, Wellcome Trust and 
others. None of these agencies fund clinical projects. 
 
 
Brazil 
 
Brazil has made significant investments to fund research in medical genetics and 
genomics. The main funder is the public sector, both state and federal.  
At the federal level, the major funders are the: 
 
 Financiadora de Estudos e Projetos (FINEP) [Financier of Studies and 
Projects181],  
 Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) 
[Coordination of Improvement of Higher Education Personnel182] and the 
 Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) 
[National Council for Scientific and Technological Development183].  
 
FINEP is acting under the Ministry of Science and Technology (MCT) 184 , which 
focuses on fostering the institutional projects (universities, companies, and institutes 
of technology). 
 
CAPES invests in training high-level human resources in the country and abroad. 
CNPq is an agency of the MCT for the promotion of scientific and technological 
research and training of human resources for research in the country. It focuses on 
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encouraging researchers and their projects, individually or in groups. CNPq, in 
particular, has supported specific actions in clinical genetics through partnerships 
with the National MoH.185 
 
Among the projects, several were structured partnerships with institutions in several 
states of Brazil, forming various networks such as Familial Cancer Network, the 
Network for Diagnosis in Inborn Errors of Metabolism (Rede-EIM-Brasil), and others.  
 
At the state level major funders are the: 
 
Fundação de Amparo a Pesquisa (FAP) [Foundations for Research Support] in each 
state of Brazil. One of these FAPs, the Fundação de Amparo à Pesquisa do Estado 
de São Paulo, FAPESP (Foundation for Research Support of São Paulo)186, is the 
fourth largest funder of scientific and technological development of the country. In 
2009 FAPESP grant aid totalled nearly $ 500 million. A major achievement of 
FAPESP was the establishment of genomic research in the country, starting with an 
agreement with the ONSA network (Organization for Nucleotide Sequencing and 
Analysis) in 1997.187  These efforts resulted in the sequencing of the genome of 
Xylella fastidiosa in 2000188 and established an expert network on advanced projects 
in genomics, with international impact. Its most important project in human genetics 
was the Human Cancer Genome Project (2011). In this project, about 2 million DNA 
sequences of normal and tumour tissue were deposited in GenBank 189 . Other 
projects, for example the Clinical Genome Cancer Project190, followed. 
 
Another form of support is the partnership of different funders (CNPq, CAPES, FAP, 
National MoH, Ministry of Education, and others) by joint financing projects, like the 
programme of the Institutos Nacionais de Ciencia e Tecnologia (INCT) (National 
Institutes of Science and Technology 2011). Released in July 2008, this programme 
has established itself as a powerful instrument for advancing science, technology, 
and innovation in the country. With over a hundred projects approved in different 
research areas, such as health, biotechnology, nanotechnology, and energy, the 
programme aims to mobilize and aggregate in networks the best research groups in 
frontier areas of science and in strategic areas for the sustainable development of the 
country.  
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The following institutes are linked to the further development in human genetics and 
medicine:  
 
 National Institute of Science and Technology Cell Therapy, based in the 
Faculty of Medicine of Ribeirão Preto University of São Paulo191;  
 National Institute of Science and Technology of Stem Cells in Human Genetic 
Diseases, based at the Institute of Biosciences, University of São Paulo192;  
 National Institute of Science and Technology for Cancer Control, based at the 
National Cancer Institute193 (linked to the National MoH194);  
 National Institute of Population Medical Genetics195, based at the Hospital de 
Clinicas de Porto Alegre–Federal University of Rio Grande do Sul 196 
(INAGEMP 2011);  
 National Institute of Science and Technology of Molecular Medicine, based at 
the Faculty of Medicine, Federal University of Minas Gerais197; and the  
 National Institute of Science and Technology in Oncogenomics, based at the 
Cancer Hospital of São Paulo198. 
 
Research funding by private parties in Brazil 
 
Some pharmaceutical and biotech companies are funding clinical research in the field 
of new drugs, mostly phase 3 and 4 studies, especially for rare diseases. 
 
Known co-operations with international funding agencies in Brazil 
 
The Human Cancer Genome Project 199 . In this project, about 2 million DNA 
sequences of normal and tumour tissue were deposited in GenBank200 and used for 
other projects as the Clinical Genome of Cancer Project.201 
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China 
 
In China, government funding is available, mainly through the Natural Science 
Foundation of China (NSFC)202 and the Ministry of Science and Technology. The full 
funding scheme consists of three groups: 
 
(i) research projects (funding is limited to individual research topic); 
(ii) research scientist developmental project (funding is limited to a person or a 
group for a specific research); 
(iii) environment condition projects (funding is limited for improving laboratory’s 
hardware condition, e.g. equipment). 
 
Medical genetic research is eligible for funding from all three funding schemes. 
Apart from the funding schemes provided nationally by the central government, each 
province, autonomous region and municipality also offers funding for encouraging 
research locally. 
 
During the last decade, the central government has undertaken concerted efforts to 
move the country into the upper echelon of genetic and genomic research world-
wide. In 1998, the Ministry of Science and Technology203 established the Chinese 
National Human Genome Centre (CHGC) in Beijing204 and Shanghai205, and in 1999 
the Beijing Institute of Genomics (BGI) 206  as centres of excellence for genome 
sequencing and analysis. The establishment of these institutes enabled China to 
participate in the Human Genome Project and to contribute to the International 
Human HapMap Project.  
 
China is also a partner in the International Cancer Genome Consortium (ICGC). 
 
Since the establishment of two large-scale population-based biobanks: the Kadoorie 
Study of Chronic Disease in China (KSCDC) and the Guangzhou Biobank Cohort 
Study (GBCS), China is in the process of setting up large-scale population-based 
biobanks. China’s diverse population of 56 different ethnic minorities are of special 
interest in regard to genetic disorders but also in regard to hereditary evolution. 
Understanding of the genetic bases of chronic diseases reflects the changing 
morbidity and mortality pattern caused by China’s epidemiological transition. A new 
initiative of longitudinal cohort study for pregnancy outcome has promoted a 
biobanking of pregnancy-related specimens that may allow researchers to investigate 
the nature of pregnancy and its outcomes on a long term basis.  
 
 
                                                        
202
 www.nsfc.gov.cn (accessed May 16, 2013) 
203
 www.most.gov.cn (accessed May 16, 2013) 
204
 www.chgb.org.cn (accessed May 16, 2013) 
205
 http://chgc.sh.cn/en (accessed May 16, 2013) 
206
 www.genomics.cn/en (accessed May 16, 2013) 
 113 
 
Research funding by private parties in China 
 
Research funding received from various private sources is available. Most of funding 
is bound to an operative body, generally a university, for a short term. The 
universities review and fund acceptable research projects for their own staff and 
students. Unlike in the Western countries, pharmaceutical companies in China have 
almost none investment supporting research. Family or individual-driven associations 
for a particular disease, are a limited funding resource due to limited fund raising 
opportunities for this type of initiative.  
 
Known co-operations with international funding agencies in China 
 
Chinese researchers in human genetics collaborate with international research teams 
and have received international funding from bodies such as the NIH, Fogarty 
Foundation, WHO, Bill & Melinda Gates Foundation, Welcome Trust, CDC, MoD and 
the EU FPs.  
 
 
Egypt 
 
In Egypt, research in human genetics/genomics is primarily done at the NRC, the 
largest research and development centre in Egypt 207 ). In addition, research in 
genetics along with other research and surveys under the theme “prevention of 
disabilities” is included within the yearly plan for research presented by the MoH&P’s 
Children with Special Needs Department. 
 
Research funding by private parties in Egypt 
 
International pharmaceutical companies fund pharmacogenetic related research. 
Other private companies (e.g. Clinilab and Genzyme) provide equipment and drugs 
for research purpose.  
 
Known co-operations with international funding agencies in Egypt (some data 
are unavailable): 
 
(i) The EU funded project with the Kasr El-Einy friends association is 
researching prevention, early detection and early intervention in Egyptian 
children with genetic disability and children at risk. Ten metabolic disorders are 
screened using tandem mass (MS/MS technique) for screening and diagnosis. 
Filter paper stored blood specimens from 25000 newborns is utilized in 
screening for CH. 
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(ii) A EU funded project is screening for PKU and Galactosemia on 60.000 filter 
paper neonatal blood specimens previously used in neonatal screening for 
CH. The specimens were acquired in the three main zones in Alexandria. 
(iii) EUMEDIS (Euro-Mediterranean Information Society)208 project; MEDGENET 
(Euro-Mediterranean Network for Genetic Services209). A EU funded project in 
collaboration with the European Genetic Foundation, Bologna, Italy. 
 
 
India 
 
During the last decade, substantial funds have been made available by the DST210, 
DBT211 , CSIR212  and the ICMR213  to fund genetics/genomics research. All these 
organizations have identified priority areas for funding especially in the area of 
infectious diseases, but including non-communicable disorders. 
 
In 1998, the Functional Genomics Unit was established at the Center for Biomedical 
Technology, later renamed CSIR Institute of Genomics and Integrative Biology 
(IGIB), focussing mainly on genomics and bioinformatics 214 . In 2009, the IGIB 
mapped the human genome for the first time in India. 
 
In 2009, the government approved the establishment of the National Institute of 
Biomedical Genomics 215  (NIBMG) as an autonomous institution. This is the first 
institution in India devoted specifically to capacity building in biomedical genomics, 
and to conduct of basic, clinical and translational research in biomedical genomics in 
an interdisciplinary and integrated way. NIBMG will house an interdisciplinary 
infrastructure that is required for frontier research and applications in biomedical 
genomics, and for training students and scientists in medical-genetic research, 
translation and service. 
 
The Indian government has declared 2010-2020 as the “Decade of Innovation”. The 
programme will be focusing on developing new capabilities in emerging areas such 
as genomics and biotechnology arguing “The sequencing of the human genome in 
India by Institute of Genomics and Integrative Biology (IGIB), Delhi, a constituent 
laboratory of Council of Scientific and Industrial Research (CSIR) has helped India 
join the league of select countries undertaking advanced research in the area of 
genomics.”.216 
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Like China, India is part of the ICGC.217 India is focussing on oral cancer, as this 
cancer is common in the Indian population. 
 
Another international project is the Stanford India Bio-Design that aims at training the 
next generation of medical technology innovators in India.218  
 
India is determined to prevent foreign bio piracy of human bio resources. National 
guidelines not only require Indian DNA samples to be analysed by national scientists 
in national laboratories but also forbids the transfer of DNA samples out of the 
country.219 
 
Research funding by private parties in India 
 
Some of the pharmaceutical companies and biotech companies are funding research 
in the field of genomics for drug discovery. The Chatterjee Group, an investment 
company in the USA, through its Institute of Molecular Medicine has set up a Centre 
of Genomic Application in Delhi and a Centre for Population Genomics in Kolkata. 
 
Known co-operations with international funding agencies in India 
 
A large number of projects in various medical institutions and universities are being 
carried out in collaboration with NIH, CDC and other universities in USA, UK, and 
Europe. There are a number of projects funded by the EU. 
 
 
Oman 
 
In Oman, funds are offered from the TRC220 which prioritises projects benefiting the 
local community. Furthermore, SQU 221  funds small and medium –size research 
programmes, and His Majesty Sultan Qaboos’ Research Fund offers substantial 
research grants. 
 
Research funding by private parties in Oman 
 
Private companies offer limited research grants 
 
Known co-operations with international funding agencies in Oman 
 
The Human Genetic Unit of the MoH222 collaborates with centres of excellence in 
Germany, the Netherlands, UK and USA as well as the SQU. 
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The Philippines 
 
In the Philippines, genetics and genomics compete with other disciplines in securing 
funding for research grants. Genetic and genomic research continue to compete with 
the top 10 causes of morbidity and mortality for available research funds. The DoH is 
offering funding opportunities for operational research in genetics. The Department of 
Science and Technology has dedicated funding support for the Philippine Genome 
Center (PGC) but limited its use to certain diseases (i.e. neglected tropical diseases, 
cardiovascular diseases and diabetes). 
A new development (since January 2013) is that the government will, through a 
special government budget of the CHED and with the creation of the Philippine 
California Advanced Research Institutes (PCARI), support innovative health and 
translational research. 
The IHG-NIH223 is the major public research institute for both congenital and genetic 
disorders and complex diseases. 
 
Research funding by private parties in the Philippines 
 
There is very limited funding from private parties. Some pharmaceutical companies 
involve local researchers in international projects. 
 
Known co-operations with international funding agencies in the Philippines 
 
There are several collaborations being undertaken by researchers, especially for 
complex diseases. Two current collaborations are: 
(i) the PBDS Project224 – supported by MoD Global Network for Maternal and 
Infant Health; 
(ii) sub-phenotyping and genetics in oral-facial cleft families in the Philippines – 
in collaboration with the University of Iowa (USA) and the University of 
Pittsburgh (USA). 
 
 
South Africa 
 
In South Africa, there are no policies specifically covering funding for research in 
human or medical genetics/genomics. However, the government does fund some 
medical research, including research in the field of human genetics/genomics, 
through two bodies, the SA Medical Research Council (SAMRC)225 and the National 
Research Foundation (NRF)226. 
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Through the NRF the National Department of Science and Technology (NDST)227 
has a programme that financially augments certain research grants and this has 
aided medical genetics/genomics research. The NDST, through its biotechnology 
strategy has funded two Biotechnology Regional Innovation Centres (BRICS). These 
are high throughput genomics laboratories, namely the LifeLab at the University of 
KwaZulu Natal228 and Centre for Proteomics and Genomic Research at the University 
of Cape Town229, in the Western Cape Province. In the former laboratory work is 
mainly on infectious diseases and in the latter contract research in the field of human 
genetics/genomics is undertaken. The NDST also funded the National Bioinformatics 
Network and, recently, has provided funding for 2010 and 2011 for Phase 1, the 
planning phase, of a National Human Genome Initiative. The NHLS230 Research 
Trust231 funds research in pathology, including medical genetics. Staff across the 
NHLS received 367 research grants during the 2008-2009 year, valued at ZAR 124 
million (~10.6 million €/ 13.9 million US$ in April 2013), with ZAR 21 million (~1.8 
million €/ 2.3 million US$ in April 2013) coming from the NHLS Research Trust.232 
The amount awarded specifically for human genetics research is not available. 
However, projects in human genetics receive funding (on a competitive basis), every 
year, as well as some long-term funding. 
 
Research funding by private parties in South Africa 
 
Research funding is received from various private sources for short term projects 
(generally) on an ad hoc or regular basis. The universities screen and fund research 
projects for their own staff and students. Further, several private donor research 
foundations (e.g. Richard Ward Foundation at WITS University) held by universities 
have funded genetics projects from time to time. Some of the funding for human 
genetics projects at the University of Cape Town comes from genetic support groups, 
such as Retina South Africa who have funded research on inherited retinal disease, 
over many years, and the Muscular Dystrophy Foundation who fund various research 
projects in their field. Also, the Cancer Association of South Africa (CANSA) funds 
research on cancer at several universities. 
 
Known co-operations with international funding agencies in South Africa 
 
South African researchers in human genetics collaborate with international research 
teams and have received international funding from bodies such as the NIH, Fogarty 
Foundation, WHO, Wellcome Trust, US Aid, CDC, the MoD and the EU through the 
EU FPs. Also, the Genographic Project of the National Geographic Society has 
supported (2006-present) population genetic studies in the Human Genome Diversity 
and Disease Research Unit, at WITS University. 
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Current centres of excellence in genetics/genomics research 
 
Currently centres of excellence in genetics/genomics research are present in most of 
the countries, apart from South Africa. However, approximately 10 years ago the 
SAMRC233 awarded 3 MRC of South Africa Human Genetics Research Units. These 
units of excellence are at WITS University234 (Human Genome Diversity and Disease 
Unit), the University of the Western Cape 235  (Unit for Capacity Development in 
Bioinformatics), and the University of Cape Town 236  (Human Genetics Research 
Unit). These units are focused on capacity development. 
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In conclusion 
 
In contrast to largely underdeveloped, underfunded genetic services in the public 
domain, the governments of most GenTEE countries have put substantial 
resources into genetic, mainly genomic, research during the last decade. This 
includes Brazil, China, India, South Africa, the purpose being to promote research 
with the aim to become self-reliant in frontline research areas.  
 
Even lower-middle-income countries have committed funds into furthering genomic 
research as in the Philippines where the government founded a national genome 
centre.  
 
Countries such as Brazil, China and India clearly pursue the strategic goal to move 
their countries into the vanguard of genomics research. This often addresses 
research outside the field of medical genetics, and includes oncogenomics, 
pharmaceutics, communicable disease control, vaccine development and 
pharmacogenomics.  
 
Although Brazil, China and India have developed cutting-edge capacity in a 
remarkably short period of time to undertake genetic/genomic research, huge gaps 
exist in the translation of such research into routine health services due to the 
lack of capacities in the health care sector and poorly developed genetic services 
policy and infrastructure in the public domain. As a result, in most GenTEE countries 
genomics research is not connected with public health services. 
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VIII Patient organizations and public education in genetics 
 
Establishment of patient organizations, main activities including lobbying and 
advocacy activities 
 
Argentina has a long tradition of patient organizations as advocates for services and 
research and the number and strength of patient organization is growing. 
 
Most patient organizations link with health professionals and research scientists to 
stimulate the development of new treatments and prevention strategies. 
While most patients’ organizations deal with a particular condition, there has been 
recently a tendency toward union in umbrella groups. One such umbrella group is the 
Geiser Foundation. 237 
 
Due to lobbying activities of patient organizations, a number of laws have been 
passed in Congress for the support of patients with specific conditions and research. 
The National Ministry of Science and Technology has funded a research project on 
the needs of patients and families with rare diseases, which detailed those needs 
and presented them to Congress in 2009.238 
 
 
Brazil: There are at least 100 different organizations, some just plain “kitchen table” 
and very few more professionally organized, such as the Associação Brasileira de 
Assistência a Mucoviscidose (ABRAM).239 
It is very hard to access data on how many organizations for genetic disorders exist 
in Brazil. Data provided by the Aliança Brasileira de Genetica (ABG240) show there 
are 40 affiliated organizations. But this is certainly underestimated, as the Federação 
Brasileira das Associações Síndrome de Down 241  is not part of the ABG, and 
congregates more than 60 associations of Down syndrome and other organizations. 
The structure of patient organizations varies widely, although most operate on a 
voluntary basis. Even the ABG does not have its own formal structure; it is helped by 
its members when necessary and by demand. 
The main activities of the patient organizations comprise: educating health 
professionals and the society, advocacy for public policies. Some are providing care 
for patients and support for parents. Advocacy actions include better social inclusion 
and education, public awareness of rare diseases, research funding and treatment 
for rare diseases. Most patient organizations are linked to a university, research/ 
reference diagnostic or treatment centre for genetic disorders. 
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China: Currently, there exists no independent patient organization officially 
recognized by the government. All patient organizations are registered under the 
administration of the National Bureau of Public Organization, Chinese Ministry of Civil 
Affairs. The organizations generally have an elected committee. Members include 
parents, family members, affected individuals and other interested people. Some 
groups (such as the Autism group) have a medical advisory board and few of them 
have a fund-raiser.  
 
The objectives of most of the patient groups are similar and aim at seeking political 
legislation/policy support, raising awareness about the condition they represent in the 
community; offering support, advice and literature for affected individuals and their 
families. 
 
Some policy and lobbying activities take place, such as making contact with the 
Central MoH and the Ministry of Education regarding promotion on special education 
for specific disorders (e.g. Down syndrome) and to the Communist Party’s Central 
Secretary Committee and printing brochures on specific disorders. 
 
 
Egypt: There are approximately 10 NGOs active in the field of genetics. They play a 
crucial role in supporting the community genetic counselling programme. In addition, 
there are 120 NGOs working in the field of maternal and child health and disabilities.  
 
Most NGOs provide support for genetic patients. Some are funding training courses 
in early detection of genetic and congenital disorders for nurses and social workers 
and practical training in genetics for physicians. Some offer CBR services, early 
stimulation, behavioural modification speech therapy and other rehabilitation services 
to the patients at no cost. 
 
 
India: Patient organizations have a long tradition in India. The current number of 
parent organizations for genetic disorders is unknown. 
 
There are nearly 50 haemoglobinopathy patient organizations. Some of these 
organizations are very active such as: Thalassemics India, National Thalassemia 
Welfare Society, Thalassemic Society of India and the Thalassemia and Sickle Cell 
Society of India. Parent organizations have formed the “Federation of Indian 
Thalassemics”.242 The federation has created a network to coordinate services and to 
pressure the government to provide free treatment such as factor VIII. (Factor VIII 
treatment is now provided free in government hospitals in many states.) 
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A large number of organizations is working in the field of mental retardation, cerebral 
palsy and autism. The organizations for mental retardation and cerebral palsy have 
succeeded in having a count of the disabled people in India in the national census 
for 2011. They have also successfully lobbied the government to provide homes for 
the care of the mentally handicapped. 
 
The Federation of Indian Thalassemics succeeded in having the excise and custom 
duties on iron chelators to be reduced substantially, resulting in the availability of 
cheaper drugs in India.  
Patient organizations have been successful in having Indian Railways to provide free 
transport for affected persons. 
 
5-6 organizations are in the field of muscular dystrophies. There is no single umbrella 
alliance under which patient organizations operate. 
 
Most organizations organize regular meetings and CMEs on proper management and 
often with the help of foreign experts. 
 
 
Oman has several parent/patient organizations, mainly the Oman Society for 
Handicapped, Oman Association for Handicapped Children funded by the Ministry of 
Social Development, the Oman Blind & Deaf Society, the Early Intervention Society, 
and the Sickle Cell &Thalassemia Association. 
Their main functions include: providing funds and supervision of schools, 
manufacturing and distribution of hearing aids, offering educational, counselling and 
joint social activities, providing wheal-chairs and jobs in sheltered workshops, 
providing rehabilitation and vocational training, professional training, providing early 
intervention for children with developmental delay at the age of 1-6 and offering 
assistance to affected families, including medications. 
 
The “National Programme for Prevention of Genetic Blood Disorders” education 
campaign includes lectures, media appearances, printed educational materials, 
advocacy sessions tailored to the needs of affected families. 
 
 
The Philippines: The main parent/patient organizations are: the Down Syndrome 
Association of the Philippines, Inc (DSAPI), the Philippine Society of Orphan 
Disorders (PSOD) and Balikatang Thalassemia. 
 
The DSAPI was established in 1992 to offer support to families who have a child with 
Down syndrome and to initiate, develop, promote, encourage and support 
programmes and projects concerning Down syndrome. 
 
Through the efforts of the parents, the month of February was declared as the 
“National Down Syndrome Consciousness Month” by the President of the Philippines 
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in 2002.243 Based on this proclamation government departments (DoH, Department 
of Education, Department of Labor and Employment, Department of Social Welfare 
and Development) and related agencies and appropriate NGOs were enjoined to 
support and cooperate with the activities of the DSAPI.244  
 
The PSOD was founded in June 2006 with a main objective to continue the efforts of 
physicians (mostly from the IHG-NIH-UP) to ensure sustainability of medical and 
financial support of patients with “rare disorders.” 
 
The PSOD is currently lobbying the enactment of the “Rare Disease Act of the 
Philippines.”245  
 
Project Rare Program was launched by the PSOD in 2009. The project kicked off a 
public awareness campaign to support the care of children born and afflicted with 
rare diseases. A series of activities aim at (i) increasing the registry of patients and 
referring them to the IHG-NIH for diagnosis and available treatment, (ii) building a 
network of voluntary partners and friends and, (iii) building an endowment fund to 
sustain the lifelong medical treatment and therapies of patient members. 
 
The endowment fund helps to sustain the lifelong treatments of patients as well as to 
provide financial support for research on rare disorders. The fund also aims at 
making the PSOD self-sustaining. An emergency fund helps to address immediate 
needs of patients with medical emergencies. This can include, but is not limited to, 
providing life-saving medicines, hospitalization, purchase of supportive medical 
devices, and other support. 
 
The Balikatang Thalassemia foundation was founded in 1995 with the main objective 
to provide medical assistance, education, and counselling to thalassemic patients, 
their parents, and families. To make thalassemia a public health concern and to 
ensure government support for its different programmes, the organization supported 
the enactment of the National Services Act of 1994 which was activated in 1999 as 
the Republic Act 7719. This act mandated the Children’s Medical Center Philippines 
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(now the Dr. Fe Del Mundo Medical Center) as the “Thalassemia Center of the 
Philippines”. 
 
The National Council for Disability Affairs (NCDA) [formerly National Council for 
the Welfare of Disabled Persons (NCWDP)] is the national government agency 
mandated to formulate policies and coordinate the activities of all agencies, whether 
public or private, concerning disability issues and concerns.246 
 
The NCDA is the lead agency tasked to steer the course of programme development 
for persons with disabilities and the delivery of services to the sector. The NCDA 
monitors the implementation of laws to ensure the protection of persons with 
disabilities’ (PWD) civil and political rights.  
 
South Africa: Parent/patient groups for a number of the common genetic conditions 
are established. Many were started in association with and with encouragement from 
the Southern African Inherited Disorders Association (SAIDA). This association was 
initiated by a medical geneticist and genetic counsellor in 1975, in response to the 
request of a couple with a child with Tay Sachs disease. There are currently 25 
groups who are members of SAIDA, a further 24 groups who have been members in 
the past, and a few who are loosely connected or function independently. Most 
groups operate from the big cities and offer country-wide services to anyone affected 
by or interested in their specific disorder. 
 
Some policy and lobbying activities take place, such as making contact with the 
National DoH Genetic Services division to print brochures on specific disorders (e.g. 
Turners syndrome), or the Department of Education regarding inclusion and 
mainstreaming policies (e.g. for children with Down syndrome), or the Department of 
Labour regarding employment for disabled people. Advocacy activities also occur 
(e.g. self-advocacy courses for adults with Down syndrome), and empowerment 
activities (e.g. affected individuals seeking free provision of sun-barrier cream for 
people with albinism at government hospitals). 
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Below Box 8.1 lists the most important parent/patient organizations in GenTEE 
countries. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Box 8.1 Parent & Patient Organizations in GenTEE countries (2012) 
 
Argentina Asociacion Sindrome de Down de la Republica Argentina (ASDRA) (http://www.asdra.org.ar)  
Geiser Foundation (http://www.fundaciongeiser.org/?lang=en)  
 
Brazil  Aliança Brasileira de Genetica (http://www.abg.org.br)  
Associação Brasileira de Assistência a Mucoviscidose (http://www.abram.org.br)  
Federação Brasileira das Associações Síndrome de Down (http://www.federacaodown.org.br)  
 
China  Home for Premature Babies 
 
Egypt  Egyptian Thalassaemic Friends Association 
 
India  Down’s Syndrome Care Association (DSCA) (http://www.dscaindia.org) 
  Down Syndrome Federation of India (http://www.downsyndrome.in)  
  Indian Association of Muscular Dystrophy (http://www.iamd.in)  
Muscular Dystrophy Foundation India (http://www.mdfindia.org/stage/index.php) 
Thalassemics India (http://www.thalassemicsindia.org)  
  National Thalassemia Welfare Society (http://www.thalassemiaindia.org)  
  Thalassemia and Sickle Cell Society of India (http://www.tscs.in)  
Muskaan (Parents organization for children with mental retardation (http://muskaan-delhi.com/)  
Action for Autism (http://www.autism-india.org/)  
Fragile X syndrome society of India (http://www.fragilex.in)  
 
Oman  Early Intervention Society for Children with Disabilities (http://www.aei.org.om)  
Oman Blind & Deaf Society 
Oman Hereditary Blood Order Association (http://www.omancares.org/en) 
  Oman Society for Handicapped 
         
The Philippines Balikatang Thalassemia (http://www.thalassemiapatientsandfriends.com/)  
Down Syndrome Association of the Philippines, Inc (DSAPI) (http://dsapi.org)  
Philippine Society of Orphan Disorders (PSOD) (http://www.psod.org.ph/ver2/) 
    
 
South Africa Down Syndrome South Africa (DSSA) (http://www.downsyndrome.org.za)  
Southern African Inherited Disorders Association (SAIDA) (http://www.saida.org.za/)  
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Funding 
 
Argentina 
Patient organizations get funding from their own members, from private foundations 
and from the government 
 
 
Brazil 
Most patient organizations are financed by donations and by their members; support 
from the society in general is quite rare. There is no information regarding financing 
of the organizations. 
 
 
China 
Fund raising is generally undertaken in a very limited way, unless the association is 
well recognized and a financial professional is involved in the actual 
operation/organization of the association. Most support groups receive very little 
funding via various sources. Government seldom funds the small public 
organizations, the majority of the funding come from membership fees and donations. 
Some large associations may own their own retailing or publishing company as their 
continuous solid source of funding. 
 
 
Egypt 
Sources of funding are donations through fundraising activities. 
 
 
India 
Patient organizations are funded by donations, memberships dues and are 
sometimes supported by the government. 
 
 
Oman 
Sources of funding are donations through fundraising activities 
 
 
The Philippines 
DSAPI is a non-stock, non-profit organization, whose members are volunteers. The 
primary sources of funding come from membership fees, voluntary contributions and 
donations from friends and supporters. 
 
PSOD is a non-stock, non-profit organization, the endowment fund and the 
emergency fund sustain the lifelong medical treatment and therapies of patient 
members. 
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Balikatang Thalassemia is a non-stock, non-profit, non-political corporation founded 
in 1995.  
 
South Africa 
Fund raising is generally undertaken in a limited way, unless a fund-raiser is 
employed or a member of the group undertakes this responsibility systematically (e.g. 
Retina South Africa, who have a large budget and support research). Most support 
groups receive very little or no regular government funding (with the exception of the 
Cleft Pals Support Group that has some government funding) and fund themselves 
through membership fees and donations. Where fund-raising is undertaken, most 
funding comes from private businesses, corporate and individual donors, sometimes 
from pharmaceutical companies, and in a few cases from international bodies (e.g. 
the Haemophilia Foundation receives some support from the World Federation for 
Haemophilia) and grants from the national lottery. 
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Public education in genetics 
 
Argentina 
Primary prevention measures focus on folic acid fortification, rubella immunization, 
campaigns against tobacco and alcohol 
 
 
Brazil 
There is no specific focus from the government or the National MoH on the 
prevention of congenital / genetic disorders.  
Brazil has a policy of flour fortification (wheat and maize); salt is iodised. 
Rubella immunization is available and the programme includes specific awareness 
campaigns for women in reproductive age; 
There are labels in alcoholic beverages and cigarettes informing about consumption 
risks during pregnancy; 
Women are informed about the importance of newborn screening during prenatal 
care. 
 
 
China 
Due to the increased awareness of the central government, protocols have been 
established to address congenital/genetic disorders. China provides free folic acid 
supplement to women from 3 months before to 3 months after the beginning of 
pregnancy. As a result the prevalence of neural tube defects has fallen by approx. 
30% nationally, and by 50% 247 in some provinces that had higher prevalence rates 
of neural tube defects previously. Salt has been iodised for many years. 
 
Lay groups, such as labour unions, women’s unions or residential societies, may 
routinely organize talks given by human genetics professionals. Although genetic 
counselling is not recognized as a health profession currently in China, obstetricians 
and gynaecologists are counselling and giving educational lectures to both 
professionals and to the public. Maternal & child health hospitals and other 
professional/governmental groups (including voluntary groups such as Best Baby 
Association and National Health and Family Planning Commission248) may compile 
leaflets for distribution on a number of common disorders, as well as on PND and 
genetic counselling services. 
 
 
Egypt 
The MOH&P has adopted several ways to improve the knowledge, attitude and 
practice of the women in the childbearing period for the prevention of congenital and 
genetic disorders including health education seminars, social mobilization 
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 Data provided by Nanbert Zhong, Peking University Center of Medical Genetics, Beijing, People’s Republic of 
China. 
248
 http://www.npfpc.gov.cn/ (accessed April 25, 2013) 
 128 
campaigns, designing educational leaflets and brochures for proper nutrition, safe 
pregnancy and safe motherhood. A yearly budget is allocated for training and 
education of nurses and community outreach visitors on health education including 
the proper methods to deliver health education massages for the community and 
certain specific messages for the preventive national programmes like the importance 
of antenatal visits, inter-conceptual care programme and community genetic 
counselling programme. 
 
 
India 
The Indian government focuses on the reduction of the prevalence of low birth weight 
and premature deliveries.  
The use of folic acid before pregnancy is advocated by health professionals. 
The Micronutrient Initiative India249 supports India’s salt iodization programme and 
has initiated pilot projects on iron folic acid. 
 
 
Oman 
A number of educational materials has been produced in the past 10 years including 
management guidelines and educational booklets250: 
Education is provided through media including radio and TV interviews, TV spots and 
mobile telephone messages. Education activities in schools and colleges include 
lectures, public events and a marathon. 
 
The National Programme for the Control of Genetic Blood Disorders provides 
community counselling and education for haemoglobinopathies. 
 
 
The Philippines 
There is a national campaign for the newborn screening panel including since 2012 
six disorders (CH, CAH, galactosemia, G6PD deficiency, PKU and Maple Syrup 
Urine Disease (MSUD)). 
 
The Volunteer Youth Leaders for Health - Philippines (VYLH), a network of youth 
leader volunteers from the different youth organizations, assists in the advocacy of 
the campaign on folic acid awareness. Currently, the network is doing advocacy and 
promotional work in their respective schools and communities on increasing 
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 http://www.micronutrient.org/english/view.asp?x=603 (accessed May 8, 2013) 
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 Published MoH materials include: 
1.“Facts of Life” for school and university students explaining healthy living (has genetic disease section), 
2. Picture guide “Understanding heredity” for individuals with limited ability to read explaining heredity with help of 
visual graphics (units of heredity, chromosomal inheritance and basis of Autosomal Recessive inheritance.), 
3. Information for: Sickle Cell disease patients with explanation of pathology, possible treatments and inheritance 
4. Information for Beta-Thalassemia patients with explanation of pathology, possible treatments and inheritance 
5. Information for understanding of pathology of G6PD deficiency, avoidance of crises and inheritance 
6. Information for understanding Down syndrome with medical management plan and rehabilitation 
7. Leaflets produced: Carriers of Sickle Cell, Carriers of Beta-Thalassemia, G6PD Deficient, Explaining x-linked 
inheritance 
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awareness among women in their reproductive age on the significance of folic acid 
supplementation. Also included in the activities are: increasing public awareness in 
saving babies from mental retardation and death through newborn screening and 
lobbying public support for the passage of the Rare Disease Act. The youth 
volunteers are handing out promotional flyers and posters on newborn screening; 
delivering lectures and exhibits on folic acid; organizing and conducting symposia on 
newborn screening, congenital and genetic disorders surveillance and folic acid 
campaign; and conducting signature campaign for the Rare Disease Act. 
 
 
South Africa 
Due to concerted lobbying, South Africa has had fortification of basic foods, such as 
bread and maize meal, for some years, and as a result the prevalence of neural tube 
defects has fallen by 30%.251 Salt has been iodised for many years preventing most 
cases of postnatal iodine deficiency disorders and goitre.  
 
Public and professional education, covering recognition and prevention of congenital 
disorders, takes place at many levels. Health professionals, including nurses, receive 
some basic teaching in medical genetics during their degree and diploma studies, as 
well as in-service training when they are employed. Lay public groups, such as rotary 
clubs and women’s groups, have talks from human genetics professionals when they 
request them. These professionals also give radio interviews when asked to do so. 
Genetic counsellors give educational lectures to a number of professional and lay 
groups252 and compile leaflets for distribution on a number of common disorders (e.g. 
genetics of breast cancer), as well as on PND and genetic counselling services. 
SAIDA puts out an annual educational newsletter, which is distributed to professional 
and lay groups.  
 
Furthermore, SAIDA, with support funding from the Human Genetics sub-directorate, 
National DoH, and more recently the national lottery, offers a short-term course, the 
Medical Genetic Education Programme (MGEP) on basic genetics for primary 
healthcare workers. The course is directed at doctors and nurses working in primary 
healthcare clinics and covers aspects of basic genetics, including the identification, 
basic treatment and counselling (particularly breaking bad news) for affected children 
and their parents. The course consists of a combination of contact days, with lectures 
and workshops, as well as self-directed learning by using a provided text-book. In this 
manner, it is hoped that more patients and their families are reached and that earlier 
diagnoses can be made, as well as earlier intervention and care implemented. 
Nurses and doctors alike are participating in these courses, and it is hoped that a 
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 Sayed A-R, Bourne D, Pattinson R, Nixon J, Henderson B (2008). Decline in the prevalence of neural tube 
defects following folic acid fortification and its cost-benefit in South Africa. Birth Defects Research (Part A); 82: 
211-216. 
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 Kromberg JGR, Krause A, Wessels T (2009). Roles of Genetic Counsellors in South Africa. SA Society for 
Human Genetics 13th congress, 5-8 April 2009, Stellenbosch, South Africa. Book of Abstracts p36. 
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result will be more accurate reporting of congenital and genetic disorders, which will 
add to the epidemiological data for the country.  
 
One day workshops are held, occasionally, for general practitioners in Johannesburg, 
and in some other urban areas of the country. However, due to the inadequate 
number of medical geneticists and genetic counsellors working in the country, 
availability of skilled human resources for the expansion of community education 
programmes remains a challenge. 
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Civil society engagement: Patient organisations in GenTEE countries 
 
Comment by Alastair Kent, Genetic Alliance UK 
 
Although each of the GenTEE countries are different in terms of their social structures and their health 
care systems they all have emerging patient support organisations. While there are clear differences 
between each of the participant countries in the extent to which these groups have emerged, there are a 
number of similarities that can be identified. 
 
The first of these, and one of the most significant, is the hand to mouth existence forced on many patient 
organisations by the lack of any infra-structural funding from the state. Whilst no-one has a right to 
financial support simply by virtue of existing, the absence of reliable core funding forces patient groups 
back on their own resources supplemented by what can be raised through fundraising and other efforts. 
For groups which comprise patients and carers, already constrained by the limitations of their condition 
and the impact this has on their everyday opportunities, this can be a significant limitation to the 
achievement of their potential. 
 
A second common element is the way in which families affected by relatively common genetic conditions 
tend to be the ones that come together to form support groups first. Thus where haemoglobin disorders 
are common there tends to be a better established group than for many of the rarer conditions. Down 
syndrome too is an early condition for the emergence of support groups. 
 
Thirdly, coverage is by no means universal. Many patients do not have a support group to turn to for help, 
and where these exist it is perhaps as a result of the initiative of a particularly charismatic individual, 
possibly working in partnership with a clinician of an established centre. 
 
A fourth feature groups have in common is that, despite any progress they might make in improving 
services and support for their member families from the statutory sector, direct services and support, 
particularly the dissemination of practical advice on day to day issues remains a key strand of their work. 
 
There is an emerging trend for condition specific support groups to come together in alliances to create 
common ground and generate the critical mass necessary to be effective in the strategic advocacy role 
that many aspire to. This is most notable in South Africa and Brazil, where established alliances have 
played a significant role in profile raising and the generation of awareness, but there are signs of this 
trend elsewhere too. 
 
Looking at the GenTEE country reports as a whole, what can be observed is a growing recognition of the 
legitimacy of the patient and family perspective (albeit to a varying degree for instance there are still 
strict limitations for establishing parent and patient organizations in China and Oman) on what and how 
services and support can and should be provided.  
 
This is developing as a collaborative issue, with the different contributions from all; key stakeholders 
gradually being recognised and made a formal element of the process whereby clinical and medical 
genetics services are provided to communities and populations. This has to be a welcome development, 
but there are major challenges to be overcome before the patient and family voice is automatically seen 
as part of the process for determining service provision and for the promotion of the opportunity for high 
quality research into causes and cure for genetic disease. The grass roots movement of the patient 
community is, on the basis of these country reports at least, determined to play a role in shaping the 
future of genetic medicine and genetic services, and the organisations representing patients and families 
have a vital role to play in bringing this about. To succeed they will need support, resources and most of 
all the opportunity to be at those tables where decisions are taken as a right, not as a favour. This will 
necessitate the other stakeholders moving over to make space for this new entrant. It will require 
systems and established ways of working to be adjusted to allow this voice to be heard, and it will require 
investment in promoting and developing the voice of patient organisations so they can articulate the 
needs and issues of their members in ways that can be heard and responded to. The evidence of this 
survey is that there are encouraging steps being taken towards this goal. This is welcome, but the 
development is fragile in many situations and needs to be nurtured to full development. This is the task 
for the coming decade. 
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IX Drivers and barriers for genetic services development 
 
Argentina: 
 
Drivers:  
 
Policies to improve capacity and access to services 
 
In Argentina, the National MoH has recently shown interest in improving access to 
and performance of the clinical genetics services throughout the country. 
 
A National Commission on Genetics and Health, appointed in 2005, conducted 
countrywide studies on the situation of genetic services and submitted a proposal to 
the Ministry for their improvement. The proposal asked that the number of positions 
of clinical geneticists in public hospitals be increased and that the laboratory 
equipment for cytogenetics and molecular genetics in several hospitals countrywide 
be modernized and expanded. The Commission conducted a survey of genetic 
services and proposed the organization of a network of genetic services to maximize 
their efficiency, avoid duplication of services, and channel referrals in a regionalized 
manner.253 
 
Acting on such recommendations, in 2010 the National MoH started some actions to 
improve the capacity of the existing genetic units in the public system. 
 
In addition, RENAC has begun in 2009 in selected provinces, centrally coordinated 
by the National Medical Genetics Center, an agency of the National MoH. In the 
period 2009-2011, 182,070 live neonates (28% of the total annual number of births of 
the country) were examined in 107 hospitals, finding 3,234 neonates with major 
structural defects (1.78%).254 This will lead to the availability of better actionable data 
for informed policy decision making to improve services. 
 
Service providers’ initiatives 
 
The National Pediatric Hospital Garrahan has taken a leadership role in conducting 
training in clinical genetics for primary care health personnel in several underserved 
areas of the country. 
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 Alba A, Barbero P, Barreiro C, Chertkoff L, Dain L, Ferreiro V, Francipane L, Frechtel G, Gallego M, Liascovich 
R, Meroni ME, Rozental S (2007). Diseño y organización de una Red Nacional de Genética Médica (Design and 
organization of a national network of medical genetics.) Spanish. Unpublished, available from the author. 
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 RENAC-Ar (2012). Registro Nacional de Anomaías Congénitas de Argentina. Publication of the Ministry of 
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Barriers: 
 
Barriers are mainly bureaucratic as each province has its own set of policies and 
budget, and the National MoH does not have much leverage or resources to impose 
policies. 
 
 
Brazil:  
 
Drivers:  
 
Policies to improve capacity and access to services 
 
The Brazilian MoH published a decree in 2009, which proposes the creation of a 
“Política Nacional de Atenção Integral em Genética Clinica no SUS” (National Policy 
for Comprehensive Care in Clinical Genetics at SUS).255 However, the decree is still 
waiting for implementation. Currently, a commission is elaborating a policy for rare 
disorders which may include a policy for genetic disorders (expected to be 
implemented in 2013). 
 
 
Brazil has made significant investments to fund research in medical genetics and 
genomics. The main funder is the public sector, both state and federal. 
 
Barriers: 
 
 Delayed implementation of national policies to improve genetic services; 
 Geographical unavailability of services; 
 Lack of universal coverage; 
 Availability of services at primary care level very limited; 
 Legal constraints concerning abortion; 
 Medical genetics not a formal specialty in the Unified Health System (SUS) 
leading to few available job positions for geneticists. 
 
Future outlook: 
 
Organizing a network in clinical genetics 
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 Brasil (2009a), Ministério da Saúde, portaria GM no. 81, 20 de janeiro de 2009 – Institui, no ambito do Sistema 
Único de Saude (SUS), a Politica Nacional de Atenção Integral em Genetica Clinica. Diário Oficial da União 
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The network configuration of services in clinical genetics (regionalized, hierarchical 
and functional, as recommended in the creation of the SUS) will be a crucial item for 
care in medical genetics. 
 
Government initiatives that already exist need to be consolidated 
 
In addition to formalizing and carrying out the organization of a network in clinical 
genetics in Brazil, other actions need to be implemented for the system not only to 
properly function, but also to be gradually expanded and adapted to the country´s 
growing needs. Government initiatives that already exist need to be consolidated, 
and non-governmental programmes may eventually be added and enrich the system. 
As examples of optimization and integration, informing city officials about the 
importance of the correct completion of "Field 34" of the “Liveborn Declaration” 
(“Field 34” addresses congenital anomalies present at birth) needs to be 
encouraged.256 
 
Integration of genetic services into the Unified Health System/SUS 
 
Considering the magnitude of the impact that congenital and genetic disorders 
already have on health, in a country like Brazil, as well as all the perspectives 
generated by the advances in this field, it must be assured that genetic services and 
testing are appropriately integrated into health care in Brazil and become part of the 
SUS. 
 
Supporting parent and patient organizations 
 
The importance of patient-parent organizations should be reinforced; besides offering 
support and comfort to their members, such associations have as objectives the 
dissemination of information among lay people and to physicians. These non-
governmental associations can play a fundamental role of introducing new topics on 
the political agenda.  
 
Improvement of education in genetics including ethical issues 
 
The issue of prevention needs to be addressed including MToP. 
 
 
China:  
 
Drivers: 
 
Policies to improve capacity and access to services 
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China is a fast developing country with the largest population size in the world. The 
economic situation and quality of life of the population have improved dramatically in 
the past 20 years. Since the founding of the Republic in 1949, the central 
government has given a great deal of attention to maternal and child health. As a 
consequence, during the last two decades, China made substantial progress in 
reducing maternal, infant and under-five mortality. 
 
Barriers: 
 
Nevertheless, national figures for maternal, infant health indicators mask large 
disparities, which exist between urban and rural populations, and across different 
regions of China. There is limited access to medical genetic services and maternal 
and infant death rates are highest among the rural poor and migrant population, and 
in those regions with least access to antenatal and intrapartum care, such as the 
western provinces. 
 
Future outlook: 
 
The governmental awareness in health service is moving towards coverage for the 
whole population as well as to the development of state of the art molecular 
diagnostic centers. It is widely believed that in the short future, the imbalance of 
health service between urban and rural areas will be improved, and more molecular 
tests will be available for the public. 
 
 
Egypt257 
 
 
India: 
 
Drivers: 
The control of infectious diseases through immunizations and therapy has led to the 
emergence of congenital and genetic disorders as important causes of morbidity and 
mortality in urban areas. The government has realized the burden of non-
communicable disorders. Parent and patient organizations have put pressure on the 
government to pay attention to the burden of congenital and genetic disorders like 
autism, haemophilia and thalassemia. States now provide free treatment to patients 
with thalassemia and provide free factor VIII therapy to patients with haemophilia 
through government hospitals. Recently the government has launched an ambitious 
programme to screen for congenital disorders such as blindness, deafness, cleft lip 
and palate, autism, cognitive decline and others, starting in about 20 districts and 
then spreading this programme to all districts in India.258 The National Rural Health 
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Mission (NRHM)259 established by the government of India is improving primary care 
for easily recognizable congenital defects. 
 
 
Funding agencies (DST, DBT, ICMR, CSIR) are investing heavily in genetic 
biotechnologies and genetic research realizing the potential of the new 
genetic/genomic technologies available in the post-human genome project era.  
 
Barriers: 
 
The sheer size of the country and its vast population, living predominantly in the rural 
areas, has hindered the provision of genetic services to many people. The cost of 
genetic testing services, the lack of medical geneticists and genetic counsellors is 
also a barrier. The mindset of the government administrators (priority given to 
infectious disorders, limited understanding of the burden of congenital and genetic 
disorders and of the scope of available interventions for care and prevention) is not 
yet attuned to providing genetic services and therefore administrators still lack 
political will and commitment to these services. The money is there but genetics still 
has a very low priority for the government. 
 
 
Oman:  
 
Drivers: 
 
The main drivers for the development of medical genetic services are 
 
(i) the increasing recognition by policy-makers of community needs for genetic 
services and  
(ii) the increasing availability of new genetic information evolving from the 
advancement of the science of genetics and better understanding of 
genetic predisposition to adult-onset disorders. 
 
 
Policies to improve capacity and access to services 
 
The MoH Health of The Sultanate of Oman has recognized the need for genetic 
services and genetic technologies as means for controlling genetic diseases in the 
Sultanate and aims at ensuring high standard medical care in the era of rapidly 
expanding genetic science and biotechnology. 
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A National Committee for the Prevention of Genetic Diseases was established in 
2004 and includes representatives from Ministries of Health, Education, Social 
Affairs, Information and National Economy. 
 
In 2005, the MoH of the Sultanate of Oman published its 7th Five-Year Plan for 
Health Development (2006-2010) 260  which included a national strategic plan on 
genetic diseases in order to reduce the infant and under-five morbidity and mortality 
to the lowest international rates. 
 
Among the strategies implemented to achieve these objectives, a National Genetic 
Centre to provide clinical and laboratory diagnostic services was established to 
provide care services and to support community prevention programmes, conducting 
training activities and research in the field of genetic health. The construction of the 
National Genetic Centre has been completed in December 2012. 
 
Extensive training of Omani nationals is underway to prepare for functions of the 
National Genetic Centre. 
 
Barriers: 
 
Lack of Omani specialists trained in genetic counselling and bioinformatics. Oman 
still relies on “consultants” from abroad. 
Limited availability of genetic testing services for late-onset disorders and rare 
disorders.  
Due to the scarcity of skilled experts current services are ill-prepared to take 
advantage of the new genetics/genomics technologies and to use new 
genetic/genomic knowledge in clinical patient pathways. 
 
 
The Philippines:  
 
Drivers: 
 
Policies to improve capacity and access to services 
 
The Philippines is one of the most active countries in Southeast Asia in regard to 
genetic services development. 
 
Service providers’ initiatives 
 
The IHG-NIH has taken a leading role to improve the availability and capacity of 
genetic services especially in regard to the successful implementation of a national 
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newborn screening programme, developing counselling services and training of 
manpower in genetics. 
 
 
Barriers: 
 
Being a developing middle-income country, the Philippines is faced with the 
challenge of providing healthcare for all Filipinos. Although one of the most active 
countries in southeast Asia with regard to genetics, the country still has a shortage of 
geneticists and genetic counsellors. Difficulties exist for continued research and 
integration of healthcare services into the public health system. The main barriers to 
accessing genetic services in the Philippines are:  
 
(i) financial, since most families cannot afford out-of-pocket expenses for the 
expensive genetic testing and treatment;  
(ii) geographical, being an archipelago of 7,107 islands; 
(iii) lack of awareness among different stakeholders, i.e., health professionals 
and parents; 
(iv) compromised access to genetic services at the regional and provincial level; 
and 
(v) lack of geneticists and genetic counsellors. 
 
However, despite these shortcomings, the IHG-NIH views a promising future for 
medical genetics in the country, with the help of the government and support of the 
community. 
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South Africa 
 
Drivers:  
 
Policies to improve capacity and access to services 
 
The Constitution, Laws, and Policy Guidelines for the Management and Prevention of 
Genetic Disorders released in 2001, all mandate for the development of services for 
the care and prevention of congenital and genetic disorders. However, as noted 
above, the intention of these has been lost in translation. 
 
Service providers’ initiatives 
 
Medical genetic services was mainly developed in the country by leading medical 
geneticists prior to the onset of the HIV/AIDS and TB epidemics These service would 
have provided an excellent base on which a more comprehensive service can be 
built in the future. 
 
There are four academic departments of human genetics in four of the major 
universities situated in three provinces which have already set up clinical services, 
compatible with any in developed countries, as well as laboratory services, which 
have the expertise to offer genetic testing services to the country and to the rest of 
Africa.  
 
They have also developed a research capacity so that local genetic disorders can be 
investigated on many different levels.  
 
Two of these universities, in collaboration with the NHLS, have established training 
for all the categories of expert staff required to run a sophisticated genetic service. 
 
However, the aging of laboratory equipment and lack of financial support for the 
introduction of new technology are making it difficult for these capable scientists to 
keep up to date with new developments in the field. 
 
 
Although expansion is difficult in the current circumstances, members of the South 
African human genetics community are networking with interested people in the rest 
of Africa and, in March 2011, the first combined congress was organized by the SA 
Society of Human Genetics (SASHG), in conjunction with the African Society of 
Human Genetics (AfrSHG), and held in Cape Town. At this meeting there were 
international experts, as well as those from Africa, networking and sharing their 
expertise, knowledge, insights and needs, which will both benefit and stimulate the 
field of human genetics on the African continent in future. At this stage there is some 
hope that the investment by international and local agencies in, for example, the 
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Southern African Human Genome261 project and the Human Heredity and Health in 
Africa (H3Africa)262 programme, may raise the profile of medical genetic services and 
contribute to their upgrading. 
 
Barriers: 
 
Burden of HIV infection and TB epidemics 
 
South Africa is a country in transition. However, the proportion of the global burden 
of disease borne by South Africa with a population of only 49 million is 
disproportionately high. The total disability adjusted life years for high burden 
diseases in South Africa is almost equivalent to that of Bangladesh, which has a 
population three times as large and living in much worse poverty. 263 One of the 
greatest challenges it faces is the control of the concomitant HIV and TB epidemics. 
In 2007, the country, with 0.7% of the world’s population, had 17% of the global 
burden of HIV infection, and one of the world’s worst TB epidemics, compounded by 
rising drug resistance and HIV co-infection. 264  South Africa is currently 
underperforming in its efforts to control HIV and, although it has the resources and 
capability to rise to these challenges, it has not been able to deliver on the four 
priorities listed in the Strategic Plan for South Africa for HIV/AIDS.265 Since medical 
genetics services are, presently, being developed and delivered against this 
background, it is not surprising that the recommendations in the Policy Guidelines for 
the Management and Prevention of Genetic Disorders266 have not been met. 
 
Declining political commitment to invest in the provision of clinical genetic 
services 
 
The commitment to provide clinical genetic services in South Africa has declined 
over the last few years. There is continued discussion as to whether these services 
should be centrally co-ordinated from the National DoH and provided by the 
provincial Departments of Health, as occurs in the Western Cape and Free State, or 
whether they should be all be provided by the NHLS, as occurs in Gauteng. Until this 
issue is resolved or another solution found, clinical genetics services will not improve 
and are at risk of deterioration. Laboratory genetic services are also at risk from 
increasing demand for tests in the face of reducing staff availability. 
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These issues will be considered by the newly appointed NHLS Expert Committee for 
Medical Genetics Services, and it is hoped that solutions to the situation will be 
found. 
 
Lack of employment opportunities for qualified professionals leading to brain 
drain and understaffed services 
This has become a major problem in the last two years. Two medical geneticists 
have recently qualified and at least another four will qualify in the next two years. No 
posts are available for them and are unlikely to become available in the foreseeable 
future. One newly qualified medical geneticist has already left the country. A similar 
situation has developed for genetic counsellors. 
Medical genetic laboratory service units and staffing is also being reduced resulting in 
decreasing opportunities for medical genetic diagnostic scientists and technologists. 
 
Inequity of access leading to inaccessibility of genetic services for the poorer 
population 
The reducing available clinical genetic services are largely available in three centres, 
Cape Town, Johannesburg and Bloemfontein. Geographic (distance) and expense 
therefore act a serious barriers to most of the public accessing genetic services. 
 
 
Future outlook: 
 
Development of medical genetic services, in the near future, will depend partly on 
increasing the awareness of genetic disorders, partly on lobbying the decision-
makers in the health departments and NHLS, partly on the control and lessening of 
the HIV/AIDS epidemic, and mostly on the provision of more employment 
opportunities for qualified professionals. At present, the available staff can only meet 
at most 10% of the country’s genetics needs (based on a rough calculation of the 
genetic burden of disease). Further technological development (together with 
purchase of the necessary laboratory equipment) should be planned for, so that 
South Africa can approach the level of developed countries. Both political will and 
financial commitment are required to move this enterprise forward. Pressure is being 
brought to bear on key members of the National DoH and its provincial subsidiaries 
by medical genetics professionals, as well as by genetic support group 
representatives, to respond to the basic genetic needs of South Africa and make an 
adequate and appropriate medical genetic service available. Given current 
circumstances these are unlikely to succeed in the foreseeable future. 
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Below a short SWOT (Strengths, Weaknesses, Opportunities and Threats) overview 
on the current state of genetic services is provided. 
 
Drivers and barriers for genetic services development 
 
The GenTEE survey provides a detailed overview over the current state of genetic 
service and testing provision in the participating countries and addresses the 
challenges these countries face to develop an equitable service infrastructure. As of 
today in most countries (except Oman where universal coverage facilitates the access 
to services) genetic services are mainly accessible for the affluent urban upper-
middle and upper classes who can afford to pay out-of-pocket for services in the 
private sector.  
 
Lack of health professionals educated in genetics and health workforce training 
in genetics is a ubiquitous problem in all GenTEE countries. 
 
In countries like Brazil, China, India and South Africa that invest heavily in genomic 
science and research, there is a striking mismatch between highly developed 
research capacities and the non-availability of equitable services that are 
prepared to take advantage of genetic/genomic technologies and information in order 
to improve the care for their patients. 
 
Nevertheless – maybe with the exception of South Africa – in all GenTEE countries 
positive developments to improve genetic service structures can be observed – 
although in some countries developments can be painstakingly slow. The major 
challenges clearly lie in providing equitable services and integrating genetics and 
genomics into existing public health care services. 
 
The message is clear: in order to reap the potential benefits that the rapid 
development of genetic/genomic technologies and knowledge brings, the current 
service infrastructure needs to be strengthened in all GenTEE countries. This 
should ensure the successful translation of genetic/genomic laboratory and academic 
research into quality assured pathways and the improvement of both the individual 
patient outcomes and the overall population health. 
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SWOT analysis genetic testing services in GenTEE countries 
Country Strengths Weaknesses Opportunities Threats 
Argentina 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Congenital and genetic 
disorders burden: availability 
of national data/availability of 
epidemiological data on 
congenital and genetic 
disorders: 
• participates in the ongoing 
ECLAMC 
• started RENAC 
 
Congenital and genetic 
disorders burden: availability 
of national data/availability of 
epidemiological data on 
congenital and genetic 
disorders: 
• no data available on the 
impact on congenital and 
genetic disorders on health 
services 
• no data available on the 
prevalence of hereditary 
“late-onset disorders” 
 
 
 
 
 
 
 
 
 
 
 
 
Congenital and genetic 
disorders burden: availability 
of national data/availability of 
epidemiological data on 
congenital and genetic 
disorders: 
• RENAC started in 2009 in 
selected provinces and its 
expansion is ongoing;. 
current coverage: 50% of 
births in the public system, 
28% of births in the private 
system. 
 
Congenital and genetic 
disorders burden: availability 
of national data/availability of 
epidemiological data on 
congenital and genetic 
disorders: 
• genetic disorders have 
become a major disease 
burden 
• without effective interventions 
in place in the public health 
care sector, the projected 
number of infants born with 
serious congenital and 
genetic disorders will 
increase over the next 
decades with important 
service implications 
• lack of national population-
based epidemiological data 
clearly impairs health policy 
decision-makers’ abilities to 
assess the impact of 
congenital and genetic 
disorders, which in turn 
impacts severely the 
capacity to make evidence-
informed decisions on 
planned service 
development 
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Country Strengths Weaknesses Opportunities Threats 
Argentina 
 
 
 
Availability of key genetic 
services: 
• mandatory newborn screening 
programmes available 
(covering 10 disorders and 
two thirds of the population, 
close to 100% in the city of 
Buenos Aires) 
• genetic counselling services 
established in over 40 
genetic clinics in the public 
health care system 
• preconception care services 
available 
 
Availability of key genetic 
services: 
• the development of services in 
the private sector is 
opportunistic and mostly 
market-driven 
• genetic screening tests (except 
for newborn screening) are 
not widely available 
• carrier testing not available 
• reproductive genetic services 
and MToP not available in 
the public domain due to the 
illegality of abortion  
 
Availability of key genetic 
services: 
• acceptable number of genetic 
units and genetic testing 
services, however primarily 
at tertiary care level 
• increasing numbers of primary 
care centers with health 
workers trained to detect 
and refer genetic disorders 
• increasing numbers of public 
hospitals in the provinces 
with telemedicine in place for 
genetic consultation with 
tertiary centers 
 
Availability of key genetic 
services: 
• the legal restriction of abortion 
prevents the development of 
PND, PGD and MToP 
services in the public domain 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Access to genetic services: 
• there is an extended network 
of hospitals and health 
centers in the public sector, 
providing a basis for the 
expansion and improvement 
of access and quality of 
genetic services 
 
Access to genetic services: 
• inequitable access to services, 
many services are located in 
the private sector and have 
to be paid for out-of-pocket 
and are located only in 
urban areas  
• lack of universal health 
coverage; social and private 
insurances usually deny 
coverage of genetic services 
on the grounds of pre-
existing condition 
• coverage of the national 
newborn screening 
programmes less than 
adequate, given it is 
mandatory by law. 
• lack of expertise and skill 
gaps in recognizing 
congenital and genetic 
disorders by primary care 
Access to genetic services: 
• genetic centres in tertiary care 
hospitals run telemedicine 
programmes for genetic 
consultations to overcome 
geographical barriers 
• the private for profit health 
sector is under increased 
public scrutiny for the 
barriers imposed to patients 
with genetic disorders, and 
legislative action to enforce 
equitable services is in 
course; 
• health professionals are 
increasingly interested in 
medical genetics 
Access to genetic services: 
• inequitable genetic services 
due to limited geographical 
accessibility, out-of-pocket 
payments impact the ability 
of the poorer population to 
utilize services according to 
their needs 
• mostly the affluent urban 
upper-middle and upper 
classes can afford services 
• excessive waiting lists in public 
health sector genetic 
services that implicitly lead 
to non-transparent 
prioritization and rationing of 
services 
• routine points of entry to 
genetic services at primary 
care level very limited 
• skill gaps to recognize 
congenital and genetic 
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Country Strengths Weaknesses Opportunities Threats 
Argentina 
 
 
providers impedes the route 
through needed diagnostic 
care and prevention services 
disorders result in delayed 
referral 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Current state of genetic 
services: 
• recognition of medical genetics 
as a medical specialty 
• professionalization through the 
establishment of 
professional bodies and 
scientific societies’ 
development of qualification 
standards 
• postgraduate programmes for 
laboratory services available 
• education programmes in 
medical genetics and 
genetic counselling available 
for non-genetic health 
professionals 
• the basic testing technologies 
required to diagnose 
congenital and genetic 
disorders, chromosomal 
analysis, including FISH, 
and DNA testing are 
available in major centres 
• pharmacogenetic testing being 
introduced selectively 
• public genetic services are part 
of a national network of 
1,319 public hospitals and 
6,290 PHC centres 
Current state of genetic 
services: 
• the development of services in 
the private sector is 
opportunistic and mostly 
technology and market 
driven 
• genetics knowledge of 
physicians is poor as most 
medical schools do not 
include meaningful teaching 
in genetics in their curricula 
• underfunded and understaffed 
public health sector services 
that are unable to deliver the 
volume of needed services 
are the norm 
• unsatisfactory referral 
structures in the public 
domain, all too often patients 
affected with genetic 
conditions must find their 
own way to a tertiary 
hospital to find genetic 
services 
• there are no official agencies 
that control or monitor the 
analytical validity of tests, 
quality assessment of 
laboratory results relies 
mostly on the voluntary 
decision of the laboratory 
directors to participate in a 
quality control programme, 
Current state of genetic 
services: 
 the implementation of a 
national registry of 
congenital anomalies will 
bring more visibility to the 
problem of congenital 
defects; 
 the National MoH is taking 
some actions to influence 
the provinces in developing 
comprehensive genetic 
services 
Current state of genetic 
services: 
• brain drain of genetic health 
professionals due to 
unsatisfactory pay, lack of 
opportunities for career 
advancement 
• illegality of termination of 
pregnancy for foetal reasons 
impede reproductive options 
in case of genetic risks 
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Argentina 
 
 
usually of an international 
agency 
• testing services in the private 
sector are more or less 
unregulated 
• while laboratories are certified 
by a state agency, 
participation in quality 
assessment programmes is 
voluntary and regulation very 
lax 
• no national guidelines and 
recommendations for the 
provision of medical genetic 
services including ethical 
guidelines 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
National policies to strengthen 
genetic services: 
• a plan for strengthening 
genetic services in the public 
sector which was adopted by 
the National MoH as a 
national policy for 
strengthening the network of 
genetic services in the public 
sector and for supporting 
training activities in medical 
genetics addressed to 
primary health professionals 
in disadvantaged areas of 
the country; recently, 
following the EU funded 
CAPABILITY project (2007-
2009), special initiatives by 
national and provincial 
ministries of health have 
been started to improve 
genetic service delivery by 
National policies to strengthen 
genetic services: 
• the National MoH does not 
have much leverage or 
resources to impose policies 
as each province has its own 
set of policies and budget 
National policies to strengthen 
genetic services: 
• strengthening services via 
stimulating genetics 
research: in 2009, the 
Ministry of Science and 
Technology started a 
concerted effort with the 
National MoH and the 
private sector for research 
and development in genomic 
approaches in biotechnology 
and biomedical research, for 
which it has issued a 
number of calls for projects, 
with particular emphasis in 
public-private partnerships 
• building a national network of 
genetic services with proper 
regionalization and 
coordination 
• increasingly, health 
National policies to strengthen 
genetic services: 
• fragmented, underfunded and 
understaffed public health 
sector services are unable to 
deliver the volume of needed 
services and will not be able 
to timely implement benefits 
derived from research in 
medical genetics and 
genomics 
• unchecked growth of for profit 
private health sector 
conspires against equitable 
care and prevention of 
genetic disorders 
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Argentina 
 
 
 
increasing coordination and 
regionalization 
 
 
 
professionals and patient 
organizations are becoming 
more assertive in claiming 
the right to health for 
patients with genetic 
disorders 
 
Brazil 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Congenital and genetic 
disorders burden: availability 
of national data/availability of 
epidemiological data on 
congenital and genetic 
disorders: 
• “Live-born Declaration”, a 
document issued by 
hospitals that in theory 
allows congenital anomalies 
present at birth to be 
registered systematically 
• participates in the ongoing 
ECLAMC 
• estimates on the prevalence of 
hereditary breast cancer and 
hereditary non-polyposis coli 
cancer available 
 
Congenital and genetic 
disorders burden: availability 
of national data/availability of 
epidemiological data on 
congenital and genetic 
disorders: 
• no data available on the 
impact on congenital and 
genetic disorders on health 
services 
• no established comprehensive 
population based congenital 
disorder surveillance 
systems or registries that 
document the birth 
prevalence of congenital and 
genetic disorders 
• although the “Live-born 
Declaration” document has 
been developed, due to 
ineffective implementation 
congenital anomalies are 
being underreported and the 
reliability of the data is 
questionable 
Congenital and genetic 
disorders burden: availability 
of national data/availability of 
epidemiological data on 
congenital and genetic 
disorders: 
• the introduction of policies by 
the National MoH could help 
the growth of medical 
genetics in the country and 
organization of a functional 
network 
Congenital and genetic 
disorders burden: availability 
of national data/availability of 
epidemiological data on 
congenital and genetic 
disorders: 
• genetic disorders have 
become a major disease 
burden 
• without effective primary 
interventions in place in the 
public health sector, the 
projected number of infants 
born with serious congenital 
and genetic disorders will 
increase over the next 
decades with important 
service implications 
• lack of national population-
based epidemiological data 
clearly impairs health policy 
decision-makers’ abilities to 
assess the impact of 
congenital and genetic 
disorders, which in turn 
impacts severely the 
capacity to make evidence-
informed decisions on 
planned service 
development 
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Brazil 
 
 
Availability of key genetic 
services: 
• mandatory newborn screening 
programmes available 
(covering PKU; CH in 27 
states, SC in 14 states and 
CF in 3 states) 
• genetic counselling services 
established 
• provision of genetic 
counselling at primary care 
level 
• preconception care services 
available 
 
Availability of key genetic 
services: 
• genetic testing services mostly 
available in urban areas at 
tertiary care level and in the 
private sector 
• the development of services 
in the private sector is 
opportunistic and mostly 
market-driven 
• genetic screening tests (except 
for newborn screening) are 
not available 
• genetic counselling services at 
primary care level only 
available in some regions 
and for specific disorders 
• no genetic services in the 
states of Amazonas, Amapá, 
Roraima, Rondônia and 
Tocantins 
• lack of MToP services 
especially in the public 
sector 
Availability of key genetic 
services: 
• increasing number of genetic 
units and genetic testing 
services primarily in the 
private sector or at tertiary 
care level 
• providing testing services for 
others countries 
 
Availability of key genetic 
services: 
• strong lobbies by religious 
groups against MToP 
• misconceptions regarding the 
need for medical genetics by 
physicians 
 
 
 
 
 
 
 
 
 
 
Access to genetic services: 
• services available in most 
large cities 
Access to genetic services: 
• lack of universal coverage 
• inequitable access to services 
• genetic tests are often not 
available within the public 
health system due to 
insufficient number of 
services and scarce funding 
• restricted coverage of newborn 
screening (urban vs. rural 
areas) 
• disparities in the provision of 
Access to genetic services: 
• for those who have private 
insurance it has become 
progressively easier to have 
genetic testing covered 
 
Access to genetic services: 
• inequitable genetic services 
due to limited geographical 
accessibility, out-of-pocket 
payments impact the ability 
of the poorer population to 
utilize services according to 
their needs 
• excessive waiting lists in public 
health sector genetic 
services that implicitly lead 
to non-transparent 
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services between urban and 
rural areas and between the 
south, eastern, north and 
western states 
prioritization and rationing of 
services 
• routine points of entry to 
genetic services at primary 
care level very limited 
• skill gaps to recognize 
congenital and genetic 
disorders result in delayed 
referral 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Current state of genetic 
services: 
• recognition of medical genetics 
as a medical specialty  
• professionalization through the 
establishment of 
professional bodies and 
scientific societies’ 
development of qualification 
standards (~200 physicians 
have been awarded with 
board certificates) 
• postgraduate programmes for 
laboratory services available 
• education programmes in 
medical genetics available 
for non-genetic health 
professionals 
• the basic testing techniques 
required to diagnose 
congenital and genetic 
disorders, chromosomal 
analysis, including FISH, 
and molecular diagnostic 
technology are available, 
this includes the ability to 
undertake predictive testing 
for late-onset monogenic 
disorders 
Current state of genetic 
services: 
• underfunded and understaffed 
public health sector services 
that are unable to deliver the 
volume of needed services 
are the norm 
• some Brazilian regions 
completely lack basic 
genetic service 
infrastructures to ensure 
care in genetics 
• there is no specific regulation 
for medical genetics 
services, that like all other 
medical services are 
regulated and supervised by 
National MoH and its 
specific agencies, 
particularly the ANVISA; 
some quality assessment 
programmes are available 
for laboratories, so that they 
comply with international 
standards; most private 
laboratories tend to 
undertake it voluntarily, not 
specifically for genetics, but 
for all testing offered. 
Current state of genetic 
services: 
• possibility of future growth of 
the existing services with the 
new policies for genetics / 
rare diseases to be instituted 
by the National MoH 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Current state of genetic 
services: 
• the genetics content in almost 
all medical schools does not 
cover even the needs of a 
general medical education.; 
therefore, most physicians 
do not recognize the genetic 
basis of diseases with which 
they are dealing and/or do 
not know how to refer to 
genetic services and/or do 
not give the deserved 
importance to the process of 
genetic counselling. 
• internal brain drain due to no 
job positions available for 
geneticists in the SUS which 
leads trained specialists to 
move to other practices / 
medical specialties where 
they can earn a living, and 
many never go into medical 
genetics again. 
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• microarray and NGS 
introduced for diagnostic 
service purposes 
• pharmacogenetic testing 
introduced 
• national guidelines and 
recommendations for the 
provision of medical genetic 
services including ethical 
guidelines since 2003 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 National policies to strengthen 
genetic services: 
• the National MoH published a 
decree which proposes the 
creation of a “Política 
Nacional de Atenção Integral 
em Genética Clinica no 
SUS” (National Policy for 
Comprehensive Care in 
Clinical Genetics at SUS) 
 
National policies to strengthen 
genetic services: 
• the decree is still waiting for 
implementation 
National policies to strengthen 
genetic services: 
• strengthening services via 
setting research priorities: 
significant investments to 
fund research in medical 
genetics and genomics have 
been made 
• linking national institutes to 
further the development in 
human genetics and 
medicine via research 
 
 
National policies to strengthen 
genetic services: 
• insufficient service structures: 
fragmented, underfunded 
and understaffed public 
health sector services that 
are unable to deliver the 
volume of needed services 
and will not be able to timely 
implement benefits derived 
from research in medical 
genetics and genomics  
 
 
 
 
China 
 
 
 
 
 
 
 
 
Congenital and genetic 
disorders burden: availability 
of national data/availability of 
epidemiological data on 
congenital and genetic 
disorders: 
• congenital malformations are 
monitored nationally via a 
hospital-based birth defect 
surveillance network and 
then reported to the National 
Congenital and genetic 
disorders burden: availability 
of national data/availability of 
epidemiological data on 
congenital and genetic 
disorders: 
• no data available on the 
impact of congenital and 
genetic disorders on health 
services 
• no established comprehensive 
Congenital and genetic 
disorders burden: availability 
of national data/availability of 
epidemiological data on 
congenital and genetic 
disorders: 
• started to report data from 
hospital-based diagnostic 
testing laboratories to the 
HVP 
• biobanks established 
Congenital and genetic 
disorders burden: availability 
of national data/availability of 
epidemiological data on 
congenital and genetic 
disorders: 
• genetic disorders have 
become a major disease 
burden 
• lack of national population-
based epidemiological data 
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MoH annually. 
• marital & preconceptional 
health checks also involve 
screening for common 
genetic disorders, and data 
are updated to National 
Committee of Family 
Planning 
 
 
population based congenital 
disorder surveillance 
systems or registries that 
document the birth 
prevalence of congenital and 
genetic disorders 
• systematic and accurate 
centralised national data 
collection is hampered by 
the marked absence of the 
correct identification at birth 
of children with congenital 
conditions 
• no data available on the 
prevalence of hereditary 
“late-onset disorders” 
 
clearly impairs health policy 
decision-makers’ abilities to 
assess the impact of 
congenital and genetic 
disorders, which in turn 
impacts severely the 
capacity to make evidence- 
based decisions on planned 
service development 
• without effective primary 
interventions in place in the 
public sector, the projected 
number of infants born with 
serious congenital and 
genetic disorders will 
increase over the next 
decades with important 
service implications 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Availability of key genetic 
services: 
• national newborn screening 
programmes cover more 
than 90% of the newborn 
population in the affluent 
eastern provinces 
• genetic counselling services 
established 
• provision of genetic 
counselling at primary care 
level 
• preconception care services 
available 
 
Availability of key genetic 
services: 
• limited availability of genetic 
testing services 
• genetic testing services mostly 
available in urban areas at 
tertiary care level and in the 
private sector 
• genetic services cluster in the 
more affluent eastern and 
southern-eastern regions of 
China, poorer western and 
northern regions are 
underserved 
• newborn screening coverage 
falls well below 30% in the 
western provinces and is not 
available in Tibet 
• genetic counselling services at 
Availability of key genetic 
services: 
• increasing number of genetic 
units and genetic testing 
services primarily in the 
private sector or at tertiary 
care level 
• provision of testing services for 
others countries 
 
Availability of key genetic 
services: 
• the absence of professional 
regulation and guideline for 
molecular genetic services 
• insufficient number of 
specialists 
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primary care level only 
available in some regions 
 
 
 
 
 
 
 
 
 
Access to genetic services: 
• the genetic service network 
has been fully established 
covers most of Primary 
cities (e.g. Beijing, 
Shanghai and Guangzhou) 
and Secondary cities (e.g. 
Chongqing, Chengdu, 
Hangzhou, Nanjing, 
Shenyang, Shenzhen, 
Tianjin, Wuhan and 
Xiamen) 
• national newborn screening 
programmes cover more 
than 90% of the newborn 
population in the affluent 
eastern provinces 
 
Access to genetic services: 
• lack of universal coverage 
• inequitable access to services 
• most genetic tests have to be 
paid for out-of-pocket 
• restricted coverage of newborn 
screening (urban vs. rural 
areas) 
Access to genetic services: 
• government has realized the 
limited access to basic 
genetic services 
• as the total birth defect rate is 
decreasing, government 
has the option to provide 
more political and financial 
support to improve the 
coverage of genetic 
services. 
• the stable national economic 
condition allows the 
expansion of the coverage 
for national medical 
insurance. 
Access to genetic services: 
• inequitable genetic services 
due to limited geographical 
accessibility, out-of-pocket 
payments impact the ability 
of the poorer population to 
utilize services according to 
their needs 
• routine points of entry to 
genetic services at primary 
care level very limited 
• skill gaps in the recognition of 
congenital and genetic 
disorders result in delayed 
referral 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Current state of genetic 
services: 
• ~100 universities/colleges 
have medical schools. All 
these universities/colleges 
have genetics as 
compulsory, less than 10 
universities, including Peking 
University, Tshinghua 
University, and Zhejiang 
University, have specially 
designed medical genetics 
instead of genetics; none of 
these set up separate 
courses for medical genetics 
• medical genetics or overall 
Current state of genetic 
services: 
• medical genetics not 
recognized as a specialty, 
however, recognized as a 
sub-specialty in prenatal 
practice 
• the medical genetics 
professional in medical 
school has nothing to do 
with clinical genetic services. 
Genetic testing and genetic 
counselling are run 
independently in hospital, 
and generally are not 
combined and considered as 
Current state of genetic 
services: 
• heavy governmental 
investment in next 
generation sequencing 
facilities (e.g. BGI), 
biobanking and global 
cooperation initiatives (BGI, 
HVP) 
 
Current state of genetic 
services: 
• unmet needs: increasing 
numbers of people are 
demanding high quality 
genetic services 
• private sector development 
largely unregulated 
• underdeveloped clinical 
genetic services 
infrastructures will impede 
the translation process of 
technological advances 
generated in China into 
public genetic services 
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genetics is usually taught in 
the 2nd year of all medical 
undergraduate (including the 
courses for doctors, nurses, 
medical test technicians, 
public health personnel, 
medical administration 
personnel) as compulsory 
before the beginning of 
medical practice 
• the basic testing techniques 
required to diagnose 
congenital and genetic 
disorders, chromosomal 
analysis, including FISH, 
and molecular diagnostic 
technology are available, 
this includes the ability to 
undertake predictive testing 
for late-onset monogenic 
disorders 
• microarray and NGS 
introduced for diagnostic 
service purposes 
• pharmacogenetic testing 
introduced 
• quality assessment schemes 
are available and the centres 
in hospitals are exposed to 
regular peer reviews; all 
clinical laboratories offering 
genetic diagnosis are 
required to meet the 
standards of Centre of 
Clinical Testing, National 
MoH; some private 
laboratories may also 
comply with ISO15189 
“medical genetics” 
• in some small local genetic 
posts even genetic 
laboratory technicians may 
play the role of genetic 
counsellor, due to the lack of 
professional staff, although it 
is illegal 
• postgraduate programmes for 
biochemical, cytogenetic and 
molecular geneticists are not 
available 
• major hospitals provide only 
short-term professional 
training for non-genetic 
health professionals 
• brain drain/migration due to 
low salaries 
• majority of population remains 
underserved especially in 
the poorer western regions 
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(Accreditation Criteria for the 
Quality and Competence of 
Medical Laboratories) and 
obtain accreditation from the 
CAP 
• national guidelines and 
recommendations for the 
provision of genetic services 
implemented since 2001 into 
the Maternal and Child 
Health Law 
• the National MoH has 
published a list of 
regulations concerning 
ethical issues  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
National policies to strengthen 
genetic services: 
• the Maternal and Child Health 
Law of the People’s 
Republic of China includes 
genetic services 
recommendations for the 
provision of genetic services; 
in 2001, the China State 
Council published a State 
Council Order (No. 308) on 
implementing of the 
Maternal and Child Health 
Law; the law and the council 
order provide a detailed 
guideline for the 
development of maternal & 
child health care, especially 
in the area related to genetic 
diseases 
• National MoH has published a 
list of regulations concerning 
National policies to strengthen 
genetic services: 
• the implementation of 
professional regulation & 
guidelines could be delayed 
and neglected in some 
under developed rural 
areas. 
 
National policies to strengthen 
genetic services: 
• the increasing governmental 
and public awareness 
demands more legislative 
support for genetic testing. 
 
National policies to strengthen 
genetic services: 
• the absence of national 
regulation for molecular 
genetic diagnosis greatly 
limits the implementation of 
tests . 
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the management and 
implementation of human 
assisted reproductive 
technologies (e.g. PND) 
 
Egypt 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Congenital and genetic 
disorders burden: availability 
of national data/availability of 
epidemiological data on 
congenital and genetic 
disorders: 
 
 
Congenital and genetic 
disorders burden: availability 
of national data/availability of 
epidemiological data on 
congenital and genetic 
disorders: 
• no data available on the 
impact of congenital and 
genetic disorders on health 
services 
• no established comprehensive 
population based congenital 
disorder surveillance 
systems or registries that 
document the birth 
prevalence of congenital and 
genetic disorders 
• systematic and accurate 
centralised national data 
collection is hampered by 
the marked absence of the 
correct identification at birth 
of children with congenital 
conditions 
• no data available on the 
prevalence of hereditary 
“late-onset disorders” 
 
Congenital and genetic 
disorders burden: availability 
of national data/availability of 
epidemiological data on 
congenital and genetic 
disorders: 
• started to report data from 
hospital-based diagnostic 
testing laboratories to the 
HVP 
 
 
Congenital and genetic 
disorders burden: availability 
of national data/availability of 
epidemiological data on 
congenital and genetic 
disorders: 
• genetic disorders have 
become a major disease 
burden 
• high prevalence of congenital 
and genetic disorders 
especially rare disorders 
• lack of national population-
based epidemiological data 
clearly impairs health policy 
decision-makers’ abilities to 
assess the impact of 
congenital and genetic 
disorders, which in turn 
impacts severely the 
capacity to make evidence-
informed decisions on 
planned service 
development 
• underreporting birth 
prevalence of disorders  
• without effective primary 
interventions in place in the 
public health care sector, the 
projected number of infants 
born with serious congenital 
and genetic disorders will 
increase over the next 
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Egypt 
 
 
decades with important 
service implications 
 
 Availability of key genetic 
services: 
• national newborn screening 
programmes covering all 29 
governorates (>90% 
coverage) 
• genetic counselling services 
established 
• preconception care services 
available 
Availability of key genetic 
services: 
 
Availability of key genetic 
services: 
• started to develop community 
genetic services based on 
counselling centres 
• increasing number of genetic 
units and genetic testing 
services primarily in the 
private sector or at tertiary 
care level 
Availability of key genetic 
services: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Access to genetic services: 
 
Access to genetic services: 
• lack of universal coverage 
• inequitable access to services 
• coverage of genetic tests by 
the public sector is limited 
and services for poor people 
may be covered by 
donations from NGOs or 
individual charity 
• genetic services provided by 
the private sector have to be 
covered mainly by out-of-
pocket payments 
• restricted coverage of newborn 
screening (urban vs. rural 
areas) 
 
Access to genetic services: 
 
 
Access to genetic services: 
• inequitable genetic services 
due to limited geographical 
accessibility, out-of-pocket 
payments impact the ability 
of the poorer population to 
utilize services according to 
their needs 
• excessive waiting lists in public 
health sector genetic 
services that implicitly lead 
to non-transparent 
prioritization and rationing of 
services 
• routine points of entry to 
genetic services at primary 
care level very limited 
• skill gaps in the recognition of 
congenital and genetic 
disorders result in delayed 
referral 
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Current state of genetic 
services: 
• recognition of medical genetics 
as a medical specialty (the 
number of medical 
geneticists is estimated to be 
100-150) 
• professionalization through 
the establishment of 
professional bodies and 
scientific societies’ 
development of qualification 
standards 
• training courses on the 
detection of congenital and 
genetic disorders and 
referral to the community 
genetic clinics are available 
for nurses and physicians, in 
cooperation between the Ain 
Shams University 
department of paediatrics 
and the NRC; physicians 
working in the community 
genetic clinics receive 
condensed practical training 
courses of two months and 
can attend specialized 
courses. 
• the basic testing techniques 
required to diagnose 
congenital and genetic 
disorders, chromosomal 
analysis, including FISH, 
and molecular diagnostic 
technology are available, 
this includes the ability to 
undertake predictive testing 
Current state of genetic 
services: 
• medical genetics is taught only 
as part of the paediatrics 
curriculum 
• no postgraduate degree for 
any of the genetic laboratory 
specialties exists 
• inequity in the distribution of 
genetic specialists, positions 
in semi-rural, rural and 
remote areas remain 
unfilled. 
• underfunded and understaffed 
public health sector services 
that are unable to deliver the 
volume of services needed 
• no quality assessment 
schemes for genetic 
laboratories 
 
Current state of genetic 
services: 
 
Current state of genetic 
services: 
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for late-onset monogenic 
disorders 
• pharmacogenetic testing 
introduced 
• genetic services to a certain 
extent integrated into the 
primary, secondary and 
tertiary health care, 
community genetic 
counselling clinics are a 
referral site between primary 
and tertiary care 
 
 
 
 
 
 
 
 
 
National policies to strengthen 
genetic services: 
• policies and planning activities 
related to the provision of 
genetic services are 
included under the MoH&Ps 
five-year plan for the 
prevention and early 
intervention of disabilities 
• the MoH&P has established a 
national committee for 
community genetics leading 
to the development of 11 
genetic counselling clinics in 
different Egyptian 
governorates 
 
 
 
 
 
 
 
 
 
 
National policies to strengthen 
genetic services: 
 
National policies to strengthen 
genetic services: 
• NRC has a Division of Human 
Genetics to strengthen 
genetic services 
National policies to strengthen 
genetic services: 
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Congenital and genetic 
disorders burden: availability 
of national data/availability of 
epidemiological data on 
congenital and genetic 
disorders: 
• data on the prevalence of 
genetic / congenital 
disorders is available from 
study of consecutive new 
births in a large number of 
secondary and tertiary care 
hospitals and a few hospitals 
in rural areas 
• data has also been gathered 
from genetic clinics in 
different centers, and an 
ICMR sponsored study on 
the prevalence of ß -
thalassemia and other 
haemoglobinopathies from 
different regions of the 
country (Maharashtra, 
Gujarat, West Bengal, 
Assam, Karnataka and 
Punjab)  
• more recently the prevalence 
of hypothyroidism, CAH and 
G6PD deficiency is available 
from newborn screening 
studies 
Congenital and genetic 
disorders burden: availability 
of national data/availability of 
epidemiological data on 
congenital and genetic 
disorders: 
• no data available on the 
impact of congenital and 
genetic disorders on health 
services 
• no established comprehensive 
population based congenital 
disorder surveillance 
systems or registries that 
document the birth 
prevalence of congenital and 
genetic disorders, except the 
BDRI in Chennai 
(however BDRI data are 
mostly hospital-based data) 
• systematic and accurate 
centralised national data 
collection is hampered by 
the absence of national 
registry. 
• no data available on the 
prevalence of hereditary 
“late-onset disorders” 
Congenital and genetic 
disorders burden: availability 
of national data/availability of 
epidemiological data on 
congenital and genetic 
disorders: 
• with the recent emphasis by 
the government of India on 
non-communicable 
diseases, opportunity exists 
for collecting data on 
congenital and genetic 
disorders; on February 6
th 
2013 the government 
launched the national 
Rashtriya Bal Swasthya 
Karayakram programme, 
which is a screening and 
early intervention initiative; 
under this programme 
children will be screened 
from birth to 18 years of age; 
at birth screening will be 
carried out for neural tube 
defects, Down syndrome, 
talipes, hip dysplasia, 
congenital cataracts, 
congenital heart disease, 
and retinopathy of 
prematurity; children aged 6 
months to 6 years will be 
screened for nutritional 
deficiencies, skin disorders, 
hypothyroidism, sickle cell 
disease, and ß-
thalassaemia; children from 
6 to 18 years will be 
screened for developmental 
Congenital and genetic 
disorders burden: availability 
of national data/availability of 
epidemiological data on 
congenital and genetic 
disorders: 
• while congenital and genetic 
disorders have become a 
major disease burden, the 
number of under-5 years 
deaths due to infectious 
diseases and malnutrition 
remain high at the national 
level, due to 80% of the 
population living in the rural 
areas. 
• underreporting of deaths due 
to congenital anomalies, 
poor universal clinical 
diagnostic services and 
inadequate surveillance and 
reporting systems 
• lack of national population-
based epidemiological data 
clearly impairs health policy 
decision-makers’ abilities to 
assess the impact of 
congenital and genetic 
disorders, which in turn 
impacts severely on the 
capacity to make evidence-
informed decisions on 
planned service 
development 
• without effective primary 
interventions in place in the 
public health care sector, the 
projected number of infants 
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disabilities such as vision 
impairment, deafness, 
neuro-motor impairment, 
cognitive and language 
delay, and autism. In the first 
phase almost 270 million 
children will be covered. 
born with serious congenital 
and genetic disorders will 
increase over the next 
decades with important 
service implications 
India 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Availability of key genetic 
services: 
• newborn screening 
programmes established for 
five conditions, however, 
programmes not available in 
all states 
• PND is available in all care 
settings 
• genetic screening and carrier 
testing services available at 
primary, secondary and 
tertiary care level, however, 
availability is restricted 
• genetic counselling services 
established in major cities 
• preconception care services 
available 
 
Availability of key genetic 
services: 
• genetic testing services 
concentrated in urban areas 
• genetic testing is costly and 
not covered by the insurance 
companies, although it is 
highly subsidized in the 
government institutions 
 
 
Availability of key genetic 
services: 
• increasing number of genetic 
units and genetic testing 
services primarily in the 
private sector or at tertiary 
care level 
• providing testing services for 
other countries 
• increasing number of genetic 
units and genetic testing 
services primarily in the 
government sector.  
• as cost of genetic testing is low 
opportunity exists to extend 
these facilities to 
neighbouring countries. 
 
Availability of key genetic 
services: 
• increasing establishment of 
genetic testing facilities in 
the private sector with high 
costs will make these less 
accessible to the low income 
population  
 
 
 
 
 
 
 
 
 
 
Access to genetic services: 
• in the urban areas genetic 
services are available in 
most cities 
• commercial laboratories have 
extended the reach of 
genetic testing services even 
to remote areas by 
establishing blood collection 
and dispatch centers. 
Access to genetic services: 
• lack of universal coverage, 
social and private 
insurances usually deny 
coverage of genetic services 
on the grounds of pre-
existing condition 
• inequitable access to services, 
the majority of patients and 
their families cannot afford 
out-of-pocket funding for 
testing services 
Access to genetic services: 
• due to easy availability of  
trained scientific manpower 
genetic testing could be 
established in many 
government institutions 
• the excellent information 
technology services could be 
used creatively to provide 
genetic counselling services 
in remote areas through 
telemedicine and Skype  
Access to genetic services: 
• inequitable genetic services 
due to limited geographical 
accessibility, out-of-pocket 
payments impact the ability 
of the poorer population to 
utilize services according to 
their needs 
• waiting lists in public health 
sector genetic services that 
implicitly lead to non-
transparent prioritization and 
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 rationing of services 
• routine points of entry to 
genetic services at primary 
care level very limited 
• skill gaps in recognizing 
congenital and genetic 
disorders result in delayed 
referral in the rural areas 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Current state of genetic 
services: 
• recognition of medical genetics 
as a medical specialty 
• postgraduate training 
programmes for 
biochemical, cytogenetic and 
molecular geneticists 
available 
• education programmes in 
medical genetics and 
genetic counselling are 
organized as courses and 
CMEs by various groups 
• NABL inspects and accredits 
the laboratories for genetic 
tests 
• ICMR has issued ethical 
guidelines for research in 
biomedical subjects in 2006 
• ICMR has issued guidelines 
for the provision of medical 
genetic services 
• the basic testing techniques 
required to diagnose 
congenital and genetic 
disorders, chromosomal 
analysis, including FISH, 
Current state of genetic 
services: 
• not mandatory that every 
medical school should have 
a department of medical 
genetics for training 
purposes; there are only 5-6 
medical schools that provide 
advanced training in clinical 
genetics, genetics is 
presently taught under 
various specialties like 
anatomy, physiology, 
pathology, paediatrics and 
internal medicine in the 
majority of medical schools 
• underfunded and understaffed 
public health sector services 
that are unable to deliver the 
volume of services needed 
• Indian population 
underserved, the number of 
genetic specialists 
insufficient (0.06 per million 
population) 
• 54 genetic units are presently 
running in different parts of 
India, this is considered 
Current state of genetic 
services: 
• the demand for genetic 
centres in the private sector 
will drive genetic services in 
the country and provide jobs 
in the future 
 
 
Current state of genetic 
services: 
• PhD students from institutions 
that are internationally 
recognized often migrate to 
the West following 
graduation 
• underdeveloped clinical 
genetic services 
infrastructures will impede 
the translation process of 
technological advances 
generated in India into public 
genetic services 
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and molecular diagnostic 
technology are available, 
this includes the ability to 
undertake predictive testing 
for late-onset monogenic 
disorders 
• microarray and NGS 
introduced for diagnostic 
service purposes 
• pharmacogenetic testing 
introduced 
 
 
insufficient for a large 
country like India, some 
capitals of the 28 states do 
not have genetic services 
• India is a vast country and 
genetic counselling 
continues to be provided by 
general paediatricians, 
obstetricians, and physicians 
for the common genetic 
disorders occurring in Indian 
practice; there is a need to 
establish genetic centres 
with full laboratory support in 
the capital city of each state 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
National policies to strengthen 
genetic services: 
• substantial funds have been 
made available by the DST, 
DBT, CSIR and the ICMR to 
fund genetics/genomics 
research 
 
National policies to strengthen 
genetic services: 
• there are no national policies/ 
guidelines in planning 
activities for provision of 
medical genetic services in 
India 
• genetics/genomics research is 
focused on the area of 
infectious diseases which 
afflict developing countries 
and less emphasis is given 
to congenital and genetic 
disorders 
• the government has 
established the Rural Health 
Mission to improve the 
health facilities in the rural 
parts of the country; the 
major focus has been on 
providing basic health needs 
and recently non-
communicable diseases 
National policies to strengthen 
genetic services: 
• NIBMG as an autonomous 
institution of the government 
of India established (2009) 
to create the necessary 
infrastructure to serve as an 
expert base for biomedical 
genetics/genomics 
 
National policies to strengthen 
genetic services: 
• higher attention & priority given 
to infectious diseases, 
congenital and genetic 
disorders not a priority 
 164 
Country Strengths Weaknesses Opportunities Threats 
India 
 
 
have been included in their 
scope of work; the focus is 
on diabetes, hypertension, 
coronary artery disease 
rather than congenital and 
genetic disorders 
 
 
Oman 
 
 
 
 
 
 
 
 
 
 
 
 
Congenital and genetic 
disorders burden: availability 
of national data/availability of 
epidemiological data on 
congenital and genetic 
disorders: 
• strong hospital-based 
registries/surveys that 
provide figures on the birth 
prevalence of congenital 
anomalies 
• provides data on genetic 
disorders for CAGS 
 
Congenital and genetic 
disorders burden: availability 
of national data/availability of 
epidemiological data on 
congenital and genetic 
disorders: 
• no established comprehensive 
population based congenital 
disorder surveillance 
systems or registries that 
document the birth 
prevalence of congenital and 
genetic disorders 
• systematic and accurate 
centralised national data 
collection is hampered by 
the marked absence of the 
correct identification at birth 
of children with congenital 
conditions due to skill gaps 
• no data available on the 
prevalence of hereditary 
“late-onset disorders” 
 
Congenital and genetic 
disorders burden: availability 
of national data/availability of 
epidemiological data on 
congenital and genetic 
disorders: 
• empiric national data on birth 
prevalence for congenital 
and genetic disorders to 
assist Oman in planning 
future medical genetic health 
services 
 
Congenital and genetic 
disorders burden: availability 
of national data/availability of 
epidemiological data on 
congenital and genetic 
disorders: 
• genetic disorders have 
become a major disease 
burden, autosomal-recessive 
disorders are common 
• without effective primary 
interventions in place in the 
public health care sector, an 
increasing number of 
children born with 
congenital/genetic disorders 
will move into adolescence 
and adult life in the next 
years with important service 
implications 
Oman 
 
 
 
 
Availability of key genetic 
services: 
• mandatory national newborn 
screening programme 
available (covering 1 
disorder) 
Availability of key genetic 
services: 
• genetic testing services mostly 
available in urban areas at 
secondary and tertiary care 
level 
Availability of key genetic 
services: 
• increasing number of genetic 
testing services available 
•  started to develop community 
genetic services based on 
Availability of key genetic 
services: 
• lack of trained Omani genetic 
specialists 
 
 165 
Country Strengths Weaknesses Opportunities Threats 
• genetic counselling services 
established 
• provision of genetic 
counselling at primary care 
level 
• community genetic services 
available in rural areas 
providing genetic screening, 
carrier testing and genetic 
counselling services 
(primarily for haemoglobin 
disorders) 
• “Central Notification of Birth 
Defects and Congenital 
Disorders detectable at 
Birth” monitoring system 
• preconception care services 
available 
 
• the scope of currently available 
testing services is limited 
 
counselling centres 
• increasing number of 
conditions covered by the 
national newborn screening 
programme 
 
 
 
 
 
 
 
 
Access to genetic services: 
• universal coverage provided 
by the state 
 
Access to genetic services: 
 
Access to genetic services: 
 
Access to genetic services: 
• genetic services are 
concentrated in the main 
cities 
• routine points of entry to 
genetic services at primary 
care level very limited 
• skill gaps to recognize 
congenital and genetic 
disorders result in delayed 
referral 
 
 
Oman 
 
 
 
Current state of genetic 
services: 
• recognition of medical genetics 
as a medical specialty 
including qualification 
obtained abroad 
Current state of genetic 
services: 
 
Current state of genetic 
services: 
• new National Genetic Centre 
established 
Current state of genetic 
services: 
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• the basic testing techniques 
required to diagnose 
congenital and genetic 
disorders, chromosomal 
analysis, including FISH, 
and molecular diagnostic 
technology are available 
• microarray and NGS 
introduced for diagnostic 
service purposes 
• pharmacogenetic testing 
introduced 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
National policies to strengthen 
genetic services: 
• “National Programme for the 
Control of Genetic Blood 
Disorders” based on a 
community genetic model for 
controlling haemoglobin 
disorders by offering 
screening and counselling 
since 1999. 
• systematic planned national 
development of genetic 
services outlined in the 
MoH’s 5-year-plans since 
2005. 
National policies to strengthen 
genetic services: 
National policies to strengthen 
genetic services: 
 
National policies to strengthen 
genetic services: 
 
The 
Philippines 
 
 
 
 
 
Congenital and genetic 
disorders burden: availability 
of national data/availability of 
epidemiological data on 
congenital and genetic 
disorders: 
• a compulsary national 
newborn screening 
Congenital and genetic 
disorders burden: availability 
of national data/availability of 
epidemiological data on 
congenital and genetic 
disorders: 
• no data available on the 
impact on congenital and 
Congenital and genetic 
disorders burden: availability 
of national data/availability of 
epidemiological data on 
congenital and genetic 
disorders: 
• there is increasing awareness 
on genetic services among 
Congenital and genetic 
disorders burden: availability 
of national data/availability of 
epidemiological data on 
congenital and genetic 
disorders: 
• genetic disorders have 
become a major disease 
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The 
Philippines 
 
 
 
 
 
 
 
 
programme increases the 
availability of national data 
on birth prevalence of 
covered congenital/genetic 
disorders; PBDS Project is a 
national registry and 
surveillance project in the 
country that also aims to 
increase the national data on 
congenital/genetic disorders 
 
genetic disorders on health 
services 
• no established comprehensive 
population based congenital 
disorder surveillance 
systems or registries  
• no data available on the 
prevalence of hereditary 
“late-onset disorders” 
 
the health professionals and 
the general public (i.e. tri 
media campaign for 
newborn screening) 
burden  
• lack of national population-
based epidemiological data 
clearly impairs health policy 
decision-makers’ abilities to 
assess the impact of 
congenital and genetic 
disorders, which in turn 
impacts severely the 
capacity to make evidence-
informed decisions on 
planned service 
development 
• without effective interventions 
in place in the public health 
care sector, the projected 
number of infants born with 
serious congenital and 
genetic disorders will 
increase over the next 
decades with important 
service implications 
 
 
 
 
 
 
 
 
 
 
 
 
Availability of key genetic 
services: 
• Newborn Screening Reference 
Centre established 
• national newborn screening 
programmes, more than 
3000 newborn screening 
facilities being available 
throughout the country 
• genetic counselling services 
established 
• preconception care services 
available 
 
 
Availability of key genetic 
services: 
• genetic testing services mostly 
available in urban areas at 
tertiary care level and in the 
private sector 
• genetic screening tests (except 
for newborn screening) are 
not available 
• carrier testing not available 
• limited availability of 
reproductive genetic 
services in the public domain 
• genetic services only available 
in major areas such as 
Manila, Cebu and Davao 
Availability of key genetic 
services: 
• increasing number of genetic 
units and genetic testing 
services primarily in the 
private sector or at tertiary 
care level 
• plans to expand newborn 
screening by 2013, coverage 
will extend from 5 disorders 
to more than 20 
 
Availability of key genetic 
services: 
• the legal restriction of abortion 
hinders the development of 
PND, PGD and MToP 
services in the public domain 
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Access to genetic services: 
• there are 4 newborn screening 
centers all over the 
Philippines located in the 3 
major islands of the country: 
2 in Luzon, 1 in Visayas and 
1 in Mindanao; there are 
also trained geneticists in 
these centers; another 4 
newborn screening centers 
will be established in other 
parts of the country; the 
newborn screening 
programme will set up 17 
regional follow up centers for 
patients with a confirmed 
diagnosis 
Access to genetic services: 
• lack of universal coverage 
• inequitable access to services 
• genetic services and testing 
have to be paid for out-of-
pocket 
• MToP not available 
 
Access to genetic services: 
• genetic centres in tertiary care 
hospitals run telemedicine 
programmes for genetic 
consultations to overcome 
geographical barriers 
 
Access to genetic services: 
• inequitable genetic services 
due to limited geographical 
accessibility, out-of-pocket 
payments impact the ability 
of the poorer population to 
utilize services according to 
their needs 
• mostly the affluent urban 
upper-middle and upper 
classes can afford services 
• excessive waiting lists in public 
health sector genetic 
services that implicitly lead 
to non-transparent 
prioritization and rationing of 
services 
• routine points of entry to 
genetic services at primary 
care level very limited 
• skill gaps to recognize 
congenital and genetic 
disorders result in delayed 
referral 
 
 
 
 
 
 
 
 
 
 
 
 
Current state of genetic 
services: 
• the Philippine Paediatric 
Society has included 
genetics as a core topic in its 
curriculum for all medical 
schools 
• recognition of medical genetics 
as a medical specialty 
• the Department of Paediatrics, 
PGH offers a 2-year 
fellowship programme in 
Current state of genetic 
services: 
• underfunded and understaffed 
public health sector services 
that are unable to deliver the 
volume of needed services 
• there are only seven trained 
medical geneticists for the 
whole country (0.06 per 
million population) 
• genetics is taught primarily in 
medical school as topics 
Current state of genetic 
services: 
• a master’s programme in 
genetic counselling is being 
offered since 2011-2012 at 
university level (at the UP-
PGH);  
• increasing demand for genetic 
services 
• genetic research is a rapidly 
increasing field in the 
country 
Current state of genetic 
services: 
• there is an urgent need for 
expansion and capacity 
building in medical genetics; 
the limitation in available 
medical geneticists not only 
severely hampers the ability 
to diagnose and manage 
hereditable disorders but 
also the ability to incorporate 
the benefits of 
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Clinical Genetics 
• postgraduate training 
programmes for molecular 
genetics are available 
• CME courses for non-genetic 
health professional provided 
by clinical geneticists  
• newborn screening integrated 
into the public health 
delivery system; all newborn 
screening laboratories are 
considered public health 
laboratories; guidelines and 
accreditation are run by the 
DoH 
• techniques available: 
conventional cytogenetic 
techniques constitutional, 
PCR, PT-PCR, metabolic 
biochemical testing 
• both internal and external 
quality assessment 
schemes, like the CEQA 
available; for the newborn 
screening, the Newborn 
Screening Laboratory-NIH-
UP avails quality control 
samples bi-annually and 
proficiency testing samples 
quarterly from the CDC 
• all newborn screening centres 
undergo an initial 
accreditation and re-
accreditation every 3 years 
integrated in Biochemistry, 
Paediatrics, Internal 
Medicine and Obstetrics 
• formal postgraduate training 
programmes for biochemical 
genetics and cytogenetics 
are not available 
 
 
 genetic/genomics research 
into mainstream medicine 
• strongly affected by brain 
drain; the majority of trained 
original staff (of the IHG-
NIH) have been absorbed by 
genetic laboratories 
overseas, and Philippine 
students going for PhD work 
overseas do not return 
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National policies to strengthen 
genetic services: 
• guidelines for the provision of 
newborn screening stated in 
the Newborn Screening Act 
of 2004 (RA 9288) 
• aside from the newborn 
screening law, other 
available national policies for 
the strengthening of genetic 
services in the country are 
focused on research and 
ethics: Operational 
Guidelines for Ethics 
Committees Reviewing 
Biomedical Research by 
UNDP/World Bank/WHO 
Special Programme for 
Research & Training in 
Tropical Diseases (TDR); 
Ethical Guidelines for 
Genetic Research with a 
Section on Stem Cell 
Research by the Philippine 
Council for Health Research 
and Development; 
Intellectual Property Code of 
the Philippines (Republic Act 
No. 8293). 
 
National policies to strengthen 
genetic services: 
• infections remain to be the top 
priority of the DoH 
• improvement of genetic 
services are not on the 
priority list of policymakers 
 
 
National policies to strengthen 
genetic services: 
• government investment in 
genomics 
• the Philippine Genome Center 
was put up under the UP 
Administration, and it 
includes a branch focused 
on health-related research 
 
National policies to strengthen 
genetic services: 
• provision of basic genetic 
healthcare services to every 
region remains the biggest 
challenge in the country 
• lack of interest of policymakers 
in the field of genetics 
 
South Africa 
 
 
 
 
 
Congenital and genetic 
disorders burden: availability 
of national data/availability of 
epidemiological data on 
congenital and genetic 
disorders: 
• limited hospital and community 
based epidemiology on 
Congenital and genetic 
disorders burden: availability 
of national data/availability of 
epidemiological data on 
congenital and genetic 
disorders: 
• no data available on the 
impact on congenital and 
Congenital and genetic 
disorders burden: availability 
of national data/availability of 
epidemiological data on 
congenital and genetic 
disorders: 
• very limited in the current 
situation in the country 
Congenital and genetic 
disorders burden: availability 
of national data/availability of 
epidemiological data on 
congenital and genetic 
disorders: 
• while congenital and genetic 
disorders have become 
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South Africa 
 
 
common congenital 
disorders is available. 
• provides data for neural tube 
defects (SABDSS) for the 
International Clearing House 
for Birth Defects 
 
 
genetic disorders on health 
services 
• no established comprehensive 
population based congenital 
disorder surveillance 
systems or registries that 
document the birth 
prevalence of congenital and 
genetic disorders 
• stopping the SABDSS started 
in 1988 and involved the 
routine, systematic collection 
of data regarding congenital 
and genetic disorders from 
15 hospitals in the country; 
however, such data 
collection ceased in 2005 
and currently only data for 
neural tube defects is 
collected 
• systematic and accurate 
centralised national data 
collection is hampered by 
the marked absence of the 
correct identification at birth 
of children with congenital 
conditions 
• no data available on the 
prevalence of hereditary 
“late-onset disorders” 
 
 
major disease burden, the 
number of under-5 years 
deaths due to infectious 
diseases, particularly 
HIV/AIDS and TB, remain 
high 
• underreporting of deaths due 
to congenital anomalies, due 
to poor universal clinical 
diagnostic services and 
inadequate surveillance and 
reporting systems 
• lack of national population-
based epidemiological data 
clearly impairs health policy 
decision-makers’ abilities to 
assess the impact of 
congenital and genetic 
disorders, which in turn 
impacts severely the 
capacity to make evidence-
informed decisions on 
planned service 
development 
• without effective primary 
interventions in place in the 
public health care sector, the 
projected birth prevalence of 
infants born with serious 
congenital and genetic 
disorders will remain high 
over the next decades with 
important but unrecognized 
implications for mortality and 
morbidity and service needs. 
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South Africa 
 
 
 
 
 
 
 
 
 
Availability of key genetic 
services: 
• medical genetic laboratory 
services are available in 
academic/ tertiary 
institutions and the private 
sector. 
• genetic testing is available for 
those accessing the public 
health sector by referral of 
specimens to the 
academic/tertiary institutions  
• limited genetic counselling 
services are established in 
academic institutions. 
• limited preconception care 
services available 
 
Availability of key genetic 
services: 
• no mandatory national 
newborn screening 
programme 
 
Availability of key genetic 
services: 
• increasing number of genetic 
units and genetic testing 
services primarily in the 
private sector or at tertiary 
care level 
• providing testing services for 
others countries 
 
Availability of key genetic 
services: 
• the ambitious approach in the 
1990s trying to offer medical 
genetic services including 
counselling services to the 
public through primary care 
was thwarted by the 
HIV/AIDS epidemic which 
forced the National DoH to 
shift priorities 
• the stagnation of the 
academic/tertiary clinical and 
laboratory services due to 
diminished political will, 
commitment and financial, 
structural and human 
resources 
 
 
 
 
 
 
 
 
 
 
 
 
 
Access to genetic services: 
• access to testing services is 
available through referral of 
specimens to academic/ 
tertiary laboratories. 
Access to genetic services: 
• inequitable access to clinical 
services impacting the ability 
of the poorer population to 
access services 
 
Access to genetic services: 
• limited in the current climate 
Access to genetic services: 
• inequitable genetic services 
due to limited geographical 
accessibility, and limited 
affordability of services 
impacts the ability of the 
poorer population to utilize 
services according to their 
needs 
• excessive waiting lists in public 
health sector genetic 
services that implicitly lead 
to non-transparent 
prioritization and rationing of 
services 
• routine points of entry to 
genetic services at primary 
care level very limited 
• skill gaps to recognize 
congenital and genetic 
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disorders result in delayed 
referral 
•  
South Africa 
 
 
 
 
 
 
 
 
Current state of genetic 
services: 
• recognition of medical genetics 
as a medical specialty 
• the basic testing techniques 
required to diagnose 
congenital and genetic 
disorders, chromosomal 
analysis, including FISH, 
and molecular diagnostic 
technology are available, 
this includes the ability to 
undertake predictive testing 
for late-onset monogenic 
disorders 
• pharmacogenetic testing 
introduced 
Current state of genetic 
services: 
• underfunded and understaffed 
public health sector services 
that are unable to deliver the 
volume of needed services 
 
Current state of genetic 
services: 
• limited in the current climate 
Current state of genetic 
services: 
• implosion of genetic services 
in the public domain due to 
very limited political will, 
commitment and funding. 
 
 
 
 
 
 
 
 
 
National policies to strengthen 
genetic services: 
• South Africa has the 
constitutional, legal and 
regulatory framework in 
place to enable it to develop 
cogent medical genetic 
services to meet its health 
needs 
National policies to strengthen 
genetic services: 
• the national lack of political will 
and commitment, and 
probably the ability to 
implement its own 
constitutional, legal and 
regulatory framework 
National policies to strengthen 
genetic services: 
• the constitutional, legal and 
regulatory framework is 
more than adequate to meet 
the country’s current 
medical genetic health 
needs 
National policies to strengthen 
genetic services: 
• the continuing lack of 
commitment to the countries 
constitutional, legal and 
regulatory framework 
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Abstract 
Due to the epidemiological transition in the emerging economies of China, East Asia, India, Latin America, the 
Middle East and South Africa, these economies are dealing with an increasing proportion of morbidity and mortality 
due to congenital and genetic conditions, and a rising need for genetic services to improve patient outcomes and 
overall population health. For this reason, they are facing the challenge how to ensure the successful translation of 
genetic/genomics laboratory and academic research into quality assured pathways, and to develop a service 
delivery infrastructure that leads to equitable and affordable access to high quality genetic/genomic testing 
services. The GenTEE international project is intended to inform policy decisions for the challenges of delivering 
equitable high quality genetic services and to promote international collaboration for capacity building. 
A standardized survey has been carried out, that is the first of its worldwide that allows comparison of services 
internationally across a number of key dimensions by using a core set of indicators, selected by the GenTEE 
consortium for their relevance and comparability.  
To date, the GenTEE project has completed its survey that maps the current state of genetic services in the 
participating countries and identifies current drivers, barriers and opportunities for genetic services development. 
The results show that there is no equitable access to genetic services in all countries mainly due to financial barriers 
(underfunded fragmented public services, out-of-pocket expenses tend to be the norm for genetic testing 
services), geographical barriers (concentration of services in main cities) and skill gaps, resulting in inequitable 
services or delayed access. The development of services in the private sector is opportunistic and mostly 
technology and market driven. There is a marked lack of standard operating procedures and agreed quality 
assessment processes for new technologies. An international collaborative networks can provide support for 
capacity building and help to strengthen the provision of quality genetic/genomic services in emerging economies. 
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As the Commission’s in-house science service, the Joint Research Centre’s mission is to provide 
EU policies with independent, evidence-based scientific and technical support throughout the 
whole policy cycle. 
 
Working in close cooperation with policy Directorates-General, the JRC addresses key societal 
challenges while stimulating innovation through developing new standards, methods and tools, 
and sharing and transferring its know-how to the Member States and international community. 
 
Key policy areas include: environment and climate change; energy and transport; agriculture 
and food security; health and consumer protection; information society and digital agenda; 
safety and security including nuclear; all supported through a cross-cutting and multi-
disciplinary approach. 
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